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Abstract 
Birt–Hogg–Dubé (BHD) syndrome is a rare inherited autosomal dominant disorder first 
described by Birt, Hogg and Dube in 1977 (Birt et al,. 1977). BHD affects approximately  
100 families worldwide. Approximately one third of diagnosed BHD patients also develop 
renal cell carcinoma (RCC) (Schmidt et al., 2005). BHD arises as a result of loss of function 
of the Folliculin protein expressed from the BHD gene, suggesting than Folliculin serves as a 
tumour suppressor (Vocke et al., 2005). Although it is considered that FLCN represses cell 
growth, the role that FLCN plays in cancer progression and/or initiation is currently 
unresolved. It has been observed that tumours taken from BHD patients have reduced levels 
of mitochondria (Yang et al., 2008). Previous studies have also suggested that aberrant levels 
of mTOR activity are observed in Folliculin-deficient cell lines (Baba et al., 2006; Baba et   
al., 2008). Aberrant levels of mTORC1 activity have been associated with increased levels   
of Hypoxia inducible factor transcriptional activity, decreased autophagic activity (Land and 
Tee, 2007; Hands et al., 2009). There are several genes within the mTOR pathways which   
act as Tumour Suppressors. Mutations within these genes result in inherited genetic  
disorders, including Tuberous, Sclerosis complex (TSC). Loss of function of TSC1/TSC2 
results in TSC which is clinically similar to BHD (Gomez et al., 1999). Arbarrant levels of 
mitochondrial biogeneisis and HIF activity have been observed in cells deficient in TSC1 ad 
TSC2 (Land and Tee, 2007; Chen et al., 2008). Increased levels of mTORC1 activity have 
also been shown to result in decreased levels of autophagic activity in TSC2 deficient cells 
(Parkhitko et al., 2011). In order to characterise the tumour suppression function of  
Folliculin, the effects of loss of function of Folliculin on mitochondrial biogenesis and 
mitochondrial function, hypoxia inducible factor (HIF) transcriptional activity, and  
autophagic activity were investigated using multiple cell lines. The results from this study 
suggest that loss of function of FLCN results in increased production of ROS species. This 
leads to compromised mitochondrial membrane potential and decreased ATP production as a 
result of increased expression of uncoupling proteins in order to try and reduce the increased 
levels of ROS. FLCN is also phosphorylated at multiple residues by both mTORC1 and 
AMPK and activity of both mTORC1 and AMPK is increased in response to the depleted  
ATP levels as a result of increased UCP production in response to the increased ROS 
production observed upon loss of functional FLCN. This results in increased levels of 
mitochondrial biogenesis and increased levels of glycolytic activity via increased activation   
of HIFα proteins in order to compensate for this energy deficit. Furthermore, it appears that 
both mTORC1 and AMPK could drive HIF transcription and mitochondrial biogenesis 
through modulation of FLCN phosphorylation. ULK-mediated autophagy also appears to be 
upregulated upon loss of functional FLCN, possibly as a result of the increased levels of 
AMPK activation in order to provide a protection for these cells. This may be via the 
catabolising the dysfunctional mitochondria observed in cells upon loss of BHD, a process 
which may be exploited as a potential therapeutic target for BHD patients. Further 
investigations into these cellular processes may also provide clues to potential therapeutic 
targets for treatment of BHD patients. 
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1 Introduction 
1.1 Birt-Hogg-Dube Syndrome. 
The inherited autosomal dominant disorder Birt–Hogg–Dubé (BHD) syndrome was first 
described by Birt, Hogg and Dubé in 1977 (Birt et al,. 1977).  BHD is a rare disorder, 
affecting approximately 100 families worldwide, and is characterised by trichiodomas, 
acrochordons and fibrofolliculomas of the face, neck and trunk.  However, only 
fibrofolliculomas are a specific characteristic of BHD patients (Toro et al., 1999).  89% of 
patients also present with bilateral lung cysts and 24% have a history of spontaneous 
pneumothoraces (Toro et al., 2007).  Approximately one third of diagnosed BHD patients 
also develop renal cell carcinoma (RCC) (Schmidt et al., 2005).  These renal tumours may 
display multiple histological types of RCCs, which include chromophobe RCCs, clear cell 
papillary RCCs oncocytomas, and a hybrid of chromophobe RCC and oncocytoma is unique 
to BHD patients.  Patients have also been reported to present with benign renal 
angiomyolipomas (AML) (Yang et al., 2008; Byrne et al,. 2011).  Work conducted by 
Cocciolone et al. has suggested that BHD patients may also be susceptible to melanomas 
(Cocciolone et al., 2010).  It has also been reported that BHD patients may present with 
colorectal neoplasias (Nahorski et al., 2010).  
1.2 Folliculin  
Folliculin (FLCN) is a 66 kDa protein containing 579 amino acid residues and is expressed 
from the BHD gene. The function of FLCN is, as yet, unknown; however it has been found to 
be highly expressed in tissues from the skin, ovaries, testis, lungs, pancreas, prostate and  
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distal nephrons of the kidney (Hasumi et al., 2009; Hartman et al., 2009; Warren et al., 
2004). While it has been suggested that FLCN represses the growth of cells, the function of 
FLCN has in cancer initiation and development is as yet unknown.   
 
1.3 Animal models of BHD 
1.3.1 The Rat model of BHD 
A rat model of hereditary renal carcinoma containing a single nucleotide insertion within the 
BHD gene has also been discovered in a Nihon rat model.  This germline mutation within 
BHD produces a frameshift mutation which results in a premature stop codon approximately 
26 amino acids downstream of the initial mutation.  Data obtained from the Nihon rat model 
showed that homozygous mutations in BHD results in early embryonic lethality in rats as 
well as mice (Okimoto et al., 2003).   
1.3.2 The Dog model of BHD 
A mutation in exon 7 of the canine homologue of BHD has been linked to a kidney cancer 
syndrome which naturally occurs in German shepherd dogs known as renal 
cystadenocarcinoma and nodular dermatofibrosis (RCND).  RCND is characterised by 
bilateral renal tumours and nodules of the skin (Lingaas et al., 2003).  Furthermore, data 
obtained from work conducted using this model also suggests that mutations in the canine 
orthalog of the BHD gene are also homozygous lethal in a manner analogous to the Nihon rat 
model (Lingaas et al., 2003). 
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These animal models are a valuable research tool as they provide models which help to 
determine the tumour suppressor function of FLCN, and may provide a means for testing 
drugs which provide a potential therapeutic benefit for BHD patients. 
1.3.3 The Drosophila melanogaster model of BHD 
A D. melanogaster model of BHD which exhibits decreased expression of the Drosophila 
homologue of FLCN (dBHD) has also been created by Singh et al. using siRNA (Sing et al., 
2006).   
1.3.4 The S. pombe model of BHD 
A S. pombe strain containing deletion of the S. pombe FLCN homologue, LST7, has also 
been created by van Slegtenhorst et al.   As the results from experiments conducted using this 
model suggest that LST7 may activate Tor2 in yeast (van Slegtenhorst et al., 2007), this 
model may be important for determining how FLCN may function in the mTOR pathway in 
mammals. 
1.3.5 Mouse models of BHD 
Work conducted on several mouse models of BHD has shown that homozygous deletion of 
BHD is lethal in mouse embryos (Chen et al., 2008; Baba et al., 2008).  This notion is 
supported by data obtained from a mouse model containing a neomycin /β- galactosidase (β 
geo) cassette insertion in between exons 8 and exon 9 of BHD, which revealed that 
embryonic lethality was induced by day 8.5 of embryonic development upon homozygous 
deletion of BHD (Hudon et al., 2010).  These data are further supported by work conducted 
by Hasumi et al., which revealed that BHD homozygous null mice die by day 6.5 of 
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embryonic development (Hasumi et al., 2009).  However, mouse models which have kidney 
targeted BHD knockout have been developed.   
The first, developed by Baba et al., contains a deletion of exon 7 of BHD and kidney specific 
conditional homozygous inactivation of BHD (Baba et al., 2008).  The second was developed 
by Chen et al. and has a deletion within the BHD gene that incorporates exons 3 and 4 of the 
BHD gene and results in kidney specific homozygous inactivation of BHD (Chen et al., 
2008).  Hartman et al. also created a kidney specific knockout mouse model with of BHD by 
integrating a neomycin/β-galactosidase (β-geo) cassette in between exon 8 and exon 9 of 
BHD, resulting in the FLCN protein being truncated (Hartman et al., 2009).   
These mouse models are particularly useful as they are genetically modified in such a way 
that, as a direct result of the genetic modifications, they do not exhibit any additional genetic 
mutations other than those within the BHD gene, whereas the animal model systems of BHD 
may contain mutations other than those observed in the BHD gene.  These mouse models 
therefore allow researchers to observe changes occurring that directly result from the 
mutations within the BHD gene. 
 
1.4 The UOK257 cell line  
 
The initial experiments in this thesis were conducted using either the UOK257 cell line or the 
UOK257-2 cell line (a kind gift from Laura Schmidt).  The UOK257 cell line is a FLCN-
deficient kidney tumour cell line derived from a BHD patient.  The UOK257-2 cells are the 
UOK27 cells with BHD stably transfected and expressed (Yang et al., 2008). 
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1.5 Genetic studies of BHD 
1.5.1 Mutations of the BHD gene in BHD patients 
Work conducted by Voke et al. has revealed germ-line and somatic mutations of the BHD 
gene on chromosome 17p11.2, and loss of heterozygosity in tumour tissue from BHD 
patients.  BHD is highly conserved across species.  These data suggest that it is the loss of 
functional FLCN which is the foundation of tumour formation in BHD patients; and supports 
the notion that FLCN serves as a tumour suppressor (Vocke et al., 2005).  Further genetic 
analyses conducted by Schmidt et al. identified several different mutations within the BHD 
gene which result in the FLCN protein being truncated.  Mutation analyses performed on 
families of BHD patients revealed that the most common mutations are a duplication or 
deletion of a C nucleotide in a polycytosine tract located on exon 11 of BHD.  This was found 
in approximately 53% of the families tested (Schmidt et al., 2005).  However, work 
conducted has suggested that BHD patients can exhibit mutations throughout the coding 
region of BHD.  Work conducted by Kunogi et al. detected a large genomic deletion in 2 
BHD patients, one with a deletion within exon 14 of BHD and one with a deletion which 
included exons 9 to 14 of the BHD gene.  These data suggested that BHD also arises as a 
result of large deletions in the BHD gene as well as small nucleotide alterations (Kunogi et 
al., 2010).  Benhammou et al. also identified 6 unique deletions in the BHD gene in nine 
BHD patients from 6 families.  Six mutations involve deletions, where four of these deletions 
can occur in exon 1.  The other two deletions in BHD encompassed exons 2 to 5, and exons 7 
to 14.  A duplication mutation involving exons 10 and 11 was also identified.  This work 
supported the notion that large deletions or duplication within the BHD gene can result in 
BHD and that the 5'-noncoding-exon 1 may be a deletion hotspot for BHD patients 
(Benhammou et al., 2011).  Molecular analysis of BHD patients conducted by Palmirotta et 
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al. also highlighted the importance of mutations within exon 9 of the BHD gene in 
predisposition for cancer in BHD patients (Palmirotta et al., 2008). 
1.5.2  Geneotype – phenotype correlation studies in BHD patients 
Several studies have been conducted in order to determine whether there is any correlation 
between mutations in the BHD gene and the phenotype exhibited.  As BHD patients can also 
present with polycystic kidneys and RCCs, work has also been conducted in order to 
determine whether there is any correlation between mutations in the BHD gene and these 
phenotypes.   
1.5.2.1  Mutations within the BHD gene and Renal Cell Carcinomas 
Studies have suggested that although mutations within the BHD gene are rare in sporadic 
renal tumours, BHD is involved in all histological types of RCCs (Khoo et al., 2002).  Work 
conducted by Baba et al. and Chen et al. has revealed that conditional homozygous kidney 
specific inactivation of BHD in mice resulted in enlarged polycystic kidneys, which lead to 
kidney failure and fatality by the time they are 3 weeks old (Chen et al., 2008; Baba et al., 
2008).  Work conducted on a kidney targeted mouse model of BHD, also revealed that 
heterozygous BHD mutant mice develop renal cysts and neoplasia by the time they are 6 
months old. After 10 months these heterozygous BHD knockout mice also spontaneously 
developed both solid tumours and cysts in their kidneys in a manner analogous to BHD 
patients (Hartman et al., 2009).  These data are also supported by work conducted by Hudon 
et al. which revealed that heterozygous BHD knockout mice develop tumours and cysts in 
their kidneys upon loss of BHD (Hudon et al., 2010).  Collectively, these data imply that 
FLCN has a crucial function in the initiation and/or development of kidney tumourigenesis 
16 
 
Work conducted by Vocke et al. revealed that 70% of renal tumours taken from BHD 
patients had a somatic mutation within the BHD gene or loss of heterozygosity of the BHD 
gene.  75% of the somatic mutations detected within the BHD gene were frameshift 
mutations which occurred within the open reading frame of BHD.  One nonsense mutation 
was detected on exon 12 of the BHD gene.  2 other nonsense mutations were detected within 
exon 14 of the BHD gene (Vocke et al., 2005).  These differences in the mutations observed 
might influence which type of RCCs occurs in BHD patients (Yang et al., 2008).  However, 
this might also be explained by ‘secondary hits’ of additional genes or different genetic 
backgrounds of the patients.  Work conducted by Chen et al. demonstrated that there was a 
correlation between kidney targeted loss of BHD and RCC in mice (Chen et al., 2008).  Work 
conducted by Hudon et al. also showed that heterozygous mice devoid of functional FLCN 
develop early preneoplastic kidney lesions which progress to malignant tumours.  
Knockdown of FLCN in the human kidney cancer cell line ACHN via short hairpin (sh) RNA 
was also shown to result in large tumours being formed.  Furthermore, a decrease in tumour 
growth was observed in another kidney cancer cell line, 786-0, when FLCN was re-expressed 
(Hudon et al., 2010).  Okimoto et al. also observe that the primary RCCs within the Nihon rat 
model often exhibit loss of heterozygosity of BHD.  Second hits within the canine orthologue 
of the human BHD gene were also observed in a large proportion of kidney tumours from 
dogs with RCND.  These mutations were thought to result in loss of functional FLCN 
(Bønsdorff et al., 2008).  Cysts found on the surface of the kidneys in 6-8 week old puppies 
with RCND also display loss of heterozygosity of the BHD gene has also been observed in.  
Collectively, these data support the notion of FLCN functioning as a Knudson tumour 
suppressor in the kidney (Bønsdorff et al., 2009; Khoo et al., 2002) 
17 
 
1.5.2.2  Mutations within the BHD gene and Spontaneous pneumothoraces 
As BHD patients can also present with spontaneous pneumothorax and air filled lung cysts, 
work has also been conducted in order to determine whether there is any correlation between 
mutations within the BHD gene and the spontaneous pneumothorax phenotype.  Work 
conducted by Painter et al., on the genotype-phenotype analysis of BHD patients revealed 
that patients which exhibit the dominantly inherited spontaneous pneumothorax have 
sporadic mutations within exon 4 of the BHD gene (Painter et al., 2005).  Further work 
conducted by Graham et al. revealed that patients which exhibit the isolated pneumothorax 
phenotype have germline mutations within exons 9 and 12 of the BHD gene (Graham et al., 
2005).  Germline mutations in exons 6, 12 and 13 of the BHD gene have also been detected in 
patients that exhibit spontaneous pneumothoraces and lung cysts (Gunji et al., 2007).  Two 
further mutations in BHD which gave rise to spontaneous pneumothorax were identified by 
Fröhlich et al. (Fröhlich et al., 2008).  Genetic analysis conducted of a family with a history 
of spontaneous lung cysts and pneumothoraces also revealed a deletion mutation within exon 
10 (Sundaram et al., 2009).  Collectively, these studies suggested that there is an association 
between mutations in the BHD gene and spontaneous pneumothorax, and that BHD patients 
may present with spontaneous pneumothoraces and an isolated phenotype with none of the 
other characteristics of BHD present.  As there are mutations within the BHD gene that are 
associated with the isolated pneumothorax phenotype and lung cysts, it was hypothesised by 
Cho et al. that loss of function of FLCN may also contribute to chronic obstructive 
pulmonary disease (emphysema).  However, no association was found between mutations in 
the BHD gene and chronic obstructive pulmonary disease (Cho et al., 2008). 
18 
 
1.5.2.3  Mutations within the BHD gene are associated with Colorectal Cancer 
Work conducted by Fernandes da Silva et al. also resulted in the detection of somatic and 
germline and missense mutations within primary colorectal cancer tumours (Fernandes da 
Silva et al., 2003).  In some tumours, frequent deletion and insertion mutations occur in the 
microsatellite repeats within the genome, resulting in microsatellite instability (MSI).  Work 
conducted by Shin et al. revealed that mutations within the mononucleotide tract of eight 
cytosines (poly(C)8-tract) in exon 11of the BHD gene, previously identified by Schmidt et al. 
as a mutation hotspot for BHD patients, are associated with MSI sporadic colon cancer (Shin 
et al., 2003).  Analysis of genotype-phenotype correlations for BHD mutations conducted by 
Nahorski et al. revealed that carriers of a germline c.1285dupC mutation on the poly(C)8-
tract in exon 11 of the BHD gene have an increased risk of developing colorectal neoplasias.  
23% of sporadic colorectal cancers analysed also had somatic frameshift mutations within the 
poly(C)8-tract in exon 11 of the BHD gene (Nahorski et al., 2010).  These data suggested that 
loss of heterozygosity of BHD is also implicated in colorectal tumourigenesis. 
1.5.2.3  BHD may be a MSI target gene 
Work has also been conducted by Jiang et al. in order to determine whether mutations in the 
BHD gene gave rise to gastric cancer.  Somatic mutations in the poly(C)(8)-tract of the BHD 
gene were detected in 15.8% of gastric cancer patients MSI, suggesting that  mutations in the 
BHD gene rarely give rise to MSI gastric cancer.  Work conducted by Fujii et al. also 
suggested that mutations within the poly(C)8 tract of the BHD gene are associated with 
sporadic endometrial carcinoma with MSI (Fujii et al., 2006).  It may be possible that BHD is 
a MSI target gene.  Alternatively, it may be equally possible that BHD is targeted 
downstream of other MSI target genes (Jiang et al., 2007). 
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 1.6 Signalling pathways which are regulated by FLCN 
1.6.1 The Raf-MEK-Erk pathway 
Work conducted by Baba et al. using a mouse model with kidney-specific loss of function of 
FLCN has also revealed that kidney specific knockdown of BHD results in activation of the 
Raf- mitogen-activated protein kinase (MAPK)/ERK kinase (MEK)- extracellular signal-
regulated kinase (Erk) pathway (Baba et al., 2008).  The Raf-MEK-Erk pathway involves the 
MEK1/2 kinases being activated by Raf resulting in subsequent activation of ERK1/2, and 
regulates cell proliferation.  Elevated activity levels of this pathway are exhibited in many 
cancers.  (Roberts and Der, 2007).  These data suggest that loss of functional FLCN may 
result in activation of an upstream effector of the Raf-MEK-ERK pathway, resulting in 
increased levels of cell growth and proliferation (Baba et al., 2008). 
1.6.2 JAK/STAT signalling 
Work conducted by Singh et al. revealed that the FLCN may modulate tumourigenesis by 
regulating stem cells.  Increased levels of the D. melanogaster homolog of the BHD gene 
(dBhd) were observed in early stage germline stem cells (GSCs). Suppression of dBhd and 
unpaired via shRNA lead to decreased numbers of GSCs, suggesting that it may be possible 
that dBhd may function downstream or in parallel to unpaired, an activator of the JAK/STAT 
pathway.  This in turn controls the ability for GSCs to renew themselves (Singh et al., 2006).  
If stem cells are not regulated properly this may lead to premature aging, tissue degeneration 
and the development of cancer (Okimoto et al., 2003).  It may be possible that the 
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misregulation of renal stem cells due to increased levels of the JAK/STAT pathway may 
provide a mechanism for renal tumourigenesis in BHD patients.  
1.6.3 TGF-β signalling and transcriptional control 
 
Transcription factor E3 (TFE3) and Transcription factor EB (TFEB) belong to the MiTF/TFE 
transcription factor family, and have been linked to RCC development including juvenile 
renal cancer.  Work conducted by Hong et al. revealed that loss of functional FLCN leads to 
increased nuclear localisation of TFE3 and elevated levels of TFE3 activity.  These results 
suggest that increased levels of TFE3 activity may be crucial part in the development of RCC 
in BHD patients (Hong et al., 2010b).  Studies conducted by Hong et al. using xenograph 
models and gene-expression profiles suggested that FLCN also functions as a tumour 
suppressor by regulating TGF-β signalling, essential in the regulation of a range of cellular 
functions (Hong et al., 2010a).  Another study also suggested that apoptosis is regulated by 
FLCN via TGF-β-dependent transcription.  These data also suggested that autophagy 
inhibitors (such as chloroquine), and HDAC inhibitors, which are used to treat other cancer 
types, may provide potential therapeutic benefit for BHD patients (Cash et al., 2011). 
 
1.7 FLCN-binding proteins 
Two FLCN-binding proteins have also been identified.  These are known as FLCN-binding 
protein 1 (FNIP1) and FLCN-binding protein 2 (FNIP2).  FNIP1 is an evolutionarily 
conserved 130 kDa protein which interacts with and facilitates the phosphorylation of FLCN 
(Baba et al., 2006).  FNIP2 is also evolutionarily conserved and has approximately 49% 
identity and 74% similarity to FNIP1 (Hasumi et al., 2008).  Work conducted by Komori et 
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al. has revealed that FNIP2 is involved the induction of apoptosis in response to DNA 
mispairing caused by O(6)-methylguanine (Komori et al., 2009).  Binding of both FNIP1 and 
FNIP2 to FLCN has been shown to be mediated through the C-terminus of FLCN. Truncation 
of the FLCN protein via mutations in the BHD gene reduces FLCN’s ability to interact and 
form complexes with FNIP1 and FNIP2; suggesting that these interactions are of functional 
importance and are necessary for the tumour suppressor function of FLCN (Hasumi et al., 
2008; Baba et al., 2006; Takagi et al., 2008).    
 
1.8 Tumour suppressors 
 
Tumour suppressors modulate pathways within cells which are involved in processes such as 
autophagy, apoptosis, protein synthesis and metabolism which, if unregulated could lead to 
cancer.   Tumour suppressors are therefore often mutated in cancers (Lowe et al., 2004). 
 
1.8.1 Tumour suppressors and apoptosis 
 
One way in which tumour suppressors prevent uncontrolled cellular proliferation is via 
regulation of apoptosis, the process of programmed cell death.  Pro-apoptotic effectors such 
as cytochrome C are contained within the intermembrane space of mitochondria.  BH3 (Bcl-2 
homologous 3) only proteins regulate the activity of pro-apoptotic proteins such as Bad and 
Bim and anti-apoptotic proteins such as Bcl2 which regulate mitochondrial membrane 
permeability.  When expression of pro-apoptotic proteins is greater than the expression of 
anti-apoptotic proteins, mitochondrial membrane permeability is increased and the pro-
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apoptotic factors contained within the intermembrane space of the mitochondria, such as 
cytochrome C are released.   In the case of cytochrome C, this leads to the activation of the 
caspase cascade via the initiator capase, caspase 9.   Proteins essential to cellular integrity are 
cleaved by caspases, resulting in cell death and engulfment of the cell.  The apoptotic 
pathway may be regulated by tumour suppressor proteins at different levels, including 
regulating the transcription of members of the Bcl2/BH3 only family and modulating the 
transcription and expression of inhibitors of apoptosis which inhibit caspases. 
 
1.8.2 Tumour suppressors and cellular senescence 
Cellular senescence is a state of permanent cell-cycle arrest and can be induced by 
oncogenes, DNA damage and cellular stress.  Cellular senescence is regulated by tumour 
suppressors such as Rb and p53 (Lowe et al., 2004).  
1.8.3 Tumour suppressor genes regulate pathways which promote cell growth and survival 
When a cell is proliferating, the cell must generate enough energy to meet the demands of 
proliferation. The ability of a cell to proliferate is therefore regulated by its ability to obtain 
the energy and oxygen required in order to meet the energy demands of proliferation.  In 
cancer cells, changes occur in pathways involved in nutrient uptake and energy metabolism.  
Many tumour suppressors regulate pathways which promote cell growth and survival.  An 
example of this is phosphatidylinositol 3-kinase (PI3K).  Activation of PI3K results in 
activation of Akt and mTOR which plays a part in the modulation of many metabolic 
processes which support cell growth and proliferation (Jones and Thompson, 2009).  
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 1.9 The mTOR signalling pathway. 
 
mTOR functions as serine/threonine kinase and belongs to the phosphoinositide 3-kinase 
related kinase (PIKK) family (Abraham, 2004). mTOR functions as two complexes, known 
as mTOR complex 1 (mTORC1) (comprised of the lethal with sec13 protein 8 (LST8 or 
GβL), proline-rich Akt substrate 40 kDa (PRAS40), and regulatory associated protein of 
mTOR (Raptor))  and mTOR complex 2 (mTORC2) (comprised of GβL, the stress-activated 
protein kinase-interacting protein (Sin1), and the rapamycin-insensitive companion of mTOR 
(rictor)) (Rosner et al., 2008).  PRAS40 inhibits mTORC1 activity, an effect which is 
relieved upon phosphorylation of PRAS40 by Akt (Nascimento and Ouwens, 2009).  Raptor  
binds to mTOR and recruits eukaryotic initiation factor 4E binding protein-1 (4E-BP1) and 
ribosomal p70S6 kinase (p70S6K) which play a part in the regulation of protein translation 
(Nojima et al., 2003).   mTORC1 phosphorylates p70S6K and 4E-BP1, thus promoting 
protein synthesis (Watanabe et al., 2011).  S6K1 is known to phosphorylate ribsosomal 
protein S6 (rpS6), which modulates ribosomes (Rosner et al., 2008).   The FRB domain of 
mTOR binds the FKBP12/rapamycin complex and is required for mTORC1 inhibition (Chen 
et al., 1995)..  The interaction between mTOR and rictor is not inhibited by rapamycin.  Both 
mTORC2, and phosphoinositide-dependent kinase-1 (PDK1), phosphorylate and activate 
Akt.  
 
The mTOR signalling pathway is stimulated by the growth factors insulin and insulin like 
growth factor 1 (IGF1), glucose, and amino acids, and inhibited by stresses such as 
starvation, DNA damage and hypoxia.  In response to these signals, mTOR regulates 
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translation, ribosome biogenesis, metabolism, proliferation, and autophagy in order to 
promote cell growth and survival (Figure 1) (Watanabe et al., 2011). 
mTOR signalling is activated by amino acids (Figure 1).  When amino acids are present, Rag 
small G-proteins bind to Raptor, resulting in mTORC1 being translocated to the membrane 
and the binding of mTORC1 to Rheb.  This interaction results in mTORC1 being activated 
(Sancak et al., 2010).   
The mTORC1 signalling pathway is inhibited in the presence of reactive oxygen species 
(ROS).  This is due to the activation of TSC2 via LKB1 being activated by the cellular 
damage sensor Ataxia-telangiectasia mutated (ATM) and phosphorylation of AMPK.  This 
results in increased autophagic activity (Figure 1) (Alexander et al., 2010).  AMPK is also 
known to phosphorylate Raptor and inhibit mTORC1 (Gwinn et al., 2008).   
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Figure 1.  The mTORC1 and mTORC2 pathways.  mTORC1 is involved in Angiogenesis, 
Autophagy and Translation through the regulation of S6K1, 4EBP1/eIF4E, ULK1 and 
HIF1α.  mTORC2  is involved in cell survival, metabolism and proliferation through the 
regulation of MDM2, GSK3, and FOXO (Sabatini, 2006). 
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mTORC1 signalling is known to be inhibited under conditions of hypoxia.  Hypoxia triggers 
dephosphorylation of mTORC1 and the downstream targets 4E-BP1, p70S6 kinase, and rpS6 
(Figure 1).  Hypoxic inhibition of these targets is dominant to activation via insulin or amino 
acids and may be independent of AMPK phosphorylation.  This response was also thought to 
be dependent on Hypoxia inducible factor 1 (HIF1α) (Arsham et al., 2003) and likely 
involves Redd1 and Redd2.  HIF is known to promote expression of Redd1/2 which activates 
TSC2 via competitive binding for 14-3-3 proteins; leading to inhibition of mTORC1, even 
when Akt is constitutively active (Figure 1) (reviewed in (Dunlop and Tee, 2009)).  Work 
conducted by Li et al. has also suggested that Bcl-2/adenovirus E1B 19-kDa interacting 
protein 3 (BNIP3), a downstream target of HIF1α, inhibits mTORC1 activation by binding to 
Rheb (Li et al., 2007). 
mTORC1 signalling is also inhibited under conditions of reduced ATP levels in order to 
reduce the levels of cellular processes, such as protein synthesis, which are energy 
demanding.  This occurs via activation of AMP-dependent protein kinase (AMPK) via LKB1, 
which phosphorylates and activates TSC2 on Ser1345 and Thr1227, resulting in inhibition of 
mTORC1 (Inoki et al., 2003).  Work conducted by Gwinn et al. has shown that AMPK 
phosphorylates Raptor at Ser792 and Ser722.  This results in induction of the binding of 14-
3-3 proteins to Raptor and is essential for mTORC1 signalling being inhibited (Gwinn et al., 
2008).   
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 1.10 mTOR signalling and cancer. 
 
The PI3K/Akt/mTOR pathway has been shown to be upregulated in a number of human 
cancers.  Studies conducted by Park et al. have also shown that an increased level of mTOR 
signalling is important in the tumourigenesis of bladder cancer.  Furthermore, the 
phosphorylation status of rpS6 (an indicator of mTORC1 activity) has been shown to highly 
correlate with the recurrence, cancer progression and survival of bladder cancer patients 
(Park et al. 2011). 
The PI3K/Akt/mTOR pathway signalling is upregulated in over half of pancreatic cancers.  
Activation of the PI3K/Akt/mTOR pathway reported within pancreatic cancers is associated 
with a poor prognosis (Schlieman et al., 2003; Chadha et al., 2006).  A positive relationship 
between increased phosphorylation of p70S6K which indicates increased levels of mTORC1 
activity, and poor prognosis in patients with breast cancer has also been observed (Shaw and 
Cantley, 2006). 
Results from studies conducted on prostate cancer cells have shown mTORC1 inhibition via 
treatment with the rapalogue, RAD001, may provide potential therapeutic benefit for prostate 
cancer patients when used in combination with other reagents (Wedel et al., 2011). 
Increased levels of the PI3K/Akt/mTOR signalling have also been implicated in the 
development of RCCs, and a correlation has been observed between phosphorylation of 
mTOR and poor prognosis of patients with RCC (Elfiky et al., 2011).  Inhibitors of mTOR 
have been shown to have some effect on the development of RCCs, inhibiting angiogenesis 
and cell proliferation.  Clinical trials investigating whether derivatives of rapamycin may 
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provide therapeutic benefit for patients with RCC have shown that treatment with the 
rapamycin derivatives, temsirolimus and everolimus, significantly inhibited tumour 
progression and prolonged overall survival in metastatic RCC patients with poor prognosis.  
However, there were some RCC patients for whom inhibitors of mTOR did not provide 
therapeutic benefit, revealing that there are variable outcomes with drug treatment (Wysoki, 
2009).  mTORC1 may be a therapeutic target for RCC (Husseinzadeh and Garcia, 2011).  
However work conducted by Elfiky et al. has suggested that targeting both mTOR and PI3K 
has a synergistic effect on the development of RCC, implying that inhibitors which target 
both PI3K and mTOR may provide greater therapeutic benefit for patients with RCC (Elfiky 
et al., 2011). 
PI3K may itself function as an oncogene or be activated by mutations in upstream effectors 
of PI3K such as insulin-like growth factor receptors.  Increased PI3K activity has been shown 
to contribute to tumour development in ovarian and gastrointestinal cancer (Guertin and 
Sabatini, 2007; Chiang and Abraham, 2007; Wullschleger et al., 2006; Jiang and Liu, 2008).  
Akt has also been shown to be upregulated in breast and ovarian cancer (Wullschleger et al., 
2006; Manning and Cantley, 2007; Guertin and Sabatini, 2007).  
 
1.11 Tumour suppressor genes within the mTOR pathway 
There are several other genes within the mTOR pathway which act as Tumour Suppressors.  
Mutations within these genes result in inherited genetic disorders.  These include VHL, 
LKB1, TSC1 and TSC2, NF1 and PTEN.  Mutations in these genes give rise to Von Hippel-
Lindau, Peutz-Jeghers Syndrome, Tuberous sclerosis complex (TSC), Neurofibromatosis and 
Cowden Syndrome, respectively (Figure 2).  mTORC1 signalling is upregulated within these 
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syndromes as a result of loss of function of these upstream tumour suppressor proteins; 
causing aberrant levels of cell proliferation and growth.  Examining the similarities and 
differences between BHD and these other inherited genetic disorders which arise as a result 
of mutations within these genes may prove useful for determining the function of FLCN. 
 
1.11.1 Tuberous Sclerosis Complex. 
BHD patients present with symptoms which are clinically similar to TSC.  TSC arises due to 
mutations within the TSC1 or TSC2 genes which code for the proteins hamartin (TSC1) and 
tuberin (TSC2), which function as tumour suppressors (Figure 2) (Green et al., 1994a; Green 
et al., 1994b).  These mutations within the TSC1 or TSC2 genes result in hamartomas in the 
kidneys, and skin, and pulmonary cysts in a similar manner to that observed in BHD patients; 
as well as hamartomas of the brain, heart and eyes (Gomez et al., 1999).  The TSC1 and 
TSC2 inhibit mTORC1 signalling by acting as a GTPase activating protein (GAP) and 
reverting Rheb (Ras homolog enriched in brain); a potent activator of mTORC1 when bound 
to GTP, to its inactive GDP-bound form (reviewed in Dunlop and Tee, 2009).  The TSC1-
TSC2 complex also activates mTORC2 and thus promotes Akt activation.   Work conducted 
by Tee et al. has revealed that tumours from patients with TSC may arise due to abnormally 
elevated levels of mTORC1 signalling (Tee et al., 2002).  Increased phosphorylation levels of 
ribosomal protein S6 kinase 1 and 4E-BP1 have also been observed in TSC1 and TSC2 
deficient cells which is inhibited by rapamycin; consistent with constitutive activation of 
mTORC1 (Kwiatkowski et al., 2002).  TSC2, along with PTEN and LKB1, is thought to 
regulate HIF and VEGF.  It has therefore been suggested that increased HIF and VEGF levels 
may be a regular feature of inherited hamartoma syndromes. It has even been suggested that 
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part of the tumour suppression function of TSC2 may be it’s regulation of HIF transcriptional 
activity (Brugarolas and Kaelin, 2004).  
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Figure 2.  Tumour suppressors in the mTORC1 signalling pathway 
mTORC1 is regulated by a number of tumour suppressors, including LKB1, NF1, PTEN, and 
TSC1/2.  Loss of function of these tumour suppressors results in the cancer syndromes Peutz-
Jeghers syndrome, Neurofibromatosis, Cowden syndrome, and Tuberous Sclerosis complex 
respectively.  It may be possible that FLCN is another tumour suppressor which regulates the 
mTORC1 signalling pathway, where loss of FLCN function results in Birt-Hogg-Dubé 
syndrome. 
 
1.11.5 Von-Hippel-Lindau disease 
Von-Hippel-Lindau disease (VHL) arises due to mutations within the VHL tumour 
suppressor gene and subsequent loss of function of the VHL protein; resulting in increased 
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stability of HIFα proteins and heightened expression of their gene targets (Krieg et al., 2000).  
VHL is characterised by tumours in the brain, the retina of the eyes, kidneys (clear cell 
carcinomas), adrenal glands, and the pancreas (Rosner et al., 2008). 
 
1.12 Constitutive activation of mTORC1 may also contribute to the development of tumours 
in BHD patients. 
 
Work conducted by van Slegtenhorst et al. has suggested that loss of the yeast BHD 
homologue, LST7, results in inhibition of Tor2 in an opposing manner to that described upon 
loss of TSC, suggesting that LST7 may activate Tor2 and thus be important in the regulation 
of amino acid homeostasis in yeast (van Slegtenhorst et al., 2007).  However, work 
conducted by Baba et al. has shown that the phosphorylation status of downstream mTORC1 
substrates is enhanced upon loss of functional FLCN, indicating that the Akt/mTOR pathway 
is elevated in cells deficient of FLCN (Baba et al., 2008; Baba et al., 2006).  Work conducted 
by Hasumi et al. also suggested that levels of mTORC1 and mTORC2 activity are elevated 
along with increased expression levels of Rictor (a component of mTORC2) in tumours from 
Bhdd/+ mice and human BHD patients (Hasumi et al., 2009).  mTORC2 has been shown to 
phosphorylate and stabilise Akt (Facchinetti et al., 2008), suggesting that it is the activation 
of mTORC2 which is the primary mechanism by which Akt is activated in BHD-deficient 
tumours.  Collectively, these results of these studies imply that FLCN may be part of a 
negative feedback loop which suppresses PI3K-Akt-mTOR signalling (Hasumi et al., 2009).  
Loss of functional FLCN therefore results in increased levels of mTORC2 activity which in 
turn activates Akt and thus mTORC1 signalling.  Results obtained from work conducted by 
Hartman et al. suggested that the increased levels of mTORC1 activation observed in BHD-
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deficient cell lines was not a primary effect of loss of BHD, but mTOR may later be activated 
due to activation of Akt or other upstream kinases which regulate the TSC/Rheb/mTOR 
signalling pathway; in a manner analogous to TSC-deficient cell lines (Hartman et al., 2009).  
These results suggest that FLCN regulates mTORC1 signalling in a context-dependent 
manner, and that the relationship between FLCN and mTOR is highly complicated and 
presumably involves negative feedback mechanisms and cell adaption to loss of FLCN 
function (Piao et al., 2009). 
 
The mTOR signalling pathway is also associated with pathways which have been implicated 
in the development of benign and malignant tumours.  The increased levels of mTOR activity 
observed upon loss of function of FLCN have therefore been implicated in the development 
of melanomas in BHD patients (Cocciolone et al., 2010).  Treatment with rapamycin has also 
been shown to extend survival and inhibit further development of cysts in kidney-specific 
BHD knockout mice exhibiting polycystic kidneys, hyperplasia, and cystic RCC.  These 
results suggest that the phenotypes exhibited by these mice arose as a result of activation of 
the mTOR pathway upon loss of FLCN (Chen et al., 2008).  These data suggest that BHD is 
another tumour suppressor in the mTOR pathway and that abnormally high levels of mTOR-
mediated signalling may contribute to the development of tumours in BHD patients.  
Furthermore FLCN-mTOR signalling may regulate cell growth/proliferation. 
 
1.13 FLCN is differentially phosphorylated by AMPK and mTOR. 
Data from work conducted by Baba et al. revealed that phosphorylation of FLCN was 
partially blocked by rapamycin and amino acid starvation (Baba et al., 2006).  Further work 
conducted by Piao et al. identified Ser62 and Ser302 as phosphorylation sites of FLCN that 
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were differentially regulated by mTORC1.  Downstream kinases of mTORC1, such as S6K1, 
appear to enhance phosphorylation of FLCN at Ser302 (Piao et al., 2009).  Work conducted 
by Piao et al. has revealed that loss of TSC2 via shRNA resulted in phosphorylation of 
FLCN.  Increased phosphorylation of FLCN at Ser62 and Ser302, was observed upon 
expression of Rheb, suggesting that tuberin signalling regulates the phosphorylation of FLCN 
(Piao et al., 2009).  These data suggest that the mTORC1 signalling pathway regulates the 
phosphorylation status FLCN and most likely its tumour suppression function.   
Baba et al. revealed that inhibition of AMPK by adenine 9-β-D-arabinofuranoside (AraA) 
inhibited the phosphorylation of FLCN in UOK257-2 cells and they observed 
phosphorylation of GST-tagged FLCN in vitro AMPK kinase assays.  It is possible that 
FLCN is phosphorylated at multiple, as yet unidentified, residues, by both mTORC1 and 
AMPK.  Further work conducted by Wang et al. also revealed that the phosphorylation status 
of FLCN at the Ser62 site is enhanced by an AMPK-related pathway (Wang et al., 2010).  
AMPK has also been shown to bind to both FNIP1 and FNIP2 (Takagi et al., 2008; Baba et 
al., 2006), and enhance the phosphorylation status of FNIP2 (Takagi et al., 2008).  Work 
conducted by Piao et al. also suggested that phosphorylation of FLCN regulates the formation 
of the FLCN/AMPK complex (Piao et al., 2009).  As AMPK is known to inhibit mTORC1 
signalling by phosphorylating and activating TSC2, and FLCN has been shown to be 
phosphorylated by AMPK and mTOR, it has been suggested that phosphorylation of FLCN 
may be associated with feedback mechanisms which mTOR signalling pathways (Piao et al., 
2009). 
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 1.14 AMPK and cancer 
AMPK functions as an energy sensor and provides metabolic changes in order to adapt to 
conditions of depleted ATP (Yun et al., 2005).  AMPK modulates activity of acetyl CoA 
carboxylase (ACC), involved in fatty acid synthesis, and mTOR under conditions of elevated 
AMP levels in order to reduce the levels of cellular processes which are energy demanding, 
thus conserving ATP for survival.  AMPK has therefore been shown to be upregulated in a 
number of cancers (Chhipa et al., 2011), and has been shown to inhibit apoptosis under 
conditions of glucose deprivation in cancer cells (Luo et al., 2005).  However, it has also 
been suggested that arberrant levels of AMPK activity may inhibit the growth and survival of 
cancer cells due to the inhibition of mTOR and fatty acid synthesis (Luo et al., 2005). 
 
1.15 Both AMPK and mTOR positively regulate mitochondrial biogenesis 
 
Mitochondria are fundamental to cellular metabolism and energy production. Oxidation of 
fatty acids and glucose produces high-energy electrons that subsequently enter the electron 
transport chain within the intermembrane space of the mitochondria.  Energy from these 
reduced electrons is converted into a proton gradient which is used by the mitochondrion to 
generate ATP (Moiseeva et al., 2009).  Mitochondria also play a part in cell death pathways 
such as apoptosis and play a critical role in cellular senescence in response to oncogenic 
genes.  It has been shown that the activation of oncogenic genes results in increased levels of 
mitochondrial DNA, mitochondrial mass and mitochondrial superoxide production.  These 
changes subsequently lead to further elevated levels of ROS production, decreased 
mitochondrial membrane potential and the activation of AMPK (Moiseeva et al., 2009).   It 
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has been shown that elevated levels of AMPK activity results in increased levels of 
mitochondrial biogenesis due to activation of peroxisome proliferator-activated receptor 
gamma, coactivator 1 alpha (PGC1α) (Zong et al., 2002).  PGC1α interacts with and 
coactivates many nuclear and nonnuclear receptors directly responsible for the transcription 
and replication of mitochondrial DNA (Bogacka et al., 2005).  PGC1α is therefore able to 
enhance mitochondrial biogenesis and oxidative function. 
 
It has also been shown that mTOR and Raptor associate with ying yang 1 (YY1) and mTOR 
has been shown to regulate mitochondrial oxidative function by regulating the YY1 –PGC1α 
transcriptional complex (Cunningham et al., 2007).  
 
1.16 Both AMPK and mTOR positively regulate Hypoxia Inducible Factor transcriptional 
activity 
 
Another way in which AMPK provides changes to cellular metabolism in order for cells to be 
able to adapt to low cellular ATP levels is by enhancing the transcriptional activity of HIF-
mediated transcription through a signalling pathway independent of the PI3K/Akt (Lee et al., 
2003).  HIF1α subsequently increases the transcription of several genes in order to provide 
adaptations which enhance metabolism under hypoxic conditions.  HIF is also able to 
enhance expression of genes which regulate cell survival and proliferation (Maxwell, 2005).  
Aberrant HIF activity levels have therefore been found to contribute to tumour development 
in several inherited diseases that give rise to RCCs (Maxwell, 2005).   
mTOR has also been shown to positively regulate HIF transcriptional activity.  This may be 
via modulation of the interaction between HIF1α and Raptor (Land and Tee, 2007).  
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However, it may also be possible that mTORC1 regulates HIF indirectly via activation of 
S6K (Jefferies et al., 1994).  mTORs ability to activate HIF is considered an important part of 
mTORs role in the tumourigenesis of RCCs due to HIFs ability to enhance transcription of 
genes involved in cellular processes such as angiogenesis (Elfiky et al., 2011).  This has lead 
to investigation into the effects of inhibitors of mTOR and VEGF, a HIF transcriptional target 
involved in angiogenesis, however the results of these investigations have not confirmed this 
as a viable therapeutic target for patients with RCC (Husseinzadeh and Garcia, 2011). 
 
1.17 AMPK activation results in increased autophagic activity. 
Autophagy is a process by which cells adapt to stress via the catabolism of unnecessary 
structures such as organelles and proteins, and has been shown to provide a protective 
function for tumour cells when moderately elevated (Schönthal et al., 2009).  AMPK may 
conserve ATP for survival via activation of autophagy, as amino acids are recycled from 
organelles catabolised during the autophagic process.  Work conducted by Chhippa et al. has 
shown that autophagy induced by activation of AMPK is a cell survival mechanism within 
androgen-dependent prostate cancer cells (Chhipa et al., 2011).  AMPK has been shown to 
bind to UNC-51-like kinase 1 (ULK1) at the proline-serine rich (PS) domain; which is 
necessary for ULK1-mediated autophagy.  When energy levels are depleted in a cell, 
activated AMPK has also been shown to recruit 14-3-3 proteins to Raptor.  This interaction 
between 14-3-3 proteins and Raptor results in inhibition of mTORC1 and thus its activity in 
the ULK1 complex (Lee et al., 2010), resulting in activation of autophagy.  mTORC1 has 
been show to negatively regulate autophagy via the ULK1–Atg13–FIP200 complex (Figure 
3) (Hosokawa et al., 2009).  Increased levels of mTORC1 activity have been shown to result 
in decreased levels of autophagic activity in TSC2-deficient cells (Parkhitko et al., 2011) and 
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inhibition of mTORC1 via treatment with rapamycin has been shown to result in elevated 
levels of autophagic activity (Turcotte and Giaccia, 2010).  Treatment with a combination of 
rapamycin and the reagent Chloroquine has been shown to have a synergistic effect on 
decreasing tumour size in TSC2-deficient tumours (Parkhitko et al., 2011).   
AMPK is also able to activate autophagy by increasing the transcriptional activity of HIF1α. 
HIF1α is able to mediate autophagy via the induction of BNIP3 (Bellot et al., 2009).  
Multiple studies have shown that BNIP3 induces autophagy in response to elevated levels of 
reactive oxygen species and decreased mitochondrial membrane potential and which would 
result in cell death (Burton et al., 2009). 
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Figure 3. Inhibition of the autophagic pathway via mTORC1 inhibition of the ULK1 complex 
mTORC1 has been show to negatively regulate autophagy via the UNC-51-like kinase 1 
(ULK1) –Atg13–FIP200 complex resulting in reduced formation of Autophagosomes and 
lysosomes (Ravikumar et al. 2010). 
 
39 
 
1.18 Renal cell carcinomas. 
 
RCCs can be divided into various subcategories.  These are clear cell carcinomas, 
chromophobe carcinomas, oncocytomas, type 1 papillary or hybrids of the various categories 
(Stec et al., 2009), where all these subtypes can occur in BHD patients. 
1.18.1 Clear cell renal cell carcinomas 
Clear cell RCC typically derive from the proximal tubular epithelium of the kidney and is 
characterised by a clear cytoplasm with a large prominent nucleus.  Clear cell RCCs are the 
most common subtype of malignant RCCs (Störkel et al., 1997).  Clear cell RCCs are also 
often exhibited by VHL patients (Clark, 2009). 
1.18.2 Chromophobe renal cell carcinomas.  
Chromophobe RCCs are rarer than either clear cell or papillary RCCS, accounting for 
approximately 5% of RCCs, and typically derive from cells of the collecting duct.  
Chromophobe RCCs are characterised by abundant cytoplasm and binucleation (Amin et al., 
1997).  
1.18.3 Papillary renal cell carcinomas 
Papillary RCCs are the second most common type of RCC, with approximately 10-15% of 
RCC patients presenting with this subtype.  Papillary RCCs are usually derived from the 
distal convoluted tubules.  Work conducted by Schmidt et al. observed that papillary RCCs 
have mutations within the MET proto-oncogene, resulting in activation of C-MET (Schmidt 
et al., 1997). 
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1.18.4 Oncocytomas 
Renal oncocytomas are benign tumours within the kidney and are characterized by dense 
accumulation of mitochondria.  It has been observed that mitochondrial DNA levels and the 
activity of complexes which form the electron transport chain (oxidative phosphorylation) of 
the mitochondria are increased in renal oncocytomas as a result of this accumulation of 
mitochondria (Simonet et al., 2003).   
1.18.5 Renal cell carcinoma syndromes, mitochondrial dysfunction and aberrant HIF 
signalling. 
Many cancer syndromes which give rise to RCCs exhibit decreased mitochondrial function, 
aberrant levels of HIF activity, or a combination of both.  An example of this is Hereditary 
Leiomyomatosis Renal Cell Carcinoma (HLRCC), which arises due to mutations within the 
gene coding for Fumarate hydratase (FH), an enzyme involved in the Tricarboxylic acid 
(TCA) cycle (otherwise known as the Krebs cycle).  Patients with HLRCC may develop type 
2 papillary and clear cell RCCs.  Loss of function of FH results in mitochondrial dysfunction 
due to lack of ability to generate ATP via aerobic respiration involving the Krebs cycle and 
the electron transport chain within the mitochondria.  Kidney tumour cells from HLRCC 
patients also exhibit aberrant HIF signalling (Isaacs et al., 2005; Sudarshan et al., 2011). 
If cells are unable to generate ATP through the electron transport chain, a shift in their 
metabolism towards ATP generation by glycolysis occurs, thus resulting in cells exhibiting 
the Warburg effect (Fosslein, 2008).  The term Warburg effect refers to a metabolic shift 
towards increased glucose uptake, lactate production and decreased levels of respiration that 
occurs in some cancer cells even when oxygen supplies are adequate (Semenza, 2007).  In 
clear cell renal carcinoma, aberrant  levels HIF activity have also been shown to result in 
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increased transcription of genes involved in glucose uptake, glycolysis and the production of 
lactate; thus mediating the Warburg effect (Semenza, 2007). 
 
1.19 Cyst formation 
1.19.1 Polycystic kidney disease 
Autosomal dominant polycystic kidney disease (ADPKD), the most widespread type of 
polycystic kidney disease, occurs due to mutations within the PKD1 gene encoding for 
polycystin 1 (PC1), and is characterised by renal cysts in a similar manner to TSC.  ADPKD 
patients can also exhibit mutations in TSC2 as well as PKD1 due to the fact that the two 
genes are next to each other (contiguous gene syndrome).  It has been suggested that PKD1 
and TSC2 may have a synergistic effect as patients that exhibit mutations in both genes 
present with a more severe form of ADPKD at an earlier age than patients which only exhibit 
mutations in PKD1.  It has been revealed that the localisation of PC1 to the plasma 
membrane is dependent on TSC2 (Kleymenova et al., 2001) and PC1 is able to regulate 
mTORC1 signalling via interaction with TSC2 and mTOR (Shillingford et al., 2006).   
As previously discussed, BHD patients present with lungs cysts and polycystic kidneys (Baba 
et al., 2008).  A study conducted by Torres et al. also suggested that elevated levels of 
proliferation, apoptosis and loss of polarity within the cystic epithelia all contribute to 
cystogenesis and development (Torres, 2010). 
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1.19.1 Ciliopathy and renal cyst formation 
Cilia are hair-like organelles which are involved in the detection and management of external 
signals (Hildebrandt et al., 2011).  They are also key co-ordinators of cellular signalling 
functions within a cell during development and the maintenance of homeostasis in normal 
tissue (Satir et al., 2010; Goetz and Anderson, 2010).  Primary cilia regulate several 
signalling pathways (Simons et al., 2005; Christiensen et al., 2008). Primary cilia are also 
thought to regulate mTORC1 signalling (Boehlke et al., 2010).  Mutations within proteins 
such as polycystin 1 and polycystin 2, which are located in the primary cilia and are involved 
in Ca2+ uptake, are observed in many diseases which present with cyst formation (Pazour et 
al., 2002; Yoder et al., 2002).   Data produced by Thoma et al revealed that VHL, involved in 
oxygen sensing, and GSK3β may function together to maintain cilia, and that loss of function 
of these genes results in disruption of the maintenance of the cilia, thus promoting cyst 
formation (Thoma et al., 2007).  Given that cysts also occur in the lungs and kidneys of BHD 
patients, it is possible that BHD might also be a ciliopathy. 
1.19.2 mTOR signalling and cystogenesis.  
Aberrant mTOR signalling is observed in many diseases which present with renal cyst 
formation, including BHD.  It has been shown that aberrant mTOR signalling results in 
changes in the activity levels of processes within a cell which promote cystogenesis such as 
protein synthesis.  Polycystin 1 has been shown to interact with TSC2 which, when 
complexed with TSC1, regulates mTORC1 activity.  Furthermore, it has been shown that 
TSC1 localises to the basal body of the primary cilium (Hartman et al., 2009).  TSC1, TSC2, 
and polycystin 1 have also been shown be involved in the maintenance of cell polarity in pre-
cystic renal and hepatic cells, and important for the prevention of cystogenesis (Bonnet et al., 
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2009).  LKB1, another tumour suppressor protein in the mTOR signalling pathway, is also 
localised to the primary cilia.   
Renal primary cilia monitor urinary flow through the tubules of the kidney via polycystin 1 
and polycystin 2 (Boehlke et al., 2010).  Work conducted by Boehlke et al. has also shown 
that bending of the cilia by urine flow results in inhibition of mTORC1 (Boehlke et al., 
2010).  As aberrant levels of mTORC1 signalling appears to be involved in the 
tumourigenesis exhibited in BHD patients, and BHD patients present with polycystic 
kidneys, it may be possible that ciliopathy also occur upon loss of functional FLCN (Baba et 
al., 2008; Baba, et al., 2006).  
1.20 Aims and Objectives of this Project 
There are 3 main aims of this project: 
(i) To examine the effect of  FLCN on mitochondrial biogenesis 
(ii) To investigate the effect of FLCN on HIF. 
(iii) To examine autophagy in the context of BHD 
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 2 The effect of loss of functional Folliculin on HIF transcriptional activity 
 
2.1 Introduction 
 
Hypoxia inducible factor (HIF) exists as a complex containing α and β subunits.  HIF1α and 
HIF2α function as heterodimers and are activated under conditions of low oxygen.  Under 
normoxic conditions, the HIFα subunits are hydroxylated at three sites; an asparagine residue 
which is located in the C-terminal transactivation domain (C-TAD) and two proline residues 
that are located in the oxygen dependent degradation domain (ODDD).  The ODDD of HIF 
contains proline residues which are hydroxylated by prolyl hydroxylases.  This provides the 
recognition signal to allow for capture of HIF by a specific E3 ligase protein, VHL.  This 
leads to the polyubiquitylation of the HIFα proteins and their subsequent degradation by the 
proteasome.  The asparagine residue on the C-terminus is hydroxylated by a HIF asparagine 
hydroxylase.  It is this modification which prevents the recruitment of CBP/P300 and controls 
HIF transcriptional activity (Figure 4) (Maxwell, 2005).  Loss of functional VHL protein 
leads to the HIFα proteins being stabilised and subsequent increased levels of HIF mediated 
gene expression (Semenza, 2004).  
HIF1α and HIF2α function as transcription factors and enhance the expression of over 100 
genes involved in processes such as angiogenesis; as well as glucose uptake and metabolism.  
HIF activation also plays an important part in cell proliferation and survival (Maxwell, 2005).  
HIF1α is known to enhance the gene expression of BNIP3 involved in autophagy and cell 
death, Beclin-1 which is involved in autophagy, and vascular endothelial growth factor 
(VEGF) which is involved in angiogenesis (Figure 5). 
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 HIF-1α is over-expressed in a number of tumour types, including breast, pancreatic, colon, 
lung, gastric, prostate, ovarian, and skin cancers.  HIF also appears to have a crucial role in 
several inherited diseases that give rise to RCCs (Maxwell, 2005) including VHL, HLRCC 
and TSC (Krieg et al., 2000).  HLRCC is another hereditary disorder which gives rise to 
RCC.  HLRCC arises as a result of mutations in the Fumarate Hydratase (FH) gene which 
results in inhibition of prolyl hydroxylases and the stabilisation of HIF1α protein (Pollard et 
al., 2005).  Further work conducted by Sudarshan et al. has also suggested that aberrant HIF 
signalling may also occur upon loss of FH via a VHL-independent mechanism (Sudarshan et 
al., 2011).  HLRCC patients also exhibit skin lesions similar to those observed in BHD 
patients. 
 
HIF is also thought to play a part in the growth of tumours in Tuberous Sclerosis Complex 
(TSC) patients (Liu et al., 2003).  TSC arises from mutations in either the TSC1 or TSC2 
genes.  The proteins encoded by these genes form a complex which negatively regulates 
mTORC1 (Brugarolas et al., 2003).  Activation of mTORC1 results in increased transcription 
of HIF target proteins and increased HIF-mediated transcriptional activity (Land and Tee, 
2007).  TSC2-deficient cells exhibit increased levels of mTORC1 activity and increased HIF 
activity compared to those expressing functional TSC2 which was reversed upon treatment 
with the mTOR inhibitor rapamycin (Land and Tee, 2007).  TSC patients exhibit overlapping 
characteristics to BHD patients; including benign tumours (called harmatomas) in the skin, 
kidneys and lung. 
 
mTOR inhibition has been shown to significantly reduce expression levels of HIFα protein in 
most cell types (Knaup et al., 2009).  However; the exact mechanism as to how HIF is 
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regulated by mTOR remains unclear.  Studies conducted by Land and Tee revealed that 
HIF1α interacts with Raptor.  This interaction requires an mTOR signaling (TOS) motif 
which is located in the N-terminus of HIF1α.  HIF1α is unable to bind to its co activator 
CBP/p300 when this TOS motif is absent; resulting in decreased levels of HIF activity under 
hypoxic conditions (Land and Tee, 2007).  This work implies that HIF1α is a direct mTORC1 
substrate.  However it has also been suggested that mTORC1 regulates HIF indirectly via 
S6K; a well characterised mTORC1 substrate (Dunlop and Tee, 2009).   
 
It has also been shown that the translation of mRNAs containing a 5′-terminal tract of 
polypyrimidines (5′-TOP) and the phosphorylation of ribosomal protein S6 is selectively 
repressed upon treatment with rapamycin.  Therefore, it was hypothesised that 40S ribosomes 
containing rpS6 may selectively recognise these terminal pyrimidine tract mRNA motifs or 
proteins which bind to it and mediate their translation.  Phosphorylation of rpS6 by S6K1 
would therefore result in increased translation of 5'TOP mRNAs (Jefferies et al., 1994).  The 
5′-untranslated region (UTR) of HIF-1α has pyrimidine tracts downstream of nucleotide + 32; 
suggesting that translation of HIF1α may also be regulated as a 5'TOP message (Iyer et al., 
1998).  However work conducted by Stolovich et al. suggested that S6K1 activation is not 
required for the translation of 5'TOP mRNAs (Stolovich et al., 2002).  The mechanism as to 
how 5′-TOP mRNA translation is regulated by mTORC1 and whether HIF-1α mRNA is 
regulated by mTORC1 as a 5′-TOP message therefore remains unclear (Dunlop and Tee, 
2009). 
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Figure 4. The regulation of the HIF complex by oxygen through hydroxylation of the HIFα 
subunit 
In the presence of oxygen, the asparagine residue in the C terminal transactivation domain 
(CTAD) and the prolyl residues in the ODDD are hydroxylated.  This allows the HIF protein 
to be captured by VHL resulting in subsequent ubiquitylation and proteosomal degradation of 
HIF (Maxwell, 2005). 
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Figure 5.  HIF-1 regulates the transcription of genes involved in autophagy, cell death and 
angiogenesis.   
Under conditions of hypoxia, HIF-1 regulates the transcription of BNIP3 which is involved in 
the regulation of cell death and autophagy, Beclin 1 which is involved in the regulation of 
autophagy while VEGF is involved in angiogenesis and Glut 1 is involved in glycolysis 
(Melillo, 2010). 
 
 
Given that HIF appears to have a crucial role in the pathology associated with other inherited 
cancer syndromes which give rise to RCC, and have overlapping or similar clinical symptoms 
to those exhibited in BHD patients, I wanted to examine whether FLCN deficient cells had 
increased levels of HIF-mediated gene expression that would result in a cancer phenotype.  In 
this chapter, HIF-mediated signalling events are analysed within cell lines deficient in 
functional BHD. 
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2.2 Results 
2.2.1 Cells lacking functional FLCN have increased levels of HIF-mediated transcription. 
In order to determine whether HIF-mediated gene-expression was upregulated within cells 
deficient in FLCN, the mRNA levels of downstream transcriptional targets of HIF were 
compared within the UOK257 cell line and the UOK257-2 cell line.  The mRNA levels of 
BNIP3 (a HIF1α transcriptional target, (Figure 6A) ( Guo et al., 2001)), CCND1 (a HIF2α 
transcriptional target (Figure 6B) (Maxwell, 2005)) and VEGF-A (a transcriptional target of 
both HIF1α and HIF2α (Figure 6C) (Maxwell, 2005)) were measured using RT-PCR.  The 
results suggested that, under conditions of normoxia and hypoxia, there is a significant 
increase in the transcription of genes which are regulated by HIF1α and HIF2α in the FLCN-
deficient UOK257 cells compared to the UOK257-2 cells.  I also observed increased 
expression of HIF1α and HIF2α transcriptional targets in the presence of normal levels of 
oxygen.  The results also suggested that the mRNA levels of BNIP3 (Figure 6B) and CCND1 
(Figure 6C) were inhibited under hypoxic conditions in the FLCN-deficient UOK257 cells 
when treated with the specific mTORC1 inhibitor, rapamycin.  Therefore mTORC1 may play 
a role in the upregulation of HIF-mediated transcription in FLCN-deficient UOK257 cells.  
However, treatment of FLCN-deficient UOK257 cells with rapamycin did not appear to 
result in a decrease in the mRNA levels of VEGF-A (Figure 6C).  Interestingly, under 
conditions of both normoxia and hypoxia, only very low mRNA levels were observed for 
BNIP3, CCND1 and VEGF-A (Figure 6A, Figure 6B, and Figure 6C respectively) were 
detected in the UOK257-2 cells under conditions of both normoxia and hypoxia.  In fact, 
these data show no increase in the CCND1 and VEGF-A mRNA levels in the UOK257-2 
cells under normoxic conditions compared to hypoxic conditions, suggesting that when 
FLCN is overexpressed, this hypoxic response is lost.  No difference in VEGF-A mRNA 
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levels was observed under conditions of rapamycin treatment, suggesting that the elevated 
levels of VEGF-A gene transcripton in these cells lacking FLCN is rapamycin insensitive. 
 
The mRNA levels of HIF transcriptional targets which regulate the metabolism of glucose 
were also analysed; glucose transporter 1 (GLUT1) (Figure 6D) and glucose-6-phosphate 
dehydrogenase 1 (G6PD1) (Figure 6E).  GLUT1 is involved with the uptake of glucose into 
the cell while G6PD1 helps maintain cellular redox homeostasis via the pentose phosphate 
pathway.  Increased levels of both GLUT1 and G6PD1 mRNA were observed in the FLCN-
deficient UOK257 cells under conditions of both normoxia and hypoxia.  Treatment of either 
cell line with rapamycin did not result in a difference in mRNA levels of GLUT1, suggesting 
that transcription of GLUT1 (like VEGF-A) is rapamycin insensitive.  Higher levels of 
GLUT1 mRNA suggest that there are likely to be higher levels of glucose uptake in the 
UOK257 cells and that these cells may be more glucose dependent than the UOK257-2 cells. 
 
To confirm that loss of functional FLCN causes increased protein expression of downstream 
HIF transcriptional targets, the total protein levels of CCND1, BNIP3, GLUT1, and VEGF-A 
were analysed via western blot (Figure 6F).  I observed an increase in BNIP3, VEGF-A and 
GLUT1 protein levels in the UOK257 cells under conditions of normoxia and hypoxia when 
compared to the UOK257-2 cells.  Increased protein levels of CCND1were also observed in 
the FLCN-deficient UOK257 cells compared to the UOK257-2 cells under conditions of 
hypoxia. 
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Figure 6. HIF transcriptional activity is negatively regulated upon expression of FLCN.   
The levels of BNIP3 mRNA (A), CCND1 mRNA (B), VEGF mRNA (c), GLUT1 mRNA 
(D), and G6PD1 mRNA (E) were determined within UOK257 and UOK257-2 cell lines 
maintained in 21% or 1% oxygen and treated with 50nm rapamycin where indicated by RT-
PCR.  The levels of mRNA for each of the genes were standardised against β-Actin mRNA. n 
= 3.  * = significant at the 0.05 significance level. ** = significant at the 0.01 significance 
level.  (F) Western blot analyses were performed on cell lysates prepared from UOK257 and 
UOK257-2 cells maintained in 21% or 1% oxygen where indicated.  Protein levels of 
Folliculin, BNIP3, VEGF-A, GLUT1, CCND1, and β-Actin were determined.  
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2.2.2 Loss of functional FLCN in UOK257 cells does not affect HIF1α or HIF2α protein or 
mRNA levels 
To establish if HIF1α and HIF2α are regulated by BHD at the gene-expression level, HIF1α 
mRNA levels (Figure 7A) and HIF2α mRNA levels (Figure 7B) were compared within the 
UOK257 and UOK257-2 cell lines using RT-PCR.  Under conditions of both normoxia and 
hypoxia no significant difference in the mRNA levels of HIF1α was observed between the 
UOK257 and UOK257-2 cell lines.  A significant increase in HIF2α mRNA levels was 
observed when cells were subjected to hypoxia; however FLCN did not appear to regulate 
this increase.  Li et al. also observed that hypoxic conditions resulted in an increase in HIF2α 
mRNA levels in glioma stem cells but HIF1α mRNA levels were unaffected (Li et al., 2009).  
When the protein levels of both HIF1α and HIF2α were analysed under normoxic and 
hypoxic conditions via western blot, an accumulation of HIF1α and HIF2α protein under 
conditions of hypoxia was observed in the UOK257 and UOK257-2 cells (Figure 7C).  In 
both of the cell lines, the accumulation of HIF1α protein was to a similar level; however there 
was an increased level of HIF2α protein in the UOK257-2 cells under hypoxic conditions. 
 
The effect of over-expression of FLCN on HIF activity was further analysed by transfecting 
FLCN-deficient UOK257 cells with a luciferase reporter construct containing 7x HIF 
response elements (HRE), together with either Flag-tagged BHD or pRK7 empty vector.  A 
higher level of HIF activity was observed in the FLCN-deficient cells (lane 1, Figure 7D) 
which was decreased when the cells were transfected with BHD (Lane 2, Figure 7D).  
Rapamycin did not appear to repress HIF activity to the same extent as FLCN (Lanes 3 and 4, 
Figure 7D).  Together, these data imply that over-expression of FLCN results in impaired 
HIF transcriptional activity rather than affecting the protein levels of HIF1α or HIF2α either 
through protein stability or gene-expression. 
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 Figure 7. Increased levels of HIF1α and HIF2α – mediated transcription in FLCN-deficient 
cells  
 (A) HIF1α and (B) HIF2α mRNA levels were compared within UOK257 and UOK257-2 
cells maintained under normoxic (21%) and hypoxic conditions (1%) overnight, where 
indicated, by RT-PCR.  mRNA levels were standardised against β-Actin mRNA. n = 3.  (C) 
Western blot analyses were performed on cell lysates obtained from UOK257 and UOK257-2 
cells maintained under normoxic (21%) and hypoxic (1%) conditions and protein expression 
levels of HIF1α and HIF2α were determined.  (D)  BHD- UOK257 cells transiently 
transfected with a HIF luciferase reporter construct containing 7x HIF response elements and 
either Flag-tagged BHD or pRK7 empty vector were maintained in hypoxia (1%) and treated 
with 50nm rapamycin for 24h where indicated. Levels of luminescence are representative of 
levels of luciferase and therefore HIF transcriptional activity. Western blot analyses were 
performed to determine protein levels of Folliculin, S6, and S6 (P-S235/236) were 
determined. n = 3.   
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2.2.3 HIF activity is enhanced upon BHD knockdown by small hairpin (sh)RNA under 
hypoxic conditons 
To verify the results obtained from the experiments conducted in the UOK257 cell lines, 
another model was tested where endogenous BHD is knocked down by small hairpin (sh) 
RNA.  The levels of HIF1α and HIF2α protein were determined along with HIF activity 
levels within the human kidney cancer cell line, ACHN, which had been stably transfected 
with either FLCN shRNA (BHD-) or scrambled shRNA (BHD+) (a kind gift from Arnim 
Pause).   Protein levels of HIF1α and HIF2α within the ACHN BHD+ and BHD- cell lines 
under normoxic and hypoxic conditions were also analysed via western blot.  These data 
showed that knockdown of BHD did not enhance the rise in HIF1α and HIF2α protein levels 
under hypoxic conditions (Figure 8a).   
However, when HIF activity was determined by transfecting BHD+ and BHD- ACHN cells 
with a luciferase reporter construct containing 7x HIF response elements a threefold increase 
in HIF activity in the BHD- ACHN cells was observed compared to those transfected with 
BHD (Figure 8B).  Further confirmation that HIF transcriptional activity levels were 
upregulated in ACHN cells devoid of FLCN was obtained using RT-PCR by analysing 
VEGF-A mRNA levels within BHD+ and BHD- ACHN cells (Figure 8C).  These results 
suggested that BHD- ACHN cells have increased levels of VEGF-A mRNA when compared 
to the BHD+ ACHN cells.  Collectively, these data support the data from the UOK257 cells 
suggesting that HIF activity under hypoxic conditions is enhanced upon loss of BHD.   
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Figure 8. HIF transcriptional activity is upregulated in ACHN cells upon loss of BHD via 
shRNA. 
 (A) Western blot analyses were performed on cell lysates prepared from ACHN cells which 
have been stably transfected with BHD shRNA (BHD-) or scrambled shRNA (BHD+) and 
maintained under normoxic (21%) and hypoxic (1%) conditions.  Protein expression levels of 
HIF1α and HIF2α were determined.  (B)  ACHN cells stably transfected with scrambled 
shRNA (BHD+) or BHD shRNA (BHD-) were transiently transfected with a HIF luciferase 
reporter construct containing 7x HIF response elements and a renilla control under normoxic 
(21%) and hypoxic (1%) conditions where indicated. Levels of luminescence are 
representative of levels of luciferase and therefore HIF transcriptional activity. Western blot 
analyses were performed and protein levels of Folliculin were determined. n = 3.  (C) The 
mRNA levels of VEGF-A were compared within ACHN cells stably transfected with 
scrambled shRNA (BHD+) or BHD shRNA (BHD-), maintained under normoxic (21%) and 
hypoxic (1%) conditions overnight, and treated with 50nm rapamycin where indicated, by 
RT-PCR.  mRNA levels were standardised against β-Actin mRNA. n = 3.  * = significant at 
the 0.05 significance level. ** = significant at the 0.01 significance level. 
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 To support the work conducted using the UOK257 and ACHN cell lines HIF activity and 
protein levels were analysed in two other cell lines.  HIF activity was analysed within BHD+/+  
and BHD-/- Mouse Embryonic Fibroblasts (MEFs) (a kind gift from Prof. Arnim Pause) by 
transfecting BHD+/+  and BHD-/- MEF cells with a luciferase reporter construct containing 7x 
HIF response elements.  An increase in HIF activity was apparent in the BHD-/- MEF cell line 
(Figure 9a).  The mRNA levels of BNIP3 (Figure 9B) within the BHD+/+ and BHD-/- MEF 
cells were also analysed using RT-PCR.  These results suggested that BHD-/- deficient MEF 
cells have increased levels of BNIP3 mRNA compared to the BHD+/+ MEF cells.  This data 
was consistent with increased HIF activity levels in the BHD-/- MEF cells observed in Figure 
9a. 
 
HIF activity was also analysed in Human Kidney 2 (HK2) cells (a kind gift from Prof. 
Maurice Van Steensel's lab) which had been stably transfected with either scrambled shRNA 
(BHD+) or BHD shRNA (BHD-).   BHD+ and BHD- HK2 cells were transfected with a 
luciferase reporter construct containing 7x HIF response elements.  An increase in HIF 
activity in the BHD- HK2 cells compared to the BHD+ HK2 cells was observed (Figure 10a).  
Protein levels of VEGF-A and BNIP3 (Figure 10B) were also analysed within BHD+ and 
BHD- HK2 cells under hypoxic conditions via western blot.  These results suggest that BHD-
deficient HK2 cells have increased protein expression of VEGF-A and BNIP3 protein.  These 
data supported the increased levels of HIF activity in the BHD- HK2 cells observed in Figure 
5a; and support the notion that HIF activity under hypoxic conditions is enhanced upon loss 
of FLCN. 
58 
 
020
40
60
80
100
120
140
+-
+- - +
-+Rap
A
BHD
H
IF
 a
ct
iv
ity
+ -BHD
B
N
IP
3 
m
R
N
A 
Le
ve
ls
B
MEF
cells
MEF
cells
*
*
 
S6(P-S235/236)
S6
Folliculin
1 2 3 4lane
Β-Actin
 
 
Figure 9. HIF1α transcriptional activity is upregulated in BHD-/- MEF cells.   
(A)  BHD+/+ and BHD-/- MEF cells were transiently transfected with a HIF luciferase reporter 
construct containing 7x HIF response elements and a renilla control under hypoxic (1%) 
conditions and treated with 50nm rapamycin where indicated. Levels of luminescence are 
representative of levels of luciferase and therefore HIF transcriptional activity. Western blot 
analyses were performed and protein levels of Folliculin, S6, and S6 (P-S235/236) were 
determined. n = 3.  (B) The mRNA levels of BNIP3 were compared within BHD+/+ and BHD-
/- MEF cells maintained in hypoxia (1%) overnight by RT-PCR.  mRNA levels were 
standardised against β-Actin mRNA. n = 3.  * = significant at the 0.05 significance level. ** 
= significant at the 0.01 significance level. 
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 Figure 10. HIF transcriptional activity is upregulated in HK2 cells upon loss of BHD.   
(A) HK2 cells stably transfected with BHD shRNA (BHD-) or scrambled shRNA (BHD+) 
were transiently transfected with a HIF luciferase reporter construct containing 7x HIF 
response elements and a renilla control under hypoxic (1%) conditions and treated with 50nm 
rapamycin where indicated. Levels of luminescence are representative of levels of luciferase 
and therefore HIF transcriptional activity. Western blot analyses were peformed and protein 
levels of Folliculin, S6, and S6 (P-S235/236) were determined. n = 3.  * = significant at the 
0.05 significance level. ** = significant at the 0.01 significance level.   (B) Western blot 
analyses were performed on cell lysates prepared from HK2 cells which had been stably 
transfected with scrambled shRNA (BHD+) or BHD shRNA (BHD-) and maintained under 
hypoxic (1%) conditions.  Protein expression levels of VEGF-A, BNIP3, Folliculin and β-
Actin were determined.   
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2.2.4 UOK257 cells exhibit a metabolic profile which resembles the ‘Warburg effect’ 
As the work conducted on multiple cell lines shows that loss of functional FLCN results in 
increased HIF activity, it was hypothesised that energy metabolism would also be modulated 
within these cells due to the increase in HIF activity.  As part of this study, work was 
conducted by Dr. Andrew Tee into determining the activity levels of a series of metabolic 
enzymes (shown in Figure 11a) within the UOK257 cell lines.  Enzymes analysed were 
involved in the Krebs cycle, fatty acid oxidation as well as glucose metabolism.  These data 
revealed no significant differences in the activity of hexokinase between the UOK257, 
UOK257-2, and HEK293 cell lines (representative of a 'normal' human kidney cell line) 
(Figure 11B).  However increased activity levels of the enzymes Pyruvate kinase (Figure 
11C) and Lactate dehydrogenase (LDH) (Figure 11D) was observed in the FLCN-deficient 
UOK257 cell line.  These increased levels of LDH and Pyruvate kinase activity within 
FLCN-deficient cells should lead to an increase in L-lactate production.   
An increase in 3-hydroxy-acyl- CoA was also observed in the FLCN-deficient UOK257 cells 
(Figure 11E), implying that fatty acid oxidation may also be upregulated within the UOK257 
cell line.  No difference in the activity of citrate synthase (Figure 11F) and malate 
dehydrogenase (Figure 11G) (involved in the Krebs cycle) was observed between the 
UOK257, UOK257-2 and HEK293 cell lines.  The term 'warburg effect' refers to the ability 
of tumour cell lines to break down glucose via glycolysis at an increased rate compared to 
normal cell lines, even in the presence of oxygen, resulting in glucose being converted to L-
lactate (Warburg, 1956).  These data collectively suggest that UOK257 cells lacking FLCN 
exhibit a metabolic profile that resembles the ‘Warburg effect'. 
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Figure 11. The levels of activity of the enzymes pyruvate kinase, HOAD and lactate 
dehydrogenase are increased in FLCN-deficient UOK257 cells.  
(A) Diagram showing aerobic and anaerobic metabolism of glucose and fatty acids. Enzyme 
activity levels of (B) hexokinase, (C) pyruvate kinase, (D) lactate dehydrogenase, (E) 3-
hydroxyacyl-CoA dehydrogenase, (F) citrate synthase, (G) malate dehydrogenase in BHD- 
UOK257, FLCN+ UOK257-2) and HEK-293 cells were determined by enzyme activity 
assays. (Work conducted by Dr. Andrew Tee).  * = significant at the 0.05 significance level. 
** = significant at the 0.01 significance level. 
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2.2.5 UOK257 cells lacking FLCN favour glycolysis 
Pyruvate is a substrate for either LDH, which results in the production of L-lactate, or 
pyruvate dehydrogenase (PDH), which converts pyruvate to acetyl CoA which then goes into 
the Krebs cycle (shown in Figure 11a). Under conditions of low oxygen, PDH is 
phosphorylated and inhibited by pyruvate dehydrogenase kinase 1 (PDK1), resulting in more 
pyruvate being converted to L-lactate by LDH and the conversion of pyruvate to acetyl-coA 
being limited (Wigfield et al., 2008). Given that an increase in LDH activity was observed in 
the FLCN-deficient UOK257 cells, I wanted to analyse the phosphorylation status of PDH 
within the UOK257 cell line as an indication of PDH activity.  Therefore, Western blot 
analyses were performed in order to analyse the protein expression of PDK1 and 
phosphorylated PDH (Figure 12).  PDK1 protein levels were significant increased in the 
FLCN-deficient UOK257 cells compared to UOK257-2 cells under both normoxic (Figure 
12, lanes 1 and 3) and hypoxic conditions (Figure 12, lanes 5 and 7).  Increased levels of 
PDH phosphorylation in the FLCN-deficient UOK257 cells were also observed (Figure 12, 
lanes 3 and 7), suggesting that PDH is phosphorylated and inhibited by PDK1 in these cells.   
The protein levels of phosphorylated ribosomal protein S6 were also analysed as an 
indication of the levels of mTORC1 signalling.  In line with previous reports by Hartman et 
al., (2009) I observe an increase in the level of rpS6 phosphorylation in the FLCN-deficient 
UOK257 cells, suggesting that there is an increased basal level of mTOR signalling within 
the FLCN-deficient UOK257 cells.  This increase in rpS6 phosphorylation was effectively 
repressed upon treatment with rapamycin (Figure 12, lane 4).  Only low levels of rpS6 
phosphorylation were detected within the FLCN-deficient UOK257 cells under hypoxic 
conditions (Figure 12, lane 7).  This result was expected, as hypoxia is known to repress 
mTORC1 signalling (Liu et al., 2003).   
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The western blot also revealed that there are increased levels of Thr308 phosphorylation of 
AKT within the FLCN-deficient UOK257 cells (figure 12, lanes 3 and 7).  These data suggest 
that UOK257 cells exhibit increased levels of LDH activity and PDH phosphorylation; 
implying that UOK 257 cells may convert pyruvate to L-Lactate more readily. 
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Figure 12. The Krebs cycle enzyme PDH is inhibited by enhanced expression of PDK1 upon 
loss of FLCN.  
UOK257-2 and UOK257 cells growing in DMEM were washed with fresh DMEM and 
maintained in 21% oxygen or 1% oxygen and treated with rapamycin as indicated.  Protein 
expression levels of PDK1, PDH, PDH (P-S293), Akt, Akt (P-T308), Akt (P-S473), S6, S6 
(P-S2350236), Folliculin and β-Actin were determined.   
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 2.2.6 L-lactate is used by FLCN-deficient UOK257 cells as a metabolic fuel 
The next stage in determining whether glycolysis is increased in UOK257 cells was to 
examine whether there was increased L-Lactate production via facilitated diffusion within 
these cells.  Interestingly, when extracellular acidification was measured as an indication of 
L-lactate production and glycolytic rate, no difference was observed between the UOK257 
and the UOK257-2 cell lines (Figure 13a).  However, monocarboxylate transporter 1 
(MCT1), involved in L-Lactate influx, and MCT4, involved in the efflux of L-Lactate, 
revealed that the BHD- UOK257 cells express more of the MCT1 but not of the MCT4 
(Figure 13b lanes 1 and 4).   
65 
 
 g  
BHD + -
L-
La
ct
at
e 
re
le
as
ed
 in
to
 
m
ed
ia
 a
fte
r 
6h
rs
 (m
M
)
MCT1
MCT4
Folliculin
+ -BHD + -
21%
Rap +- +-
LDH
B
A
UOK-
257
UOK-
257
Β-actin
  
 
Figure 13. UOK257 cells are able to use L-lactate as a metabolic fuel. 
(A)  UOK257 and UOK257-2 cells growing in DMEM were washed with fresh DMEM and 
maintained in 21% oxygen.  After 6 hours this media was removed.  L-lactate levels within 
these samples were analysed using an EnzyChrom L-Lactate Assay Kit according to 
manufacturer’s protocol.  Level of absorbance is representative of the amount of L-lactate 
within the growth media of the cells after 6 hours.  (B) Western blot analyses were performed 
on cell lysates prepared from UOK257 and UOK257-2 cells treated with and without 50 nm 
rapamycin as indicated.  Protein expression levels of MCT1, MCT4, LDH, Folliculin and β-
Actin were determined.   
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 2.3 Discussion  
 
2.3.1 Increased levels of HIF activation may be involved in cancer progression and the 
development of renal tumours and cyst formation in BHD patients 
 
HIF plays a pivotal role in tumour development in a number of inherited genetic disorders 
which result in RCCs.  These include VHL, HLRCC and TSC (Kaelin, 2005; Isaacs et al., 
2003; Liu et al., 2003).  HIF promotes tumour progression by mediating the expression of 
genes involved in cellular metabolism, glucose transport, cell survival, angiogenesis and 
metastasis.  The data presented suggests an abnormal level of HIF activation may be involved 
in cancer progression and the development of renal tumours and cyst formation in BHD 
patients (Tuder et al., 2006).  The fact that increased levels of HIF activity are observed 
across multiple FLCN-deficient cell lines suggests that these findings may be applicable to 
multiple types of tumours found in BHD patients.  This notion is further supported by the 
immunohistochemical data provided by Prof Maurice Van Steensel's lab conducted on 
chromophobe carcinomas from patients with BHD; in which increased levels of BNIP3, 
VEGF-A and GLUT 1 are observed (Preston et al., 2011).   
 
2.3.2 Increased levels of BNIP3 mRNA levels may serve a protective function in BHD-
deficient cells 
 
Data obtained from multiple BHD cell line models revealed that cells deficient in BHD have 
increased levels of both BNIP3 mRNA and protein.  Immunohistochemistry (provided by 
Prof Maurice Van Steensel) also showed elevated levels of BNIP3 staining in the BHD 
patient chromophobe carcinoma tissue.  Although multiple studies have shown that cell death 
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via either necrosis or apoptosis is induced by BNIP3, contrasting results have also suggested 
that BNIP3 promotes cell survival; possibly via upregulation of autophagy (Burton et al., 
2009).  Therefore, it may be possible that the change in expression pattern of BNIP3 is 
indicative of a protective function of BNIP3 in the chromophobe tumour.  Furthermore, this 
work highlights the possibility that autophagy may be functioning as a protective mechanism 
within these tumour cells (further discussed in chapter 4).   
 
2.3.3 HIF transcriptional activity rather than HIF protein stability is enhanced upon loss of 
functional FLCN. 
 
The way that HIF signalling becomes disregulated varies between different inherited 
disorders.  In VHL and HLRCC, Increased stability of HIFα proteins is considered a major 
factor in tumour development (Bratslavskey et al., 2007; Issacs et al., 2005).  The data 
obtained from the ACHN cell line suggested that the BHD- ACHN cells have an increased 
basal level of HIF1α protein under normoxic conditions compared to the ACHN cells 
expressing endogenous BHD.  However no difference in the protein levels of HIF1α or 
HIF2α was observed between the BHD- ACHN cells and the ACHN cells expressing 
endogenous BHD under hypoxic conditions.  This is further supported by data obtained from 
the UOK257 cell line which revealed no significant difference in the mRNA or protein levels 
of HIF1α between the UOK257 (BHD-) and UOK257-2 (BHD+) cell lines under conditions 
of both normoxia and hypoxia.  An increased level of HIF2α protein in the UOK257-2 
(BHD+) cell line compared to the UOK257 (BHD-) cell line was also observed under hypoxic 
conditions.  It is probably increased levels of HIFα activity rather than protein stability which 
result in the increased HIF-driven gene expression observed in the BHD deficient cell lines.  
However immunohistochemistry conducted by Prof Maurice Van Steensel's lab on 
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chromophobe carcinoma tissue from BHD patients showed elevated levels of HIF1α protein 
in the chromophobe carcinoma tissue of the BHD patient (Preston et al., 2011).  It is likely 
that the increased protein levels of HIF1α observed in the chromophobe carcinoma tissue is 
reflective of hypoxic tissue.  It, therefore, cannot be ruled out that protein stability of HIF1α 
may be enhanced during tumour progression in BHD patients.   
 
2.3.4 mTOR activity is enhanced upon loss of functional FLCN in BHD-deficient UOK257 
cells. 
 
The data obtained from the UOK257 cell line show that there are also increased levels of 
rpS6 phosphorylation within the BHD- UOK257 cells compared to the UOK257-2 cells.  
These data suggest that mTORC1 activity is upregulated in UOK257 cells deficient in BHD 
which was inhibited upon rapamycin treatment or over-expression of BHD.  
Immunohistochemistry conducted by Prof Maurice Van Steensel's lab on chromophobe 
carcinoma tissue from BHD patients also showed increased staining for phosphorylated rpS6 
in the chromophobe carcinoma tissue of the patient compared to normal tissue (Preston et al., 
2011).   Work conducted by Baba et al. has also shown that Akt/mTOR pathway is 
hyperactivated in cells deficient in BHD (Baba et al., 2008).  This notion is supported by the 
observation of elevated levels of phosphorylation of Akt at Ser 473 (the mTORC2 
phosphorylation site) in the BHD- UOK257 cells; indicative of increased Akt activation by 
mTORC2.  Hasumi et al. have also observed increased mTORC2 activity levels along with 
increased expression levels of rictor (a regulator of mTORC2) in tumours from BHDd/+ mice 
(Hasumi et al., 2009).  mTORC2 has also been shown to phosphorylate and stabilise Akt 
(Facchinetti et al., 2008); suggesting that it is the activation of mTORC2 which is the primary 
mechanism by which Akt is activated in FLCN-deficient tumours.  Together with data from 
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work conducted by Baba et al. which suggest that phosphorylation of FLCN was partially 
blocked by rapamycin (an mTOR inhibitor) and thus mTOR regulates FLCN function (Baba 
et al., 2006); these data suggested that FLCN is involved in a negative feedback loop which 
suppresses PI3K-Akt-mTOR signalling (Hasumi et al., 2009).  Increased phosphorylation 
levels of ribosomal protein S6 kinase 1 and 4E-BP1 have also been observed in TSC1 and 
TSC2 deficient cells which is inhibited by rapamycin; consistent with constitutive activation 
of mTORC1 (Kwiatkowski et al., 2003).  These data suggest that mTOR activity is elevated 
upon loss of functional FLCN in a manner analogous to TSC1 and TSC2-deficient cells.  This 
is quite the reverse to the results from work conducted by Hartmen et al., which showed that 
mTOR is inactivated in BHD-deficient mice.  The results obtained by Hartman et al. 
suggested that the increased levels of mTOR activation observed in cell lines such as the 
UOK257 cell line was not a primary effect as a result of loss of BHD, but mTOR is activated 
later in the cancer development due to increased activity levels of kinases such as Akt 
upstream of mTOR in a similar manner to that exhibited in TSC deficient cell lines (Hartman 
et al., 2009).  However, these diffences of opinion on the effects of loss of functional 
folliculin may be attributed to the differences in the models used in this study and that 
conducted by Hartman et al. and the length of time that functional folliculin has not been 
expressed. 
2.3.5 HIF transcriptional activity may be regulated via mTORC1- dependent and 
independent mechanisms in BHD deficient cells. 
 
In TSC, upregulation of mTORC1 signalling is known to mediate increased HIF activity 
(Land and Tee, 2007).  Land and Tee observed increased levels of HIF activity in cells 
deficient of TSC2, which was reversed when TSC2 was added back to the cells or mTOR was 
inhibited with rapamycin (Land and Tee, 2007).  In fact, mTOR inhibition has been shown to 
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significantly reduce expression levels of HIFα protein in several types of cells (Knaup et al., 
2009).  Given that increased levels of mTOR signalling are observed in the UOK257 cells it 
may be possible that increased mTORC1 signalling may also be promoting the activity of 
HIF within the FLCN-deficient UOK257 cells.  This notion is supported by the fact that 
inhibition of mTOR via treatment with rapamycin impairs the accumulation of G6PD1, 
CCND1 and BNIP3 mRNA within the BHD- UOK257 cell line under hypoxic conditions.  
HIF activity within the BHD- UOK257 cell line and the BHD-/- MEF cell line, as analysed 
using a HIF luciferase reporter construct, is also significantly reduced upon treatment with 
rapamycin.   
 
Elevated levels of rpS6 phosphorylation are observed under hypoxic conditions in the 
UOK257 cells compared to the UOK257-2 cells, suggesting that activation of mTOR may 
play a part in the regulation of HIF transcriptional activity under hypoxic conditions.  This is 
supported by the fact that hypoxia-driven accumulation of G6PD1, CCND1 and BNIP3 
within the BHD- UOK257 cell line is impaired when mTORC1 is inhibited via treatment with 
rapamycin.  HIF activity within the BHD- UOK257 cell line and BHD-/- MEF cell line under 
hypoxic conditions, as analysed using a HIF luciferase reporter construct, is also reduced 
upon treatment with rapamycin.  However, rpS6 phosphorylation is still decreased in the 
UOK257cells under hypoxia compared to normoxic conditions.  Work conducted by Knaup 
et al. suggests that HIF represses rpS6 under hypoxic conditions and that stimulation of HIFα 
by mTORC1 may only be relevant under mildly hypoxic, or even normoxic conditions.  
Knaup et al. also observed that in the majority of cancer cells they studied, no influence of 
mTOR inhibitors on HIFα protein levels was observed under severe hypoxic conditions 
(Knaup et al., 2009).  Hypoxia triggers dephosphorylation of mTORC1 and the downstream 
targets 4E-BP1, p70S6 kinase, and rpS6.  Hypoxic inhibition of these targets is dominant to 
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activation via insulin or amino acids.  This response was also thought to be independent of 
HIF1α (Arsham et al., 2003).  However, HIF is also known to express Redd1/2 which 
activate TSC2 via competitive binding for 14-3-3 proteins; leading to inhibition of mTORC1 
(reviewed in Dunlop and Tee, 2009).  The elevated mRNA levels of GLUT1 and VEGF-A 
observed in BHD- UOK257 cells also did not appear to be rapamycin sensitive under hypoxic 
conditions.  This result may also be explained by the increased levels of BNIP3 mRNA and 
protein expression observed in the FLCN-deficient cell lines, as work conducted by Li et al. 
suggested that BNIP3 inhibits mTORC1 activation by binding to Rheb (Li et al., 2007).  
Therefore it is probable that mTORC1 signalling is required for transient bursts of HIF 
activity in the cells, rather than long term activation.   
 
2.3.6 The increased levels of HIF activity observed in BHD-deficient cells is resulting in a 
metabolic profile similar to the ‘Warburg effect’. 
 
HIF1α is able to alter the metabolic profile of a cell by enhancing the gene-expression of 
glycolytic genes such as glucose transporter 1 (GLUT1) allowing increased glucose uptake.  
Under hypoxia, glucose is converted to pyruvate and then subsequently to L-lactate.  
Activation of glycolytic genes is considered a crucial adaptation to hypoxia (Kim et al., 
2006).   The data obtained from the UOK257 cell line show that the BHD- UOK257 cells 
have increased mRNA and protein levels of GLUT1 compared to the BHD+ UOK257-2 cells.  
Immunohistochemistry work conducted by Prof Maurice Van Steensel also revealed 
increased level of GLUT1 staining in chromophobe carcinoma tissue compared to normal 
tissue from BHD patients (Preston et al., 2011).  Together these data suggest that the BHD- 
UOK257 cells have increased levels of glucose uptake into the cell.  Increased mRNA levels 
of another HIF1α transcriptional target, glucose-6-phosphate dehydrogenase 1 (G6PD1),  
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were also observed in the (BHD-) UOK257 cell line when compared to the (BHD+) UOK257-
2 cell line under both normoxic and hypoxic conditions.  G6PDH is a NADPH-generating 
enzyme of the oxidative pentose phosphate pathway (OPPP).  These data imply that BHD-
deficient UOK257 cells may be more dependent on glucose than UOK257-2 cells expressing 
BHD and therefore are increasing the amount of glucose uptake and metabolism into the cell 
in order to meet their energy demands.   
 
HIF1α also actively suppresses metabolism through the Krebs cycle by activating the gene 
encoding PDK1.  PDK1 phosphorylates and inhibits PDH, which normally converts pyruvate 
to acetyl-CoA which can then enter the Krebs cycle.  This causes a metabolic switch resulting 
in pyruvate being converted to lactate via the enzyme lactate dehydrogenase.  Data obtained 
from examining the phosphorylation status of PDH within the UOK257 cells revealed that 
there are increased levels of PDK1 protein and phosphorylated PDH in the UOK257 cells 
under conditions of both normoxia and hypoxia.  These data suggested that PDH activity was 
inhibited in the BHD- UOK257 cell line, which was rescued in the UOK257-2 cells 
expressing BHD.   
 
Data obtained from work conducted by Dr. Andrew Tee on the metabolic profile of the 
UOK257 cell line also suggested that the BHD- UOK257 cells exhibit increased levels of 
LDH activity, along with increased levels of 3-hydroxy-acyl-CoA; implying that fatty acid 
oxidation may also be upregulated within the UOK257 cell line.  These data suggest that 
BHD- UOK257 cells exhibit an altered metabolic profile that resembles the ‘Warburg effect' 
as these cells appear to break down glucose via glycolysis at an increased rate, even in the 
presence of adequate oxygen levels, resulting in more glucose being converted to L-lactate in 
a manner analogous to that described by Otto Warburg (Figure 14) (Warburg, 1956).  It may 
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appear more disadvantageous for the UOK257 cell line to favour glycolysis over oxidative 
phosphorylation, even in an adequate oxygen environment, as approximately 18 times less 
ATP is generated by glycolysis compared to oxidative phosphorylation.  However, the 
metabolic changes observed when a cell exhibits the 'warburg effect' result in glucose 
entering the pentose phosphate pathway more readily, leading to increased production of 
nucleotides, aromatic amino acids and fatty acids, all of which are essential for cell 
proliferation (Van der Heiden et al., 2009).  There is also growing evidence that some cancer 
cells use L-Lactate as a metabolic fuel.  Oxygenated cells on the outside of the tumour may 
take up and oxidise the L-Lactate which is produced by the cells situated in the hypoxic 
conditions within the core of a tumour (Sonveaux et al., 2008).   
 
v
0
0
Glucose
HK
Glucose
GLUT1
Pyruvate
HIF1
LDH
ROS
Lactate
PDK1
Acetyl-CoA
PDH
Krebs cycle
H2O
O2
NADH, FADH2
   
74 
 
Figure 14. HIF activation and the Warburg effect. 
HIF1 activates hexokinase 2 (HK2) and pyruvate dehydrogenase kinase 1 (PDK1), which results in 
inhibition of pyruvate dehydrogenase (PDH) and prevents glucose being converted from pyruvate to 
acetyl-CoA. As a consequence, pyruvate is instead preferentially converted to l-lactate. This is a 
contributing factor in the development of the ‘Warburg effect’ type metabolic profile (Dang; 2008). 
Data from the UOK257 cell line suggest that although the BHD- UOK257 cells exhibit 
increased LDH activity, which would increase L-Lactate production, no difference in L-
Lactate secretion into culture media was observed between the BHD- UOK257 and BHD+ 
UOK257-2 cells.   
This may be explained by the observation that BHD- UOK257 cells exhibit elevated protein 
expression levels of the L-Lactate transporter MCT1, involved in the uptake of L-lactate into 
the cell.  However no difference in another L-Lactate transporter, MCT4, involved in the 
export of L-Lactate from the cell was observed.  Work conducted by Dr Keith Barr also 
revealed that the BHD- UOK257 cells have a high capacity to oxidise L-Lactate (Preston et 
al., 2011).  Together these results imply that the BHD- UOK257 cells are able to use L-
Lactate as a metabolic fuel, and thus the ability for the UOK257 cells to readily convert 
glucose to lactate may provide a proliferative advantage.  Data from immunohistochemistry 
conducted by Prof .Maurice van Steensel's lab on BHD patient tumour samples also revealed 
increased staining for LDH and MCT1 in the chromophobe carcinoma tissue compared to the 
normal tissue (data not shown); suggesting that this may be more broadly applicable to other 
BHD cell lines and tumour types, rather than just the UOK257 cell line.   
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mitochondrial biogenesis and 
mitochondrial function 
 
 
 
 
76 
 
3 The effect of loss of functional FLCN on mitochondrial biogenesis and mitochondrial 
function. 
3.1 Introduction 
 
In eukaryotic cells, mitochondria play a central role in cellular energy metabolism (Shadel, 
2008).  Contained within the intermembrane space of the mitochondria are mitochondrial 
enzymes, such as those involved in the Krebs cycle (Shadel, 2008).  Mitochondria generate 
ATP via oxidative phosphorylation (oxPhos) of glycolysis and lipolysis products (Hock and 
Kralli, 2009).  Many classic errors of metabolism result from genetic defects resulting in 
altered expression or activity of enzymes contained within the mitochondria which are 
involved in these processes.  Some of these metabolic errors are caused by defects involving 
oxPhos complexes I-V.  Common features of defects involving the oxPhos complexes 
include loss of ATP production, elevated levels of reactive oxygen species (ROS) production 
by complexes I and III of the electron transport chain, and irregular apoptosis.  Mitochondrial 
function is also sensed and controlled by cell signalling pathways.  Therefore disruption of 
the oxPhos complex may result in defective signal transduction (Shadel, 2008).  Given their 
central roles in cellular metabolism and signalling, strict regulation of the mass and function 
of mitochondria is crucial (Hock and Kralli, 2009).   
The growth and division of mitochondria is known as mitochondrial biogenesis and is 
upregulated under conditions of environmental stresses such as cell division, renewal and 
oxidative stress (Ventura-Clapier, 2008).  The process of mitochondrial biogenesis requires 
the replication of mitochondrial DNA (mtDNA) as well as proteins and lipids being 
synthesised, imported, and incorporated into the mitochondria.  Nuclear genes encode most 
of the proteins which are imported into the mitochondria as part of mitochiondrial biogenesis 
(Hock and Kralli, 2009).  Human mtDNA is circular double stranded DNA which is 
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approximately 16.5 Kilobases in length and encodes 37 genes.  13 of these genes encode for 
integral components of the oxPhos complexes (Shadel 2008).  It has been suggested that there 
is a significant correlation between mitochondrial mRNA levels and protein levels, implying 
that the mass of mitochondria in a cell is mostly regulated at the transcriptional level.  
Mitochondrial biogenesis requires the transcription of genes in the mitochondria and nucleus 
which are essential for the process to be coordinated (Hock and Kralli, 2009).  This 
coordination is achieved via mitochondrial genes which are encoded in the nucleus, such as 
TFAM, that are induced in response to signalling pathways which promote mitochondrial 
biogenesis and regulate the replication and transcription of mtDNA (Hock and Kralli, 2009).  
This coordinates the activities of the nucleus and the mitochondria in order to regulate 
mitochondrial gene expression and oxPhos activity (Shadel, 2008).   
During mitochondrial biogenesis, mitochondria undergo fission and fusion.  This allows the 
existing mitochondria to divide and helps ensure that mitochondrial structures are organised 
correctly during biogenesis (Ventura-Clapier, 2008).  
Peroxisome proliferator–activated receptors (PPARs) regulate genes located within the 
mitochondria which are involved in uncoupling and fatty acid oxidation (Hock and Kralli, 
2009).  PGC1α interacts with and coactivates many nuclear and nonnuclear receptors such as 
NRF1/NRF2 and mitochondrial transcription factor A (TFAM), which is directly responsible 
for the replication and transcription of mtDNA (Figure 15) (Bogacka et al., 2005).  PGC1α is 
therefore able to enhance mitochondrial biogenesis and the oxidative function of a cell.  
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Figure 15. The PGC1α regulatory cascade.  
PGC1α has been shown to be regulated by several signalling pathways including activation of 
adenosine-monophosphate-activated kinase (AMPK).  PGC-1α then co-activates transcription 
factors involved in mitochondrial biogenesis such as TRβ1 and nuclear respiratory factors 
(NRFs), and PPARs, known to regulate fatty acid oxidation, and antioxidant detoxification 
(Ventura-Clapier, 2008). 
 
Related coactivators such as PGC1β also functions similarly to PGC1α (Hock and Kralli, 
2009). PGC1α may be activated via the cAMP/PKA cascade increasing PGC1α gene 
expression or by activation of the p38 MAPK and/or cAMP/p38 MAPK cascade which 
results in phosphorylation of the PGC1α protein (Bogacka et al., 2005).  Several transcription 
factors have been implied in the regulation of PGC1α gene expression.  The transcription 
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factor CRE (CAMP response element) binding protein (CREB) is able to activate 
transcription of PGC1α. This occurs via binding of CREB to a functional CRE in the 
promoter region of PGC1α (Kelly and Scarpulla, 2004). 
Expression of PGC1α in cultured white fat cells also results in a doubling of mitochondrial 
DNA content and an increase in mRNA for uncoupling protein 1 (UCP1), and several genes 
of the oxidative phosphorylation pathway. The uncoupling proteins (UCPs) are tissue specific 
intramembranous mitochondrial proteins and play an important role in thermogenesis.  It has 
been shown that both UCP2 and UCP3 uncouple respiration when expressed in mammalian 
cells. Activating mitochondrial uncoupling is a major part of adaptive thermogenesis, a 
process that occurs primarily in the mitochondria of skeletal muscle and brown fat.  During 
adaptive thermogenesis, elevated numbers of mitochondria and elevated levels of activity of 
the electron transport system in those mitochondria are observed in response to more energy 
being dispelled in the form of heat.  This occurs in response to stimuli such as decreased 
external temperature.  This may be due to the cells need to increase the overall levels of ATP 
production in order to preserve normal levels of ATP while so much energy is being 
dissipated as heat (Wu et al., 1999). 
It has been shown that the mTOR pathway is a key regulator for cellular metabolism.  mTOR 
regulates several processes which are important to a cell, such as autophagy, protein 
synthesis, and nutrient uptake.  It has also been shown that mitochondrial oxidative function 
is regulated by mTOR via alteration of the interaction of the YY1 – PGC1α transcriptional 
complex (Cunningham et al., 2007).  
TSC has also been shown to be an important regulator of cellular metabolism. Deletion of the 
TSC1 gene in hematopoeitic stem cells (HSCs) drives them from quiescence, which is 
associated with their long-term function, into rapid cell cycling, resulting in increased 
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mitochondrial DNA content together with increased transcription of mitochondrial genes 
involved in oxidative phosphorylation, including Cox5a, Atp5a1 and Ucp3.  This increase in 
the transcription of genes involved in oxidative phosphorylation subsequently leads to 
increased levels of ROS production in HSC cells deficient in TSC1.  These results suggested 
that the TSC–mTOR pathway is involved in the maintenance of the quiescence and function 
in these cells via the repression of ROS production.  When TSC1 is deleted, increased level of 
ROS are observed, which is detrimental in metabolically active HSCs (Chen et al., 2008). 
Observations have also been made that chromophobe renal tumours from BHD patients had 
abnormally high levels of mitochondria; suggesting that loss of FLCN may result in an 
accumulation of mitochondria (Yang et al., 2008).  RCC syndromes are often associated with 
mitochondrial dysfunction.  Cells within RCCs from HLRCC patients, which exhibit similar 
symptoms clinically to BHD patients, exhibit a decreased ability to generate ATP via the 
electron transport chain due to loss of function of the mitochondrial enzyme FH (Isaacs et al., 
2005; Sudarshan et al., 2011).  BHD patients also present with oncocytomas, known to 
exhibit defects within complex 1 of the mitochondria, along with increased mitochondrial 
DNA (mtDNA) content as a result of accumulation of mitochondria (Simonnet et al., 2003). 
As BHD-deficient cells also exhibit increased levels of mTOR activity in a similar manner to 
that observed in TSC-deficient cells (as discussed in Chapter 2), and both tumours from BHD 
and TSC patients, which exhibit overlapping clinical features to TSC patients, have been 
observed to have abnormal levels of mitochondria, I wanted to examine mitochondrial 
biogenesis in the UOK257 BHD patient cells line.  In this chapter, I investigate the 
expression level of genes which regulate the transcription of mitochondrial genes and the 
replication of mitochondrial DNA in the context of loss of FLCN.  
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3.2 Results 
3.2.1 Endogenous FLCN is localised to the Nucleus, Cytosol and Mitochondria.  
Given that FLCN inhibits HIF activity, and HIF is a nuclear protein, I hypothesised that 
FLCN would also be localised to the nucleus. In order to investigate this, mitochondrial, 
nuclear and cytosolic fractions were prepared from fully confluent HEK293 cells, which 
express endogenous FLCN and are representative of a 'normal' kidney cell line.  Levels of 
FLCN within these fractions were subsequently determined via western blot (Figure 16a).  
FLCN was detected in all three fractions; however the two isoforms of FLCN were 
differentially expressed in each fraction.  The upper isoform of FLCN was detected in the 
nuclear fractions whereas the lower isoform of FLCN was detected in the mitochondrial 
fraction.  Both of these isoforms were detected in the cytosolic fraction. 
I next sought to determine whether the localisation of FLCN was altered under certain drug 
treatment conditions (Figure 16B).  HEK293 cells were treated with 2-deoxyglucose (2DG); 
known to phosphorylate FLCN via activation of AMPK, and the mTORC1 inhibitor 
rapamycin, which is known to dephosphorylate FLCN (Baba et al., 2006).  Mitochondrial, 
cytosolic and nuclear fractions were prepared from these treated cells, together with untreated 
cells for comparison.   
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Figure 16. Cellular localisation of Folliculin. 
(A) Mitochondrial, nuclear and cytosolic protein lysates were created from HEK293 cells 
grown to full confluency.  Western blot analyses were then performed and the protein levels 
of BHD, lamin A/C, LDH and cytochrome C were determined.  (B) Western blot analyses 
were performed on cell lysates prepared from HEK293 cells treated for 2 h with 50 nm 
rapamycin or 50 mM 2-deoxyglucose where indicated.  Protein levels of ACC (P-S79), ACC, 
S6 (P-S235/236), and S6 were determined.  (C) Mitochondrial, nuclear and cytosolic protein 
lysates were created from HEK293 cells grown to full confluency and treated for 2 h with 50 
nm rapamycin or 50 mM 2-deoxyglucose where indicated.  Western blot analyses were then 
performed and the protein levels of FLCN, lamin A/C, LDH and cytochrome C were 
determined.   
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The results suggested that, in untreated cells, most of the Folliculin in the nucleus exists in 
the upper isoform.  However, when the cells were subjected to rapamycin treatment, both the 
upper and lower isoforms of FLCN are detected in the nucleus at approximately equal levels.  
The amount of FLCN expressed in the mitochondria is also increased upon rapamycin 
treatment, suggesting that dephosphorylated FLCN might translocate to mitochondria.  A 
third isoform of FLCN was detected in the total lysate just above the lower isoform of FLCN 
when the cells were subjected to treatment with 2DG, which indicates FLCN phosphorylation 
that occurs in an AMPK-dependent manner. 
3.2.2 Mitochondrial biogenesis is upregulated in UOK257 cells devoid of FLCN 
It has been shown that tumours from BHD patients exhibit increased levels of mitochondria 
(Yang et al., 2008).  As data from the HEK293 cells revealed that FLCN can be localised to 
mitochondria (Figure 16a), I sought to confirm whether UOK257 cells deficient in FLCN 
have increased levels of mitochondria.  The relative levels of mitochondrial and genomic 
DNA were compared within the BHD- UOK257 and BHD+ UOK257-2 cells using RT-PCR 
(Figure 17a).  Levels of a mitochondrial gene (Cytochrome B) were compared to those of a 
genomic gene (Ribosomal protein L13 (RPL13)) in both cell lines under normoxic and 
hypoxic conditions.  Cytochrome B is involved in the electron transport chain of 
mitochondria (Esposti et al., 1993).   
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Figure 17. Mitochondrial Biogenesis is upregulated in UOK257 cells devoid of BHD.  
(A) The DNA levels of cytochrome B were compared within BHD+ and BHD- cells treated 
with 50 nM rapamycin under normoxia (21%) and hypoxia (1%) overnight, where indicated, 
by RT-PCR. DNA levels were standardised against RPL13. n = 3.  (B) The mRNA levels of 
PGC1β, NRF1, NRF2/GABPA and TFAM were compared within UOK257 and UOK257-2 
cell lines by RT-PCR. mRNA levels were standardised against β-Actin mRNA. n = 3.  (C)  
BHD- UOK257 cells transiently transfected with a PGC1α luciferase reporter construct 
containing the PGC1α promoter region and either pRK7 empty vector or Flag-tagged BHD 
were maintained in normoxia (21%) or hypoxia (1%) for 24h where indicated. Levels of 
luminescence are representative of levels of luciferase and therefore PGC1α transcription. 
Western blot analyses were performed and protein levels of Folliculin were determined. n = 
3.  * = significant at the 0.05 significance level. ** = significant at the 0.01 significance level. 
85 
 
Approximately a 5 fold increase in the level of mitochondrial DNA was observed in the 
BHD- UOK257 cells under normoxic conditions.  This was significantly reduced upon 
treatment with rapamycin (Figure 17a).  This finding suggests that cells lacking FLCN have 
heightened levels of mitochondria which is driven by mTORC1.  A significant reduction in 
the level of mitochondrial DNA was also observed in the BHD- UOK257 cells under hypoxic 
conditions (Figure 17a).  These data support findings which suggest that decreased 
transcription of genes such as PGC1α is observed under hypoxic conditions, possibly in a 
HIF1α dependent manner (Gamboa and Andrade, 2009). 
 
To determine whether the increased levels of mitochondrial DNA observed within the BHD- 
UOK257 cells was as a result of enhanced transcription levels of genes involved in 
mitochondrial biogenesis in the UOK257 cell line RT-PCR was used to determine the mRNA 
levels of several genes involved in mitochondrial biogenesis. (Figure 17B).  The mRNA 
levels of Nuclear respiratory factor 1(NRF1), Peroxisome proliferator-activated receptor-
gamma coactivator 1 β (PGC1β), mitochondrial transcription factor A (TFAM) and Nuclear 
respiratory factor 2 (NRF2) were analysed under normoxic conditions in the BHD- UOK257 
and BHD+ UOK257-2 cells.  The results revealed that the BHD- UOK257 cells exhibit 
significantly increased mRNA levels of the majority of mitochondrial biogenesis markers 
analysed.  Approximately a 3 fold increase in PGC1β mRNA was observed in the UOK257 
cells, together with approximately 10 fold increases in the mRNA levels of NRF1 and NRF2.  
However no significance in TFAM mRNA levels was observed.  These data support the 
thought that mitochondrial biogenesis is upregulated in cells lacking FLCN.  Upregulation of 
mitochondrial biogenesis may therefore be involved in cancer progression in BHD tumours.  
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In order to further investigate the effect of FLCN expression on the transcription of genes 
involved in mitochondrial biogenesis UOK257 cells were transfected with a luciferase 
reporter construct whose expression is regulated by the 5' Peroxisome proliferator-activated 
receptor-gamma coactivator 1 α (PGC1α) promoter region, together with either Flag-tagged 
BHD or pRK7 empty vector (Figure 17C).  The level of PGC1α gene transcription in the 
BHD- UOK257 cells was reduced by approximately 50% upon transfection of the Flag-
tagged BHD vector.  A further reduction in PGC1α gene transcription was also observed 
when the cells were subjected to hypoxia, a known suppressor of mitochondrial biogenesis 
(Zhang and Semenza, 2007).  Collectively, these data suggest that mitochondrial biogenesis 
is upregulated within UOK257 cells upon loss of FLCN. 
3.2.3 Mitochondrial biogenesis is enhanced upon BHD knockdown by short hairpin (sh)RNA. 
In order to verify the results obtained from the UOK257 cell line, the mRNA and 
transcription levels of genes involved in mitochondrial biogenesis were analysed within two 
other cell lines; Mouse Embryonic Fibroblast cells and Human kidney 2 cells which had been 
stably transfected with either scrambled shRNA (BHD+) or BHD shRNA (BHD-).  RT-PCR 
was used to analyse the mRNA levels of two genes involved in mitochondrial biogenesis 
(PGC1α, and ATP synthase H+ transporting mitochondrial F0 complex subunit C1 (subunit 9) 
(ATP5G1)) within BHD+/+ and BHD-/- MEF cells (Figure 18a).  Approximately a 10 fold 
increase in the levels of ATP5G1 mRNA was observed within the BHD-/- MEFs, together 
with approximately a 6 fold increase in PGC1α mRNA levels.  These data suggest that 
transcription of mitochondrial biogenesis genes is increased upon loss of FLCN.  
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Figure 18. Mitochondrial Biogenesis is upregulated upon loss of BHD via shRNA. 
(A) The mRNA levels of ATP5G1 and PGC1α were compared within BHD+/+ and BHD-/- 
mouse embyonic fibroblast cell lines by RT-PCR. mRNA levels were standardised against β-
Actin mRNA. n = 3.  (B)  BHD-/- MEF cells transiently transfected with a PGC1α luciferase 
reporter construct containing the PGC1α promoter region and either pRK7 empty vector or 
Flag-tagged BHD were treated with 50nm rapamycin where indicated and maintained in 
normoxia (21%) for 24h. Levels of Luminescence are representative of levels of Luciferase 
and therefore PGC1α transcription. Western blot analyses were performed and protein levels 
of Folliculin, S6 (P-S235/236), and S6 were determined. n = 3.  (C) The mRNA levels of 
PGC1α and PGC1β were compared within HK2 5968A5 (BHD-) and HK2 NT G10 (BHD+) 
cell lines by RT-PCR. mRNA levels were standardised against β-Actin mRNA. n = 3.  * = 
significant at the 0.05 significance level. ** = significant at the 0.01 significance level. 
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The level of PGC1α directed gene expression was then analysed by transfecting BHD-/- 
MEFs with a luciferase reporter construct containing the 3.2kb 5' PGC1α promoter region, 
together with either Flag-tagged BHD or pRK7 empty vector (Figure 18B).  The results 
revealed that the level of transcription of the PGC1α gene was reduced by approximately 
50% within the BHD-/- MEFs upon transfection with BHD.  These data were consistent with 
increased level of transcription of genes involved in mitochondrial biogenesis exhibited by 
the FLCN-deficient UOK257 cells.  The level of PGC1α transcription was also analysed after 
the cells had been subjected to treatment with the mTORC1 inhibitor rapamycin.  mTORC1 
signalling is known to drive mitochondrial biogenesis via a PGC1α- YY1 complex 
(Sengupta, 2010).  Treatment with rapamycin did result in a decrease in the transcription of 
PGC1α in the BHD-/- MEFs of approximately 30%; however the reduction in the level of 
PGC1α transcription observed upon transfection with Flag-tagged BHD was not further 
enhanced upon treatment with rapamycin. 
 
RT-PCR was also used to analyse the transcription levels of two genes involved in 
mitochondrial biogenesis (PGC1α and PGC1β) within HK2 cells (Figure 18C).  A 2 fold 
increase in mRNA levels of PGC1α was observed in the HK2 cells upon loss of BHD via 
shRNA, together with approximately a 10 fold increase in PGC1β mRNA.  These data were 
consistent with increased level of transcription of genes involved in mitochondrial biogenesis 
exhibited by the FLCN deficient UOK257 and MEF cell lines and support the notion that 
mitochondrial biogenesis is upregulated upon loss of FLCN. 
3.2.4 ATP levels are depleted in UOK257 cells deficient in FLCN. 
As the work conducted on multiple cell lines had clearly shown that mitochondrial biogenesis 
is upregulated upon loss of FLCN, resulting in increased numbers of mitochondria in 
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UOK257 cells; it was hypothesised that ATP levels might be higher in cells deficient in 
BHD.  Therefore, an ATP assay was conducted in order to compare levels of ATP within the 
UOK257 (BHD-) and UOK257-2 (BHD+) cells (Figure 19).  The results suggest that, despite 
the increased levels of mitochondria observed in the FLCN-deficient UOK257 cells, ATP 
production within these cells is decreased by approximately 40%; suggesting that the 
mitochondria within the BHD- UOK257 cells do not respire efficiently.  These results are 
supported by data from work conducted by Dr. Stephen Land using a JC1 monomer which 
revealed that the BHD- UOK257 cells have reduced levels of healthy respiring mitochondria 
(Figure 20a).  Of interest, Dr. Stephen Land also observed large foci of green JC1 monomer 
in the BHD- UOK257 cells, indicative of swollen mitochondria.  The decreased levels of ATP 
production may also explain the fact that BHD- UOK257 cells exhibit increased levels of 
phosphorylated AMP-dependent protein kinase (AMPK), enhanced phosphorylation of raptor 
at S792 (an AMPK phosphorylation site) and phosphorylated Acetyl co-A carboxylase; 
indicative of AMPK activity (Figure 21).  AMPK acts as an energy sensor when ATP levels 
are low, and provides metabolic adaptations to these conditions.  These data suggest that 
levels of AMPK activity are increased within the BHD- UOK257 cells in order to provide 
metabolic adaptations in response to the depleted ATP levels exhibited by these cells.  
3.2.5 Compromised mitochondrial membrane potential in BHD- UOK257 cells results in 
increased ROS production and subsequent over-expression of Uncoupling proteins.  
Further analysis conducted by Dr. Stephen Land on the UOK257 cell line using treatment 
with a potent mitochondrial uncoupling agent, carbonyl cyanide m-chloro phenyl hydrazone 
(CCCP), also suggested that the mitochondrial membrane potential may be compromised in 
the BHD- UOK257 cells (Figure 20B).  Uncoupling proteins reduce mitochondrial membrane 
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potential within mammalian cells and inhibit the ability of a cell to generate ATP (Patanè, 
2002).  
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 Figure 19. Decreased production of ATP in FLCN-deficient UOK257 cells.   
The levels of ATP production were compared within UOK257 and UOK257-2 cells using a 
CellTiter-Glo Luminescent Cell Viability Assay.  Cells were incubated with 150µl CellTiter 
Glo Reagent for 1 hour at room temperature before the luminesence was read. n = 3.   
 
As decreased levels of ATP production and compromised mitochondrial membrane potential 
have been observed within the BHD- UOK257 cells, uncoupling protein 3 (UCP3) mRNA 
(Figure 22a) and protein levels (Figure 22B) were analysed within the UOK257 and 
UOK257-2 cell lines.  The results showed that there was a significant increase in UCP3 
mRNA and protein levels in the BHD- UOK257 cells.  No UCP3 mRNA or protein was 
detected in the UOK257-2 cells over-expressing BHD.  These data suggest that  
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Figure 20. Decreased Mitochondrial Membrane Potential in FLCN-deficient UOK257 cells. 
(A)  BHD+ UOK257-2 and BHD- UOK257 cells maintained in normoxia (21%) were treated 
with a JC1 monomer and the amount of green JC1 monomer to red JC1 aggregate were 
determined.  Amount of JC1 aggregate is representative of the amount of respiring 
mitochondria (work carried out by Dr Steven Land).  (B) BHD+ UOK257-2 and BHD- 
UOK257 cells maintained in normoxia (21%) were treated with CCCP where indicated and 
the mitochondrial membrane potential was determined (work carried out by Dr Steven Land).  
* = significant at the 0.05 significance level. ** = significant at the 0.01 significance level. 
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Figure 21. Levels of AMPK activity are increased in UOK257 cells devoid of BHD. 
Western blot analyses were performed on cell lysates obtained from BHD- (UOK257) and  
BHD+ (UOK257-2) cells maintained in normoxic (21%) or hypoxic (1%) conditions where 
indicated.  Protein levels of raptor, raptor (P-S792), acetyl-CoA carboxylase (ACC), AMPKa, 
AMPKa (P- Thr172), 4E-BP1, 4E-BP1 (P-S65), ACC (P-S79), and β-actin (used as a loading 
control) were determined. 
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Figure 22. UOK257 cells deficient in BHD exhibit increased levels of Uncoupling protein 3. 
(A) The mRNA levels of UCP3 were compared within BHD- UOK257 and BHD+ UOK257-2 
cell lines by RT-PCR. mRNA levels were standardised against β-Actin mRNA. n = 3.  (B) 
Western blot analyses were performed on mitochondrial fractions created from BHD+ 
(UOK257-2) and BHD- (UOK257) cells maintained in normoxia (21%).  Protein levels of 
UCP3, Folliculin and β-actin (used as a loading control) were determined. 
 
overexpression of uncoupling proteins may result in compromised mitochondrial membrane 
potential and decreased levels of ATP production within the BHD- UOK257 cells. 
UCPs are also produced by a cell in order to reduce ROS production (Patanè, 2002). 
However, mitochondria are the main source of ROS produced from the electron transport 
chain.  A reduced mitochondrial membrane potential therefore often results in increased ROS 
production.   Cells express antioxidants in order to effectively reduce the levels of ROS 
within a cell.  Oxidative stress occurs as a result of a cell's inability to reduce ROS efficiently 
by expressing cellular antioxidants.  This inability to reduce ROS may lead to cellular 
components being damaged by ROS, which includes mitochondria, and subsequently results 
in further mitochondrial dysfunction (Bellance et al., 2009).  Therefore, levels of hydrogen 
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peroxide (H2O2), one of many species of ROS, were analysed in order to determine the levels 
of ROS production within the BHD- UOK257 and BHD+ UOK257-2 cell line (Figure 23a).  
The results suggested that H2O2 production was increased by approximately 4-fold in the 
BHD- UOK257 cells. 
 
mRNA (Figure 23B) and protein levels (Figure 23C) of Superoxide dismutase 2 (SOD2) were 
also analysed within the BHD- UOK257 and BHD+ UOK257-2 cells via RT-PCR and western 
blot respectively.  SOD2 converts superoxide anion radicals (O2-), a byproduct of 
mitochondrial respiration, into H2O2 and oxygen.  The results showed that there was a 
significant increase in SOD2 mRNA and protein levels in the BHD- UOK257 cells.  Of 
interest; no SOD2 mRNA or protein was detected in the UOK257-2 cells over-expressing 
BHD.  These data collectively suggest that ROS production is increased in the BHD- 
UOK257 cells as a result of decreased mitochondrial membrane potential.  Production of 
UCP and antioxidants such as SOD2 is subsequently increased within these cells in order to 
reduce the excess ROS.  
3.2.6 A loss of mitochondrial cristae is observed in MEF cells upon loss of BHD. 
As depleted ATP levels are observed in the UOK257 cells, together with decreased 
mitochondrial membrane potential, and increased levels of H2O2, I hypothesised that loss of 
BHD may result in a defect in the mitochondria.  Therefore, electron microscopy work was 
conducted in order to examine the mitochondria in the BHD+/+ and BHD-/- MEF cells.   The 
results indicated a trend towards loss of cristae in the BHD-/- MEF cells (Figure 24), resulting 
in approximately a 30% decrease in the surface area of the inner mitochondrial membrane in 
these cells compared to BHD+/+ MEF cells.   
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Figure 23. UOK257 cells deficient in FLCN exhibit increased levels of ROS production. 
(A)  The levels of H2O2 within the growth media of BHD+ UOK257-2 and BHD- UOK257 
cells were analysed using an Amplex red H2O2 assay.  Cells growing in DMEM were washed 
with Krebs ringer buffer before being incubated in Krebs ringer buffer for 30mins in 
normoxia (21%).  Media was then taken from the cells and incubated with Amplex red 
reagent according to manufacturer's instructions before absorbance was read.  Level of 
absorbance is representative of the amount of H2O2 within the growth media of the cells after 
30mins.  (B) The mRNA levels of SOD2 were compared within BHD+ UOK257-2 and BHD- 
UOK257 cell lines by RT-PCR.  mRNA levels were standardised against β-Actin mRNA. n = 
3.   (C) Western blot analyses were performed on cell lysates obtained from BHD- (UOK257) 
and BHD+ (UOK257-2) cells maintained in normoxia (21%) and treated with 50nm 
rapamycin as indicated.  Protein levels of SOD2, Folliculin and β-actin (used as a loading 
control) were determined.  * = significant at the 0.05 significance level. ** = significant at the 
0.01 significance level. 
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Figure 24. A trend towards loss of cristae and reduced surface area of the mitochondria is 
observed upon loss of FLCN. 
Electron microscopy work was conducted looking at mitochondria of (A) BHD-/- MEFs and 
(B) BHD+/+ MEFs maintained in 35 mm plates in DMEM and fixed in 1% glutaraldehyde.  
(C) The surface area of the inner mitochondrial membrane of the mitochondria in the images 
obtained from these cells was then measured and the ratio of surface area of inner 
membrane/total area of mitochondria was determined.  (Work carried out by Mr. Chris Von 
Ruhland). 
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 The electron transport chain synthesises ATP by generating a proton gradient via 
oxidation/reduction reactions, which is subsequently used by ATP synthase to produce ATP 
via the phosphorylation of ADP.  The components of the electron transport chain are 
contained in the inner membrane of the mitochondria.  Cristae are formed to increase the 
surface area of the inner membrane of the mitochondria in order to increase the ability of 
mitochondria to produce ATP via the electron transport chain (Paumard et al., 2002).  The 
trend towards loss of cristae and resulting loss of surface area of the inner membrane of the 
mitochondria in the BHD-/- MEF cells therefore may contribute to the depleted levels of ATP 
production observed upon loss of FLCN. 
It has been observed that H2O2 induces a response in cardiac myocytes which results in the 
mitochondrial permeability transition pore (PTP) being opened.  This results in the loss of 
mitochondrial membrane potential, and swelling of mitochondria (Akao et al., 2006).  
Collectively these data suggest that a loss of FLCN may result in an increase in H2O2 
production, resulting in morphological changes to the mitochondria (swelling and loss of 
cristae), increased UCP levels, a reduction in mitochondrial membrane potential, and 
depleted ATP levels.  AMPK activity levels are subsequently elevated in these cells in order 
to provide metabolic adaptations in order to cope with the depleted levels of ATP as a result 
of this mitochondrial dysfunction. 
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 3.3 Discussion 
3.3.1 Different isoforms of FLCN are localised to the nucleus and the mitochondria. 
 
This chapter provides information for the first time on the cellular localisation of endogenous 
FLCN.  Data obtained from HEK293 cells reveal that FLCN localises to the nucleus, cytosol, 
and mitochondria.   These data support work conducted by Baba et al. which suggested that 
transiently expressed HA-tagged FLCN is localised to the nucleus and mitochondria where it 
interacts with transiently expressed Flag-tagged FNIP1 (Baba et al., 2006).  The results from 
these data also reveal differential expression of FLCN isoforms between the cellular 
compartments.  The upper isoform of FLCN was detected in the nuclear fractions whereas the 
lower isoform of FLCN was detected in the mitochondrial fraction.  Both of these isoforms 
were detected in the cytosolic fraction.  Work conducted by Baba et al. suggests that FLCN 
exists in several phosphorylated forms which are electrophoretically distinct; and that the 
slower migrating species of FLCN are phosphorylated forms of FLCN (Baba et al., 2006).  
These data suggest that the FLCN isoform detected in the nucleus is a phosphorylated species 
of FLCN whereas the FLCN isoform detected in the mitochondria is a dephosphorylated 
species of FLCN.  However it is also possible that the upper FLCN isoform could be as a 
result of another post-translation modification such as ubiquitination. 
 
3.3.2 Differences in the localisation of FLCN are observed upon activation of AMPK and 
inhibition of mTOR 
 
Data obtained from HEK293 cells also revealed that most of the endogenous FLCN 
expressed in the nucleus resolves as the upper isoform when cells are growing in serum.  
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However, when the cells are subjected to treatment with the mTORC1 inhibitor rapamycin, 
the lower isoform of FLCN becomes more apparent in the nuclear fraction.  This suggests 
that rapamycin inhibits the phosphorylation status of the nuclear pool of FLCN.  These 
support the work conducted by Baba et al. also who first showed that rapamycin treatment of 
the UOK257-2 cells led to dephosphorylated over-expressed FLCN in UOK257-2 cells, as 
observed by complete elimination of the upper phospho-FLCN band (Baba et al., 2006).  
These data support the hypothesis by Baba et al. that implies that the mTORC1 signalling 
pathway plays a role in the modulation of FLCN phosphorylation and presumably its tumour 
suppression function.  However it not known whether FLCN is a direct mTORC1 substrate or 
a substrate of a kinase activated downstream of mTOR.  For instance, it is possible that 
FLCN could be directly phosphorylated by S6K1 or S6K2.  Increased expression of the lower 
isoform of FLCN in the mitochondrial fraction was also observed when the HEK293 cells 
were treated with rapamycin, suggesting that dephosphorylated FLCN shuttles to the 
mitochondria.  It is possible that FLCN might be involved in regulating or maintaining 
mitochondrial function to produce energy and control ROS production. 
 
When the HEK293 cells were subjected to treatment with the AMP-dependent kinase 
(AMPK) activator 2-deoxyglucose (2-DG) a third isoform of FLCN was detected in the total 
lysate just above the lower isoform of FLCN.  Decreased expression of the lower isoform of 
FLCN was also observed in the mitochondrial fraction upon treatment with 2-DG.  Work 
conducted by Baba et al. also showed that inhibition of AMPK by AraA inhibited the 
phosphorylation of FLCN in the UOK257-2 cells and phosphorylation of GST-tagged FLCN 
by purified AMPK.  Several phosphorylation sites of FLCN have been identified.  Work 
conducted by Piao et al. identified Ser62 and Ser302 as phosphorylation sites of FLCN, and 
that mTORC1 differentially regulated the phosphorylation of these sites.  In particular, 
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downstream kinases of mTORC1 appear to phosphorylate FLCN at Ser302 (Piao et al., 
2009).  Further investigation revealed that Ser62 of FLCN is phosphorylated in the AMPK-
related pathway, but is not directly phosphorylated by AMPK (Wang et al., 2010).  These 
data support the notion that both mTORC1 and AMPK phosphorylate FLCN at multiple 
residues.   
 
Communication between mitochondria and the nucleus is important in the maintenance of 
energy homeostasis.  Mitochondrial biogenesis requires coordination of the transcription of 
genes located in the mitochondria and in the nucleus which are essential to the process (Hock 
and Kralli, 2009).  As FLCN localises to both the mitochondria and the nucleus, it may be 
possible that FLCN maintains a level of communication between the nucleus and the 
mitochondria involving energy homeostasis.  Both mTORC1 and AMPK are also potent 
drivers of mitochondrial biogenesis and it is thought to be driven by transcriptional events.  It 
is very likely that both mTORC1 and AMPK could drive mitochondrial biogenesis through 
modulation of FLCN phosphorylation.   
 
3.3.3 Mitochondrial biogenesis is enhanced upon loss of function of FLCN 
 
The data presented in this chapter reveal that mitochondrial biogenesis is upregulated in 
multiple FLCN-deficient cell lines.  Of particular interest is the enhanced level of 
transcription of PGC1α observed in the FLCN-deficient UOK257 and MEF cell lines upon 
transfection with a PGC1α luciferase reporter construct.  Results from RT-PCRs conducted 
on BHD-deficient MEF and HK2 cells also revealed that they exhibit increased mRNA levels 
of PGC1α.  Increased mRNA levels of PGC1α have also been observed TSC2 deficient cells, 
in which mTORC1 is highly active, which was rescued upon inhibition with rapamycin 
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(Cunningham et al., 2007).  mTOR and Raptor associate with YY1 and mTOR has been 
shown to regulate the interaction between YY1 and PGC1α and thus alter how they function.  
mTORC1 is therefore able to enhance mitochondrial gene expression in an Akt independent 
manner (Cunningham et al., 2007).  The fact that PGC1α transcription in the BHD-/- MEF 
cells is reduced upon treatment with rapamycin suggests that mTORC1 activity may also be 
contributing to the increased levels of PGC1α transcription and thus mitochondrial 
biogenesis, observed upon loss of FLCN.   
 
PGC1α interacts with nuclear respiratory factor 1 NRF1 and NRF2 thus enhancing 
mitochondrial biogenesis and oxidative function (Bogaka et al., 2005).  Increased mRNA 
levels of NRF1 and NRF2 are observed in the FLCN-deficient cell lines, as well as PGC1β 
and ATP5G1, in a similar manner to that observed in the TSC2-deficient cells (Cunningham 
et al., 2007).  However, although increased NRF1 mRNA levels are observed within the 
BHD- UOK257 cells, no increase in the levels of TFAM mRNA was observed.  This suggests 
that the increased mtDNA levels observed in the BHD- UOK257 cells does not occur as a 
result of increased transcription of TFAM via increased levels of NRF1.  However, increased 
mRNA levels of NRF2 are also observed in the BHD- UOK257 cells.  NRF2 sites have also 
been identified in genes encoding mitochondrial transcription factor A (TFAM) involved in 
mitochondrial transcription and DNA replication (Kelly and Scarpulla, 2004).  Therefore it 
may be possible that increased transcription of mitochondrial transcription factors via the 
increased levels of NRF2 results in the increased mtDNA levels observed in the BHD- 
UOK257 cells.  The fact that increased levels of mitochondrial biogenesis genes are observed 
in multiple BHD-deficient cell lines suggests that this may be applicable to a number of BHD 
tumour types.  The high levels of mitochondrial biogenesis observed in the BHD- UOK257 
cells is in line with observations made by Yang et al., who revealed that chromophobe renal 
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tumours from BHD patients had abnormally high levels of mitochondria. This supports the 
notion that loss of FLCN may result in an accumulation of mitochondria (Yang et al., 2008). 
 
3.3.4 Decreased levels of ATP production are observed upon loss of functional FLCN 
 
The FLCN-deficient cell lines exhibited increased mRNA levels of mitochondrial biogenesis 
genes together with elevated levels of mitochondrial DNA.  Hence it was hypothesised that 
levels of ATP production would also be increased upon loss of FLCN as mitochondria 
generate ATP via oxidative phosphorylation (oxPhos) of glycolysis and lipolysis products 
(Hock and Kralli, 2009).  When ATP levels were analysed within the BHD- UOK257 and 
BHD+ UOK257-2 cells the results revealed that ATP levels are depleted within the FLCN-
deficient UOK257 cell line.  These data, combined with work conducted by Dr. Steven Land 
(our collaborator from Dundee University) using a JC1 monomer, suggest that the 
mitochondria within the FLCN-deficient UOK257 cells do not respire efficiently, and that 
some of the mitochondria in the BHD- UOK257 cells may be swollen, indicating 
morphological changes may occur in the UOK257 cells upon loss of FLCN.  As discussed in 
Chapter 2 the FLCN-deficient UOK257 cells also appear to favour glycolysis over oxidative 
phosphorylation.  Approximately 18 times less ATP is generated by glycolysis compared to 
oxidative phosphorylation (Van der Heiden et al., 2009); possibly contributing to the depleted 
ATP levels exhibited by the BHD- UOK257 cells.  Mitochondrial biogenesis may therefore 
be increased within the FLCN-deficient UOK257 cells as a compensatory mechanism in 
response to this energy deficit.   
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3.3.5 Compromised mitochondrial membrance potential and enhanced expression of 
uncoupling proteins is observed in response to increased levels of ROS production upon loss 
of functional FLCN. 
 
Further analysis conducted on the UOK257 cell line by Dr. Stephen Land suggested that 
mitochondrial membrane potential may be compromised in the BHD- UOK257 cells.  In 
mammalian cells, mitochondrial membrane potential is reduced by UCPs that reduce the 
ability of mitochondria to generate ATP (Patanè, 2002).  Results obtained from the BHD- 
UOK257 cell line revealed elevated mRNA and protein levels of UCP3.  These data suggest 
that increased levels of UCPs within the BHD- UOK257 cells may also account for their 
compromised mitochondrial membrane potential and depleted ATP levels.  UCPs are also 
produced by a cell in order to reduce production of ROS.  Increased ROS production can lead 
to mitochondrial dysfunction as well as misregulation of cellular signalling and chromosomal 
instability.  Therefore ROS production plays a critical role in cancer progression (Bellance et 
al., 2009).  The BHD- deficient cells exhibit a 10- fold increase in ATP5G1 mRNA levels 
compared to a 5- fold increase in mitochondrial DNA content.  These results suggest that loss 
of functional FLCN results in increased transcription of genes involved in oxidative 
phosphorylation in a similar manner to that observed in cells deficient in TSC1.  This 
increase in mitochondrial oxidation in TSC1-deficient cells also results in increased levels of 
ROS production (Chen et al., 2008).  Therefore it was hypothesised that levels of ROS would 
also be increased in UOK257 cells deficient in FLCN.  The results from Amplex Red 
Hydrogen peroxide assays reveal increased levels of H2O2 within the growth media of BHD- 
UOK257 cells.  Furthermore, increased mRNA and protein levels of SOD2 are also exhibited 
in the BHD- UOK257 cell line. These data suggest that ROS production is increased in the 
UOK257 cell line upon loss of FLCN.  The fact that the BHD- UOK257 cells exhibit 
increased levels of ROS production together with increased levels of mitochondrial 
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biogenesis genes suggests that loss of functional FLCN results in the upregulation of ROS 
production and increased mitochondrial biogenesis in a similar manner to that observed in 
TSC1-deficient cells (Chen et al,. 2008). 
 
PGC1α is also a powerful regulator of ROS metabolism and has been shown to induce 
transcription of UCPs in response to ROS (Valle et al., 2005).  It has also been shown that 
PGC1α is required for the induction of SOD2 and other ROS-detoxifying enzymes (St Pierre 
et al., 2006).  It may be possible that the enhanced level of transcription of PGC1α observed 
in FLCN-deficient cells contributes to the enhanced expression of SOD2 observed upon loss 
of BHD.  Therefore the enhanced transcription of PGC1α may also serve to provide a 
protective function against elevated ROS production observed upon loss of FLCN. 
 
3.3.6 Reduced numbers of mitochondrial cristae are observed upon loss of functional FLCN. 
 
Electron microscopy conducted on the BHD+/+ and BHD-/- MEF cells revealed a trend 
towards loss of cristae and thus decreased surface area of the inner mitochondrial membrane 
of BHD-/- MEF cells.  This loss of cristae and resulting loss of surface area of the inner 
membrane of these mitochondria would reduce the ability of these mitochondria to produce 
ATP efficiently via the electron transport chain.  Therefore, it appears that the increased 
levels of H2O2 production observed upon loss of FLCN result in loss of cristae as well as 
swelling of mitochondria, compromised mitochondrial membrane potential and decreased 
levels of ATP production (Akao et al., 2006).  This may explain the fact that the BHD- 
UOK257 cells exhibit a metabolic profile that resembles the Warburg effect.  HIF-mediated 
transcription of genes such as GLUT1 may be increased in order to elevate levels of glucose 
uptake and increase metabolism via glycolysis to compensate for the resulting energy deficit.  
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The ability of FLCN-deficient cells to take up and oxidise the excess L-lactate produced by 
glycolysis may also be a compensatory mechanism in order for these cells to meet their 
energy demands in spite of their lack of ability to produce ATP via the electron transport 
system due to loss of cristae. 
3.3.7 Increased levels of mitochondrial biogenesis observed upon loss of functional FLCN 
may create a transiently hypoxic environment and enhance HIF activity levels. 
 
Enhanced expression of PGC1α and subsequent increased levels of mitochondrial biogenesis 
leads to an increased demand for oxygen.  This transiently creates a hypoxic environment 
within a cell resulting in the stabilisation of HIF1α protein and increased expression of HIF 
transcriptional target genes (Shoag and Arany, 2010).  Increased mitochondrial biogenesis 
may be creating a transiently hypoxic environment within the FLCN-deficient cells and 
consequently reducing the levels of production of ATP within these cells.  This may explain 
why increased levels of HIF transcriptional activity are observed in the FLCN deficient cell 
lines even under normoxic conditions. 
3.3.8 Increased levels of AMPK activity upon loss of functional FLCN may also enhance 
expression of HIF transcriptional targets. 
 
Data obtained revealed that UOK257 cells deficient in FLCN have increased levels of 
phosphorylated AMPK as well as increased levels of phosphorylated Acetyl CoA 
carboxylase (ACC); an indicator of AMPK activity.  Under conditions of low ATP levels 
AMPK functions as an energy sensor and provides changes to cellular metabolism in order to 
adapt to these conditions (Yun et al., 2005).  AMPK has been shown to enhance HIF-1 
transcriptional activity via a signalling pathway independent of the PI3K/Akt (Lee et al., 
2003).  AMPK has also been shown to enhance VEGF and GLUT 1 mRNA levels in a HIF1α 
independent manner (Yun et al., 2005).   It may be possible that AMPK activity levels are 
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increased within the UOK257 cells in response to increased ROS production and subsequent 
depleted ATP levels.  This may then lead to increased levels of VEGF expression, glucose 
uptake and fatty acid oxidation in a HIF1α-dependent and HIF1α-independent manner.  
 
Activation of AMPK in response to oxidative stress is required for the activation of PGC1α in 
skeletal muscle cells and thus activation of mitochondrial biogenesis (Zong et al., 2002).  
Although the levels of PGC1α gene expression within BHD-/- MEFs are reduced upon 
treatment with the mTORC1 inhibitor rapamycin, these levels are not reduced to the levels 
exhibited when the cells express FLCN.  This suggests that PGC1α gene expression is being 
enhanced by multiple mechanisms.   
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 4 The effect of loss of function of FLCN on autophagic activity  
4.1 Introduction 
Autophagy is a process by which cells adapt to stress by catabolising unnecessary structures 
such as organelles and proteins.  Macroautophagy is probably the best characterised form of 
autophagy in mammalian cells and involves the formation of autophagosomes (a double 
membrane vesicle). These autophagosomes engulf cytosolic substrates.  The autophagosomes 
then fuse with lysosomes to form autophagolysosomes and the material that was engulfed 
within the lysosome is degraded; a process which requires proteases (Figure 3) (Hands et al., 
2009). 
Evidence has been provided which suggests that at moderately elevated levels autophagy may 
provide protection for tumour cells.  However when autophagic activity is increased to 
extremely high levels autophagy abandons its protective functions and instead initiates cell 
death (Schönthal, 2009).  Autophagy is also reduced upon loss of several tumour suppressor 
proteins such as PTEN, TSC1 and TSC2, as well as LKB1/STK11 (Maiuri et al., 2009). 
 
Autophagy has also been shown to be negatively regulated by mTOR.  Although the exact 
mechanism as to how mTOR controls autophagy is not well established. (Hands et al., 2009).  
Studies have shown that mTORC1 also regulates autophagy through direct regulation of the 
UNC-51-like kinase 1 (ULK1) –Atg13–FIP200 complex (Figure 3) (Hosokawa et al., 2009).  
Furthermore, work conducted by Dunlop et al. has also revealed that ULK1 inhibits 
mTORC1 by directly phosphorylating Raptor (Dunlop et al, 2011).  Work conducted by 
Parkhitko et al. revealed that levels of autophagic activity in Tsc2−/−p53−/− murine embryonic 
108 
 
fibroblasts (MEFs), which exhibit increased levels of mTORC1 activity, are decreased 
(Parkhitko et al., 2011).   
mTOR may also regulate autophagy by activating the class I PI3K/Akt -pathway (Ren et al., 
2009).  Work conducted by Mortimore and Schworer has shown that amino acids inhibit 
autophagosome formation (Mortimore and Schworer, 1998), which is regulated by mTOR.  
mTOR is also a sensor for ATP (Dennis et al., 2001).  Autophagic sequestration and other 
post-sequestering events in the autophagic pathway have been shown to be sensitive to 
changes in cellular ATP levels (Schellens et al., 1988; Plomp et al., 1989).  
Several reports have shown that targeting mTORC1 with rapamycin induces autophagy 
(Turcotte and Giaccia, 2010).  Treatment with rapamycin has also been shown to result in 
increased levels of autophagic activity in yeast (Noda and Ohsumi, 1998) and rat hepatocytes 
(Blommaart et al., 1995). When Parkhitko et al. examined the effects of a combined 
treatment of the autophagy inhibitor Chloroquine with the mTORC1 inhibitor rapamycin on 
TSC2-deficient tumours they observed that a combination of the two reagents resulted in a 
synergistic reduction in tumour size which was greater than that observed when the tumours 
were subjected to treatment with either reagent alone (Parkhitko et al., 2011).   
The unfolded protein response (otherwise known as the Endoplasmic Reticulum Stress (ERS) 
response) is another process by which cells adapt to stress (Tsutsumi, 2004).  It has been 
shown that, although autophagy and the unfolded protein response function independently, 
when the activity of one of these processes is altered the activity of the other is also altered; 
suggesting that there are important connections between these systems.  When activity of the 
ERS response is moderate to low it has also been shown to protect a cell.  However when 
ERS activity is increased to high levels, it also abandons its protective functions and instead 
initiates cell death (Schönthal, 2009).  Elevated levels of the protective components of the 
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ERS response have also been exhibited by tumour cells as an adaptive mechanism that 
promotes cell survival and the potential anti-cancer benefits of reagents which target 
autophagy by exploiting the ERS response are being explored (Schönthal, 2009).   
FLCN-deficient cells also exhibit increased levels of mTOR activity in a similar manner to 
that observed in TSC-deficient cells (as discussed in Chapter 2) and autophagic activity is 
decreased upon loss of TSC1 or TSC2, which also results in overlapping clinical features to 
BHD patients.  Hence I wanted to examine levels of autophagic activity in FLCN-deficient 
cell lines.  In this chapter, I investigated the mRNA levels of genes involved in the regulation 
of autophagy and the expression of downstream autophagy markers in the context of loss of 
FLCN.  The potential for autophagy to be exploited as a potential therapeutic target for BHD 
patients is also investigated. 
4.2 Results  
4.2.1 Autophagic activity is upregulated upon loss of FLCN. 
In order to determine the effects of overexpression of FLCN on the regulation of autophagy, 
western blots probing for the downstream autophagy markers p62 and Microtuble-associated 
protein light chain 3 (LC3) were conducted on UOK257 (BHD-) and UOK257-2 (BHD+) 
cells treated with or without rapamycin (Figure 25a).  It has been shown that protein levels of 
p62 may be indicative of autophagic activity as well as the conversion of LC3-I (Cytosolic) 
to LC3-II (lipidated) (Wang et al., 2006).  In the BHD+ UOK257 cells; the ratio of LC3-I to 
LC3-II protein was approximately equal (Figure 25a).  However, in the BHD- cells the 
majority of LC3 was in the second isoform (LC3-II) and indicates that these cells generate 
more autophagosomes.  A decrease in the protein levels of p62 was also observed in the 
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BHD- UOK257 cells.  Together, these data suggest that autophagic activity is increased in 
UOK257 cells devoid of FLCN.  
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Figure 25. ULK-mediated autophagy is upregulated in UOK257 cells devoid of FLCN. 
(A) Lysates were created from BHD- UOK257 and BHD+ UOK257 cells maintained in 
normoxia (21%) and treated overnight with 50nm Rapamycin where indicated.  Western blot 
analyses were then performed and protein levels of P62, LC3, Folliculin and β-actin were 
determined.  (B) The mRNA levels of ULK1 were compared within the UOK257 and 
UOK257-2 cell lines by RT-PCR. mRNA levels were standardised against β-Actin mRNA. n 
= 3. (C) The mRNA levels of ULK2 were compared within UOK257 and UOK257-2 cell 
lines by RT-PCR. mRNA levels were standardised against β-Actin mRNA.  n = 3.  * = 
significant at the 0.05 significance level. ** = significant at the 0.01 significance level. 
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The effects of FLCN on the regulation of genes involved in the initiation of the autophagy 
pathway in the UOK257 cell line were then examined.  Given that ULK1 and UNC-51-like 
kinase 2 (ULK2) are vital for initiation of autophagy and ULK1 has been shown to be 
regulated by AMPK (Lee et al., 2010), I wanted to analyse ULK1 and ULK2 in the UOK257 
cell line.  RT-PCR was used to determine the mRNA levels of ULK1 (Figure 25B) and 
ULK2 (Figure 25C) in the UOK257 (BHD-) and UOK257-2 (BHD+) cell lines.  Increased 
levels of AMPK activity have been observed in the UOK257 cell line and AMPK has been 
shown to activate ULK-mediated autophagy by binding to the PS domain of ULK1 (Lee et 
al., 2010).   Approximately a 10 fold increase in ULK1 mRNA levels was observed in the 
BHD- UOK257 cells together with a 5 fold increase in ULK2 mRNA.  These data suggest 
that there is increased transcription of genes involved in the initiation of autophagy in the 
BHD- UOK257 cell lines and support the notion that autophagic activity is increased upon 
loss of FLCN.   
In order to confirm these results, the effects of loss of FLCN on the regulation of autophagy 
were examined in the BHD-/- and BHD+/+ MEF cells lines.  The expression levels of p62 and 
LC3-I versus LC3-II protein were determined via western blot analysis (Figure 26a).  The 
mRNA levels of ULK1 were determined by RT-PCR in these cells (Figure 26B).  In the 
BHD+/+ MEF cells the ratio of LC3-I to LC3-II protein was approximately equal.  However, 
in the BHD-/- MEF cells the majority of LC3 was in the second isoform (LC3-II).  A decrease 
in the protein levels of p62 was also observed in the BHD-/- MEF cells.  Approximately a 3 
fold increase in ULK1 mRNA levels was also observed in the BHD-/- MEF cells.  
Collectively, these data supported the data obtained from the UOK257 cell lines and 
suggested that autophagic activity is upregulated upon loss of FLCN. 
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Figure 26. ULK-mediated autophagy is also upregulated in BHD-/- MEF cells.  
(A) Lysates were created from BHD-/- and BHD+/+ MEF cells maintained in normoxia (21%).  
Western blot analyses were then performed and protein levels of P62, LC3, Folliculin and β-
actin were determined.  (B) The mRNA levels of ULK1 were compared within BHD-/- and 
BHD+/+ MEF cells by RT-PCR.  mRNA levels were standardised against β-Actin mRNA.  n 
= 3.  * = significant at the 0.05 significance level. ** = significant at the 0.01 significance 
level. 
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4.2.2 Increased level of BNIP3 expression observed in BHD-deficient cells does not account 
for the increased levels of autophagic activity exhibited upon loss of BHD. 
 
Several studies have shown that localisation of Bcl-2/adenovirus E1B 19-kDa-interacting 
protein 3 (BNIP3) to the mitochondria may result in decreased mitochondrial membrane 
potential and increased levels of ROS production, often resulting in necrosis or apoptotic cell 
death (Burton et al., 2009).  It has also been suggested that BNIP3 is able to induce 
autophagy by competing with Beclin-1 for binding with Bcl-2.  The binding of Bcl-2 to 
Beclin-1 inhibits the induction of autophagy, therefore it has been suggested that if there are 
increased levels of BNIP3 available to bind to Bcl-2, there is more Beclin-1 avalable to 
stimulate autophagy.  BNIP3, by binding to and repressing Rheb, may also be able to initiate 
autophagy by inhibiting activation of mTORC1, a potent inhibitor of autophagy (Burton et 
al., 2009) (Figure 27a).  It has also been shown that dysfunctional mitochondria are turned 
over by autophagy during development and under pathological conditions such as cancer 
(termed mitophagy) (Tolkovsky, 2009).  Studies conducted by Hamacher-Brady et al. have 
shown that BNIP3 mediates mitochondrial dysfunction and cell death, and that BNIP3-
mediated autophagy is increased in HL-1 cardiac myocytes as a protective mechanism against 
the BNIP3-mediated cell death observed in these cells (Hamacher-Brady et al., 2006).  
Further studies conducted by Rikka et al. revealed that mitochondrial autophagy is initiated in 
response to BNIP3-mediated mitochondrial dysfunction; resulting in increased mitochondrial 
turnover (Rikka et al., 2011).   
Work conducted by Dr. Stephen Land has suggested that the BHD- UOK257 cells have 
decreased mitochondrial membrane potential (as discussed in Chapter 3) and investigations 
into the expression levels of HIF transcriptional targets suggest that the BHD- UOK257 cells 
have increased protein levels of BNIP3 (as discussed in Chapter 2).  I therefore wanted to 
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examine whether BNIP3 may be involved in the mitochondrial dysfunction observed in the 
UOK257 cells and whether autophagy was being activated in these cells in response to 
BNIP3-mediated activation of the mitochondrial cell death pathway.   
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Figure 27 Increased BNIP3 mRNA levels do not account for the increased levels of 
autophagic activity observed in the UOK257 cells upon loss of FLCN. 
(A) Several studies have shown that BNIP3 may induce all of the main types of cell death; 
necrosis, apoptosis and/or autophagy (Burton and Gibson, 2009). (B)  Mitochondrial, nuclear 
and cytosolic protein lysates were created from BHD- UOK257 and BHD+ UOK257-2 cells 
maintained in normoxia (21%).  Western blot analyses were then performed and protein 
levels of BNIP3, Folliculin, lamin A/C, LDH and cytochrome C were determined.  (C) The 
mRNA levels of Beclin were compared within BHD+ UOK257-2 and BHD- UOK257 cells 
by RT-PCR.  mRNA levels were standardised against β-Actin mRNA.   
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As BNIP3 initiates cell death and mitochondrial dysfunction when it is localised to the 
mitochondria, the first stage of investigating whether BNIP3 was involved in the 
mitochondrial dysfunction observed in the BHD- UOK257 cells was to determine where 
BNIP3 was localised in the BHD- UOK257 and BHD+ UOK257-2 cells. Cytosolic, nuclear 
and mitochondrial fractions were created from UOK257 and UOK257-2 cell lines and 
western blots probing for BNIP3 were conducted (Figure 27B).  The results revealed that in 
the BHD- UOK257 cells, BNIP3 is localised to the nucleus whereas in the BHD+ UOK257 
cells, BNIP3 is localised to both the nucleus and the mitochondria.  Therefore it appears that 
the increased levels of autophagic activity observed in these cells are not a response to BNIP3 
mediated mitochondrial dysfunction and initiation of the mitochondrial cell death pathway.  
However, it may still be possible that increased levels of BNIP3 are contributing to the 
increased levels of autophagic activity observed in the UOK257 cells upon loss of FLCN, as 
mitochondrial autophagy initiated by BNIP3 is not dependent on the mitochondrial cell death 
pathway being initiated (Rikka et al., 2011).   
 
Beclin-1, a Bcl-2-interacting protein, has also been shown to induce autophagy in mammalian 
cells (Liang et al., 1999).  Beclin-1 is a member of the ATG family which is involved in 
autophagosome formation (Meijer and Codogno, 2004).  A positive association has also been 
revealed between HIF1α protein expression and expression of Beclin 1 (Wan et al., 2010).  
Therefore the mRNA levels of Beclin-1 in the BHD- UOK257 and BHD+ UOK257-2 cells 
were determined via RT-PCR (Figure 27C).  The results revealed that no difference in the 
levels of Beclin-1 mRNA occured in the BHD- UOK257 versus the BHD+ UOK257-2 cells.  
These data suggest that increased levels of transcription of Beclin-1 do not account for the 
increased levels of autophagic activity observed within the BHD- UOK257 cells. 
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4.2.3 Exploiting the increased levels of autophagy observed upon loss of BHD may provide a 
potential therapeutic target for BHD patients 
 
Therapeutic strategies have been developed which seek to exploit the protective components 
of autophagy and the ERS response and activate apoptotic cell death in tumour cells 
(Schönthal, 2009).  Nelfinavir was initially developed as a treatment for (HIV).  It has been 
shown that Nelfinavir triggers the ERS response via inhibiting the proteasome which leads to 
subsequent accumulation of ‘garbage’ proteins which are bound for the Endoplasmic 
Reticulum Associated Protein Degradation (ERAD) pathway which targets these proteins for 
ubiquination and degradation by the proteasome (Schönthal, 2009).  3-Methyladenine (3MA) 
inhibits autophagy by inhibiting the maturation of autophagosomes (Castino et al., 2005).  
Therefore I sought to examine the effects of these reagents on the levels of autophagy in the 
BHD+/+ and BHD-/- MEFs.  First of all, the BHD+/+ and BHD-/- MEF cells were treated with 
30 µM Nelfinavir and 5 mM 3MA where indicated and their effects on protein expression 
levels of LC3 were determined via western blot (figure 28a).  The results suggested that the 
ratio of LC3-II to LC3-I exhibited by the BHD+/+ MEF cells was increased to levels similar to 
those observed in the BHD-/- MEFs (figure 28a) when the cells were subjected to treatment 
with Nelfinavir. These data suggests that Nelfinavir induced autophagy in these cells.  
Treatment of the BHD-/- MEF cells with 3MA resulted in a reduction of the ratio of LC3-II to 
LC3-I so that both isoforms were expressed at approximately equal levels in a similar manner 
to that displayed in the BHD+/+ MEF cells (Figure 28a).   
As low to medium levels of autophagic activity are thought to provide an advantage to 
tumour cells by promoting cell survival a CyQUANT (R) cell proliferation assay was 
conducted to investigate the effects of Nelfinavir and 3MA on the proliferation of the BHD+/+ 
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and BHD-/- cells.  3MA appeared to have very little effect on the proliferation of either cell 
line. Although a general decrease in proliferation was observed when the cells were treated 
with 3MA in combination with Nelfinavir in a dose dependent manner, no difference between 
the proliferation of BHD+/+ and BHD-/- cells was observed (Figure 28B). 
As 3MA on its own did not appear to have a significant effect on the proliferation of either 
cell line, I decided to examine the effects of another drug which inhibits autophagy, 
Chloroquine.  Chloroquine is a drug which was initially developed as an anti-malarial drug 
but has subsequently been shown to inhibit autophagy by inhibiting the degradative function 
of autolysosomes through altered lysosomal pH (Degtyarev et al., 2008).  First, the BHD+/+ 
and BHD-/- MEF cells were treated with 30 µM Nelfinavir and 100 µM Chloroquine, where 
indicated, and their effects on protein levels of LC3 were determined via western blot 
analysis (Figure 29).  These results also suggested that the ratio of LC3-II to LC3-I exhibited 
by the BHD+/+ MEF cells was increased to levels similar to those observed in the BHD-/- 
MEFs (figure 29) when the cells were subjected to Nelfinavir treatment.  No difference was 
observed in the ratio of LC3-II to LC3-I in the BHD-/- MEF cells upon treatment with 
Nelfinavir, however an accumulation of LC3-II was observed in both cell lines.  Chloroquine 
treatment on its own did not appear to have an effect on the protein expression levels of p62 
in the BHD-/- MEF cells and appeared to decrease p62 protein expression levels in the 
BHD+/+ MEF cells.  An increased ratio of LC3-II to LC3-I was also observed in both cell 
lines under conditions of Chloroquine treatment.  However, in glioma cells treatment with  
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Figure 28. 3MA reduces autophagic activity in BHD-/- MEF cells but does not significantly 
affect cell proliferation.   
(A) Lysates were created from BHD-/- and BHD+/+ MEF cells maintained in normoxic 
conditions (21%) and treated overnight with 30µM Nelfinavir and 5mM 3MA where 
indicated.  Western blot analyses were performed and protein levels of LC3 were determined.  
Densitometry analyses were performed in order to determine the ratio of LC3-II to LC3-I 
(level of LC3-II as a percentage of total LC3 shown).  (B) CyQUANT (R) cell proliferation 
assays were carried out on BHD-/- and BHD+/+ MEF cells maintained in normoxic conditions 
(21%) and treated overnight with 5mM 3MA and Nelfinavir at 20µM, 30µM, and 40µM 
concentrations where indicated and absorbance was read.  Level of absorbance is 
representative of the amount of cells present and therefore the level of cell proliferation.   
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Chloroquine an accumulation of LC3-II and increased formation of autophagic vacuoles was 
observed which consequently induced cell death (Geng et al., 2010).  It may be possible that 
chloroquine is having a similar effect in these cells.  Treatment of the BHD+/+ and BHD-/- 
MEF cells with a combination of both Chloroquine and Nelfinavir resulted in a further 
decrease in p62 protein levels and an increased ratio of LC3-II to LC3-I in both cell lines; 
suggesting that a combination of Nelfinavir and Chloroquine results in the largest increase in 
autophagic activity in these cells.  A CyQUANT (R) cell proliferation assay was then 
conducted in order to investigate the effects of Nelfinavir and Chloroquine on the 
proliferation of the BHD+/+ and BHD-/- cells (Figure 30a).  The results suggested that 
treatment with Nelfinavir selectively inhibited the proliferation of the BHD-/- MEF cells in a 
dose dependent manner both on its own and in combination with 100 μM Chloroquine.  
Treatment with 100 μM Chloroquine on its own also selectively inhibited the proliferation of 
BHD-/- MEF cells by approximately 40%.   
P62
BHD
β-Actin
Nelfinavir (30μM)
Chloroquine (100μM)
BHD +
+
+ + +
+ + +
+
+
+ +
- - - -
-- - -
- - - -
 
47 96 70 73 82 99 97 100
LC3
BHD-
MEFs
Figure 29.  Treatment with Nelfinavir and Chloroquine results in an accumulation of LC3-II 
in BHD-/- MEF cells. 
Lysates were created from BHD-/- and BHD+/+ MEF cells maintained in normoxic conditions 
(21%) and treated overnight with 30µM Nelfinavir and 100µM Chloroquine where indicated.  
Western blot analyses were then carried out and protein levels of LC3, P62, Folliculin and β-
actin were determined.  Densitometry analyses were performed in order to determine the ratio 
of LC3-I to LC3-II (level of LC3-II as a percentage of total LC3 shown).   
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A combination of Nelfinavir and Chloroquine appeared to have a synergistic effect on the 
proliferation of BHD-/- MEF cells when compared to treatment with each reagent on its own. 
I next sought to determine whether Nelfinavir and Chloroquine selectively induce cell death 
in the BHD-/- MEFs rather than simply inhibit proliferation.  As the cell proliferation assay 
suggested that treatment with Nelfinavir at the 30 μM concentration produced the most 
significant difference in terms of cell proliferation between the BHD+/+ and BHD-/- MEF 
cells, 30uM Nelfinavir was used.  BHD+/+ and BHD-/- MEF cells were treated with 
Chloroquine (100 μM) and Nelfinavir (30 μM) as indicated and an anti-histone based cell 
death ELISA assay was conducted (Figure 30B).    Approximately a 4 fold increase in levels 
of cell death was observed in the BHD-/- MEF cells upon treatment with 30μM Nelfinavir 
both on its own and in combination with 100μM Chloroquine.  Treatment with 100μM 
Chloroquine on its own increased levels of cell death in the BHD-/- MEF cells by 
approximately 3 fold.   
Collectively, the results suggested treatment with Nelfinavir, Chloroquine, or a combination 
of both selectively induced cell death in the BHD-/- MEF cells at these concentrations.  
In order to determine whether Chloroquine and Nelfinavir selectively induce cell death in the 
BHD-/- MEFs at slightly lower concentration levels, BHD+/+  and BHD-/- MEF cells were 
treated with Chloroquine (50 μM) and Nelfinavir (20 μM), as indicated, and a cell death 
ELISA assay was conducted (Figure 31).  Cells were also treated with a combination of 50 
nm rapamycin and 50 μM Chloroquine where indicated for comparison. Treatment with 20 
μM Nelfinavir still induced cell death selectively in the BHD-/- MEF cells, although this 
induction of cell death was to a lesser degree than that observed when the cells were treated 
with 30 μM Nelfinavir.   
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Figure 30. Treatment with Nelfinavir and Chloroquine selectively reduces proliferation of 
BHD-/- MEF cells and selectively induces cell death in BHD-/- MEF cells. 
(A) CyQUANT (R) cell proliferation assays were carried out on BHD-/- and BHD+/+ MEF 
cells maintained in normoxia (21%) and treated overnight with 100µM Chloroquine and 
Nelfinavir at 10µM, 20µM, and 30µM concentrations where indicated and absorbance was 
read.  Level of absorbance is representative of the amount of cells present and therefore cell 
number  n=3.  (B) Cell death assays were carried out on BHD-/- and BHD+/+ MEF cells 
maintained in normoxia (21%) and treated overnight with 100µM Chloroquine and 30µM 
Nelfinavir where indicated and absorbance was read.  Level of absorbance is representative 
of the amount of histone and therefore level of cell death.  n=3.  * = significant at the 0.05 
significance level. ** = significant at the 0.01 significance level. 
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Treatment with 50 μM Chloroquine did not induce cell death in either cell line; however a 
combination of 20 μM Nelfinavir and 50 μM Chloroquine resulted in an increase in cell death 
levels in the BHD-/- MEF cells of approximately 5.5 fold.  Treatment with a combination of 
50 nM rapamycin and 50 μM Chloroquine selectively induced cell death in the BHD-/- MEF 
cells by approximately 4.5 fold; however this effect was not as great as that observed after 
combined treatment with 50 μM Chloroquine and 20 μM Nelfinavir.  These data support the 
notion that exploiting the increased levels of autophagy observed upon loss of FLCN may 
provide a potential therapeutic target for BHD patients. 
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Figure 31   Treatment with Nelfinavir and Chloroquine at lower concentrations still 
selectively induces cell death in BHD-/- MEF cells. 
(A) Cell death assays were carried out on BHD-/- and BHD+/+ MEF cells maintained in 
normoxia (21%) and treated overnight with 50µM Chloroquine, 20µM Nelfinavir, and 50nm 
rapamycin where indicated and absorbance was read.  Level of absorbance is representative 
of the amount of histone and therefore level of cell death.  n=3.  * = significant at the 0.05 
significance level. ** = significant at the 0.01 significance level. 
123 
 
 4.3 Discussion 
 
4.3.1 ULK mediated autophagic activity is upregulated upon loss of function of FLCN 
 
Autophagy may be reduced upon loss of several tumour suppressor proteins such as PTEN, 
TSC1 and TSC2, as well as LKB1/STK11 (Maiuri et al., 2009).  Although moderately 
elevated levels of autophagy may provide protection for tumour cells, apoptosis can be 
initiated when autophagic activity becomes extremely high.  The protective functions of 
autophagy are abandoned when autophagy becomes too high and triggers cell death 
(Schönthal et al., 2009).  Data from this chapter provide evidence that autophagic activity is 
upregulated in cells deficient in FLCN.  Further analysis into autophagy also suggests that 
exploitation of their high autophagic activity may provide a potential therapeutic target for 
BHD patients.  Given that BHD- UOK257 cells exhibit decreased expression levels of p62 
protein and an accumulation of LC3-II protein, it is likely that both ULK1 and ULK2 are 
driving the autophagic activity in the UOK257 cells deficient in FLCN.  This may be due to 
increased levels of AMPK resulting in activation of ULK1.  Of interest there is an 
accumulation of the second isoform of LC3 in the BHD- UOK257 cells.   
 
4.3.2 Aberrant levels of mTORC1 activity do not appear to inhibit levels of autophagic 
activity upon loss of functional FLCN. 
 
As discussed in Chapter 2; BHD- UOK257 cells exhibit increased levels of mTORC1 
activity.  Autophagy is suppressed by mTORC1 through direct regulation of the 3-MDa 
ULK1–Atg13–FIP200 complex (Hosokawa et al., 2009).  mTORC1 inhibition has also been 
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shown to reduce phosphorylation of ULK1, suggesting that mTORC1 inhibits ULK1 by 
direct phosphosphorylation (Kim et al., 2011).  Thus, increased levels of mTORC1 activity 
should lead to inhibition of ULK1-mediated autophagy.  However, RT-PCR data obtained 
from the UOK257 cell line suggested that BHD- UOK257 cells exhibit increased levels of 
ULK1 and ULK2 mRNA.  During autophagy, the cytosolic form of LC3 (LC3-I) is converted 
to LC3-II, at the same time as cytoplasmic components are being engulfed by 
autophagosomes.  LC3-II, is subsequently recruited to autophagosomal membranes.  
Lysosomes then fuse with the autophagosomes to form autolysosomes and then degradation 
of the engulfed cytoplasmic components within the autophagosomes occur (Tanida et al., 
2008).  The accumulation of LC3-II protein within the BHD- UOK257 cells could also 
suggest that the autophagosomes may have difficulties fusing with lysosomes in these cells.  
The fact that increased levels of ULK1 mRNA are also exhibited in a BHD-/- MEF cell line, 
together with decreased levels of p62 protein and an accumulation of LC3-II protein, suggests 
that ULK-mediated autophagic activity is also upregulated in these cells.  These data support 
the work conducted on the UOK257 cell line and suggest that increased autophagic activity 
can occur upon loss of FLCN. 
4.3.3 Aberrant levels of AMPK activity may be contributing to the increased levels of 
autophagic activity upon loss of functional FLCN. 
 
The mitochondrial dysfunction and subsequent reduction in mitochondrial membrane 
potential and ATP levels observed in the BHD- UOK257 cells result in the increased levels of 
AMPK activity (as discussed in Chapter 3).  The high levels of AMPK activity in these BHD 
null cells are most likely leading to ULK1 complex activation as AMPK has been shown to 
bind to, phosphorylate and activate ULK1 (Kim et al., 2011).  It is possible that the high 
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levels of AMPK induced phosphorylation of ULK1 lead to increased levels of autophagic 
activity in the UOK257 cells deficient in FLCN. 
 
4.3.4 The elevated levels of autophagic activity observed in these cells are not a response to 
BNIP3 mediated mitochondrial dysfunction and initiation of the mitochondrial cell death 
pathway. 
 
HIF is able to mediate autophagy via the induction of BNIP3 (Bellot et al., 2009).  Several 
studies have shown that BNIP3 is able to induce mitochondrial dysfunction and cell death, 
and that autophagy is upregulated in response to BNIP3-mediated mitochondrial dysfunction 
and cell death (Hamacher-Brady et al., 2006).  As I saw higher levels of BNIP3 mRNA and 
protein in the BHD- UOK257 cells, I hypothesised that the observed reduction of 
mitochondrial membrane potential and high autophagic activity upon loss of functional 
FLCN could involve BNIP3.  However, western blot analyses revealed that BNIP3 is not 
localised to the mitochondria in BHD- UOK257 cells, suggesting that the elevated levels of 
autophagic activity observed in these cells are not a response to BNIP3 mediated 
mitochondrial dysfunction and initiation of the mitochondrial cell death pathway.  However, 
it may still be possible that increased levels of BNIP3 are contributing to the increased levels 
of autophagic activity observed in the UOK257 cells upon loss of FLCN; as mitochondrial 
autophagy initiated by BNIP3 is not dependent on the mitochondrial cell death pathway being 
initiated (Rikka et al., 2011).  It could be possible that nuclear localised BNIP3 could also 
have a part to play in upregulation of gene-expression that drives autophagy.  
 
RT-PCR analyses also revealed no difference in the mRNA levels of Beclin-1 between the 
UOK257 cell lines.  This suggests that that increased levels of transcription of Beclin-1 do 
126 
 
not account for the increased levels of autophagic activity observed within the BHD- 
UOK257 cells. 
 
4.3.5 The increased levels of autophagic activity observed upon loss of function of FLCN may 
serve to protect against mitochondrial dysfunction and subsequent induction of apoptosis. 
 
Work conducted by Xu et al. has also shown that production of H2O2 leads to mitochondrial 
dysfunction which induces apoptosis and autophagy (Xu et al., 2010).  It has also been shown 
that dysfunctional mitochondria are turned over by autophagy (Tolkovsky et al., 2009).  
Investigations conducted on the UOK257 cell line revealed that BHD- UOK257 cells are not 
respiring properly due to the presence of dysfunctional mitochondria.  Further investigation 
has revealed that there are also elevated levels of H2O2 in the growth media of BHD- cells.  
Combined with the increased levels of autophagic activity in the BHD- UOK257 cells these 
data imply that increased H2O2 production may have resulted in mitochondrial dysfunction 
and that this may have led to subsequent induction of autophagy in the UOK257 cells upon 
loss of FLCN in order to try and catabolise these dysfunctional mitochondria.   
 
4.3.6 Inhibition of autophagic activity via treatment with Chloroquine selectively induces cell 
death in BHD-deficient cells. 
 
Therapeutic strategies have been developed which seek to exploit the protective components 
of autophagy and activate apoptotic cell death in tumour cells (Schönthal et al., 2010).  As 
elevated levels of autophagic activity are observed in the FLCN-deficient cell lines, I sought 
to investigate whether exploiting the protective components of autophagy may be a potential 
therapeutic strategy for treatment of BHD patients.  Data obtained from the BHD+/+ and 
BHD-/- MEF cells revealed that treatment with 3MA did not result in the selective inhibition 
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of proliferation of the BHD-/- MEF cells.  However, treatment with Chloroquine at the 100 
µM concentration did selectively inhibit cell proliferation and induce cell death in the BHD-/- 
MEFs.  Treatment with Chloroquine has been shown to increase the formation of autophagic 
vacuoles and induces cell death in glioma cells (Geng et al., 2010).  An accumulation of 
LC3-II is also observed in the BHD-/- cells when treated with 100 µM Chloroquine.  It is 
possible that Chloroquine at the 100 µM concentration induced cell death in these cells by 
impeding autophagic fluxing.  These data support the notion that the elevated levels of 
autophagic activity exhibited by these cells is providing a protective function and suggests 
that inhibition of autophagic activity may provide a potential therapeutic treatment for BHD 
patients.  It may be beneficial to investigate whether other autophagy inhibitors may provide 
therapeutic benefit for BHD patients. 
 
4.3.7 Activation of the ERS response and autophagic activity selectively induces cell death in 
BHD-deficient cells 
 
It has been shown that, although autophagy and the ERS response pathway function 
independently; when the activity of one of these processes is altered the activity of the other 
is also altered.  Work conducted by Kang et al. also suggested that ER stress inducing 
reagents may be used to selectively kill TSC1 or TSC2 mutant cells and could provide 
therapeutic benefit for patients with TSC (Kang et al., 2010).  It may be possible that 
treatment with ER stress reagents increases the already elevated autophagic activity in the 
BHD-/- MEFs to a level which would selectively induce cell death in these cells.  Evidence to 
support this notion was provided by data obtained from BHD+/+ and BHD-/- MEF cells treated 
the reagent Nelfinavir.  Data obtained from these cells revealed that treatment with Nelfinavir 
resulted in an accumulation of LC3-II protein in these cells; indicative of autophagic activity.  
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Cell death ELISAs revealed that treatment with Nelfinavir selectively inhibits cell 
proliferation and induces cell death in the BHD-/- cells (both at the 20 µM and 30 µM 
concentration).  As Nelfinavir enhanced autophagy in these cells, this work suggests that 
further increases in autophagic activity can lead to cell death in BHD deficient cells.  Another 
proteosomal inhibitor which induces ER stress is bortezomib (Velcade).  Bortezomib is 
already clinically approved for treating other cancers and may selectively induce cell death in 
the BHD-/- MEFs by inducing autophagy in a similar manner to that observed under 
conditions of Nelfinavir treatment.   
 
4.3.8 Treatment with a combination of Chloroquine and Nelfinavir appears to have a 
synergistic effect in selectively inducing cell death in BHD-deficient cells. 
 
Several reports have shown that targeting mTORC1 with rapamycin induces autophagy 
(Turcotte and Giaccia, 2010).  When Parkhitko et al. examined the effects of a combined 
treatment of Chloroquine with the mTORC1 inhibitor rapamycin on TSC2-deficient tumours 
they observed that a combination of the two reagents resulted in a reduction in tumour size 
which was greater than that observed when the tumours were subjected to treatment with 
each reagent individually.  Data obtained from BHD+/+  and BHD-/- MEF cells suggested that 
treatment with a combination of 50 nm rapamycin and 25 µM Chloroquine also selectively 
inhibited proliferation and induced cell death in BHD-/- MEF cells.  However this induction 
of cell death in the BHD-/- cells was not as great as that observed when the BHD-/- cells were 
treated with a combination of 25 μm Nelfinavir and 50 μM Chloroquine.  This work suggests 
that out of the combinations tested, treatment with both 25 μm Nelfinavir and 50 μM 
Chloroquine was the most effective at selectively inducing cell death in the BHD-/- cells.  
These data are supported by western blot analyses which revealed that treatment of BHD-/- 
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cells with Chloroquine and Nelfinavir resulted in the largest decrease in p62 protein levels 
and the greatest accumulation of LC3-II protein.  The fact that both of these reagents are 
currently administered to humans for treatment of malaria (Chloroquine) and HIV 
(Nelfinavir) enhances their potential as a therapeutic treatment for BHD as these reagents are 
safe to administer to humans.  However further analysis will have to be conducted in order to 
confirm whether these drugs have therapeutic potential in the context of BHD.  It may also be 
beneficial to investigate whether treatment with combinations of other ERS response inducers 
and autophagy inhibitors, such as those mentioned above, could inhibit proliferation and 
induce cell death in FLCN-deficient cells more effectively than the combination of Nelfinavir 
and Chloroquine, and so provide alternative drug combinations.   
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5 Final discussion 
 
Data presented in chapters 2, 3 and 4 revealed that loss of functional FLCN resulted in 
increased levels of mTOR signalling and AMPK activity.  Aberrant levels of HIF 
transcriptional activity and transcription of genes involved in mitochondrial biogenesis are 
also observed within FLCN-deficient cells, including PGC1α.   The elevated levels of 
mitochondrial biogenesis upon loss of functional FLCN have subsequently resulted in 
increased mitochondrial DNA levels.  Mitochondrial dysfunction and reduction of 
mitochondrial cristae has also been observed in FLCN-deficient cells.  Loss of functional 
FLCN results in increased levels of ROS production, depleted ATP levels and increased 
mitochondrial membrane permeability.  These changes upon loss of functional FLCN result 
in BHD-deficient UOK257 cells exhibiting a metabolic profile resembling the Warburg 
effect.  Elevated levels of ULK-mediated autophagic activity were also observed in cells 
deficient in functional FLCN.  Furthermore, data obtained from BHD-/- MEF cells suggests 
that increased autophagic activity exhibited upon loss of functional FLCN may be exploited 
as a potential therapeutic target.  Here I shall discuss my findings presented in these chapters 
that indicate how FLCN might function as a tumour suppressor. Furthermore, I will discuss 
how my findings might provide useful insight for potential therapeutic strategies to reduce 
tumour formation (cancer progression) in BHD patients. 
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 5.1 Translocation of FLCN between the nucleus and mitochondria may be involved in sensing 
ROS, and the maintenance of energy homeostasis. 
 
Data obtained from localisation studies conducted on HEK293 cells revealed that endogenous 
FLCN localised to the nucleus, cytoplasm and mitochondria.  This localisation of FLCN is 
altered upon inhibition of mTOR and activation of AMPK, both of which are involved in 
mitochondrial biogenesis and are sensitive to changes in ATP levels.  Given that increased 
levels of ROS production are also observed upon loss of functional FLCN, it may be possible 
that FLCN is involved in energy homeostasis and sensing ROS.   In response to ROS and 
other DNA damage agents, the DNA damage response pathway is activated in order to repair 
the damage and/or initiate apoptosis.  The signalling response initiated depends on the type of 
DNA damage present.  For example ATM and ATR mediate repair of double strand breaks 
while members of the Poly(ADP-ribose) polymerase family mediate repair of double and 
single strand breaks.  Mutations in genes involved in the DNA damage response pathway can 
also lead to defects within the immune, nervous and reproductive systems as well as 
premature aging and cancer (Ciccia and Elledge, 2010).  It may be possible that FLCN and its 
complexes are involved in sensing DNA damage and subsequent initiation of the DNA 
damage response pathway and apoptotic response.    
Data obtained by electron microscopy conducted on the BHD+/+ and BHD-/- MEF cells 
suggests that increased ROS levels upon loss of FLCN may lead to loss of cristae.  This 
subsequently results in decreased surface area of the inner mitochondrial membrane and 
reduced ability for these FLCN-deficient cells to produce ATP via the electron transport 
chain (Akao et al., 2003).  However, the mitochondrial damage exhibited and subsequent 
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decreased mitochondrial membrane potential may be increasing ROS production and thus 
causing DNA damage within FLCN-deficient cells.  To determine whether increased levels 
of ROS result in loss of mitochondrial cristae upon loss of functional FLCN or whether the 
cristae remodelling results in increased levels of ROS, electron microscopy work may be 
undertaken after treating BHD-/- MEF cells with antioxidants (Blokhina, 2003).  If increased 
numbers of cristae are observed after treating the cells with antioidants this may suggest that 
it is the increased levels of ROS which are causing the loss of cristae within the mitochondria 
of BHD-deficient cells. 
 
Data obtained from the BHD-deficient cells suggest that levels of PGC1α gene transcription 
are upregulated upon loss of FLCN.  The fact that the data presented in chapter 3 suggest that 
PGC1α is upregulated upon knockdown of BHD by shRNA suggests that FLCN may directly 
regulate PGC1α.  Further interaction studies conducted on purified FLCN would be required 
in order to determine whether FLCN interacts and regulates PGC1α directly.  For example 
Folliculin could be purified using immunoprecipitation and mass-spectrometry analyses 
performed in order to determine whether PGC1α is co-purified with Folliculin.       
 
The data presented in chapter 3 reveals that increased levels of PGC1α transcription drives 
mitochondrial biogenesis and mitochondrial DNA content upon loss of functional FLCN.  
Collectively, these data support the notion that loss of BHD results in an accumulation of 
mitochondria.  This accumulation of mitochondria may be as a compensatory mechanism in 
response to the depleted mitochondrial ATP levels and mitochondrial dysfunction observed 
upon loss of FLCN in order to try and increase the amount of mitochondria and thus ATP 
production in these cells.   
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 PGC1α also increases the expression of genes involved in fatty acid oxidation and 
gluconeogenesis (Liang and Ward, 2006).  Data presented in chapter 2 suggests that glucose 
uptake and fatty acid oxidation may also be upregulated in BHD-deficient cells as a result of 
increased activity of enzymes such as GLUT1 and HOAD in order to meet their energy 
demands.  The increased levels of PGC1α observed upon loss of functional FLCN may 
contribute to the increased levels of glucose utilisation and fatty acid oxidation observed in 
FLCN-deficient cells in order to compensate for the decreased levels of ATP production.  
PGC1α expression therefore could enhance energy production within the BHD-deficient cells 
via multiple mechanisms. 
 
Data presented in chapter 3 also suggests that the increased transcription of PGC1α observed 
upon loss of functional FLCN also increases the expression levels of antioxidant enzymes 
such as SOD2 as well as UCPs in response to the increased ROS production  (Valle et al., 
2005; St Pierre et al., 2006).  This increase in UCP expression may contribute to the 
compromised mitochondrial membrane potential and subsequent decrease in ATP levels 
(Patanè, 2002).  Overall, the data reflect that FLCN null cells are less capable at maintaining 
energy homeostasis. 
It may be possible that, as well as reduced cristae, FLCN-deficient cells exhibit defects within 
the complexes of the electron transport chain.  It has been documented that oncocytomas can 
exhibit defects within complex 1 of the electron transport chain along with accumulation of 
mitochondria (Simonnet et al., 2003).  It is possible that oncocytomas in BHD patients might 
have a similar mitochondrial complex 1 defect.  Further electron microscopy work as well as 
measuring the activity of the mitochondrial respiratory chain complexes would be required to 
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determine whether FLCN null cells from BHD patients exhibit defects within the 
mitochondrial complexes.  
 
5.2 FLCN modulates the transcriptional activity of HIF. 
 
Data presented in chapter 2 imply that the activity of HIF is potently increased upon loss of 
FLCN.  Increased HIF activity results in increased transcription of VEGF, BNIP3, and 
CCND1.  It is likely that the increased levels of AMPK activity exhibited by the FLCN-
deficient cells also contribute to the increased HIF1α activity levels observed upon loss of 
FLCN, as AMPK is able to regulate HIF via a signalling pathway independent of PI3K/Akt 
(Lee et al., 2003).   
Data presented in chapter 2 suggests that FLCN is translocated to the nucleus where it might 
modulate transcription factors such as HIF.  It may be possible that the increased levels of 
HIF activity observed upon loss of functional FLCN may be as a result of the nuclear pool of 
FLCN modulating HIF transcriptional activity, possibly via VHL.  FLCN patients are 
susceptible to developing cysts in the lungs and the kidneys in a in a manner analogous to 
TSC patients (Toro et al., 2007; Baba et al., 2008) and cilia are important in the regulation of 
cyst formation (Pazour et al., 2002; Yoder et al., 2002).  It may be possible that FLCN could 
regulate ciliary function.  Both TSC2 and VHL are known to localise to cilia.  Given that loss 
of function of FLCN results in cyst formation, BHD might be a ciliopathy.  Further 
localisation studies are needed to determine whether FLCN is localised to the cilia and 
whether it is a ciliopathy.   
HIF transcriptional activity may also be enhanced upon loss of functional FLCN as a result of 
the increased levels of mitochondrial biogenesis causing an increased demand for oxygen and 
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a transient hypoxic environment within a cell (Shoag and Arany, 2010).  Increased 
mitochondrial biogenesis may create a transiently hypoxic environment within a cell upon 
loss of BHD and contribute to HIF stabilisation under normoxic conditions within the FLCN-
deficient cells.  In order for these cells to restore normal function, HIF1α-mediated 
transcription of VEGF-A would promote angiogenesis and resupply these cells with oxygen.  
 
Data presented in chapter 2 showed that FLCN-deficient UOK257 cells favour glycolysis 
over oxidative phosphorylation; thus exhibiting a metabolic profile which reflects the 
Warburg effect (Preston et al., 2011).  Via personal communication with Dr Arnim Pause 
(McGill University, Canada), it appears that BHD-/- MEFS also have increased glycolysis and 
l-lactate production. The metabolic changes observed in the BHD- UOK257 cells may result 
in glucose entering the pentose phosphate pathway more readily, leading to increased 
production of nucleotides, aromatic amino acids and fatty acids.  All of these are essential for 
cell proliferation (Van der Heiden et al., 2009).  FLCN-deficient UOK257 cells also appear 
to take up and oxidise the excess L-lactate produced and use it as a metabolic fuel.  This is an 
important adaptation for tumour cells and may provide a proliferative advantage for these 
FLCN-deficient cells, particularly in the hypoxic environment of the core of a tumour where 
cells may be in energy defecit as a result of reduced ability to produce ATP via oxidative 
phosphorylation.  
The elevated levels of glucose uptake and metabolism via glycolysis and increased ability for 
FLCN-deficient cells to take up and oxidise L-lactate may also function as a compensatory 
mechanism due to these cells being energy deficient.  However, less ATP is generated by 
glycolysis compared to oxidative phosphorylation.  This may further contribute to the 
depleted ATP levels exhibited by the BHD- UOK257 cells (Van der Heiden et al., 2009).   
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 5.3 FLCN may be involved in a negative feedback loop which causes PI3K-Akt-mTOR 
signalling to be inhibited.   
 
Data obtained from the FLCN-deficient UOK257 cell line also provides evidence that loss of 
functional FLCN results in increased levels of mTORC1 activity.  This may be as a result of 
increased activation of Akt, as increased levels of Akt phosphorylation at Thr308 (a PDK1 
phosphorylation site) and Ser473 (an mTORC2 phosphorylation site) are observed in the 
UOK257 cell line upon loss of FLCN.  mTORC2 has also been shown to phosphorylate and 
stabilise Akt (Facchinetti et al., 2008), and Hasumi et al. have observed increased mTORC2 
activity levels along with increased expression levels of Rictor (a regulator of mTORC2) in 
tumours from BHDd/+ mice (Hasumi et al., 2009).  Collectively, these data suggest that 
mTORC1 signalling levels are elevated in these BHD deficient cell lines as a result of 
increased mTORC2 signalling and subsequent Akt activation.  These data also support the 
notion that FLCN might be involved in a negative feedback loop leading to inhibition of 
PI3K-Akt-mTOR signalling (Hasumi et al., 2009) 
 
5.4 Aberrant levels of AMPK and mTOR signalling may be contributing to the 
tumourigenesis observed upon loss of functional FLCN. 
 
mTOR is involved in the regulation of cell proliferation, protein translation, and cell survival.  
Aberrant mTOR signalling observed in these FLCN-deficient cancer cell lines is therefore 
important for promoting their proliferation and survival (Watanabe et al., 2011).  However, 
these are processes which require a lot of energy (Chhipa et al., 2011).  In order to meet this 
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increased demand for energy, more mitochondria are required in order to generate more ATP.  
Aberrant levels of mTOR signalling have been shown to result in increased levels of PGC1α 
transcription and mitochondrial biogenesis in TSC-deficient cells (Cunningham et al., 2007).  
Transcription of PGC1α could be further enhanced by mTOR in FLCN-deficient cells to 
increase the levels of mitochondrial biogenesis and mitochondrial levels.  Data presented in 
chapter 3 revealed that the elevated level of PGC1α gene transcription was reduced upon 
treatment with the mTORC1 inhibitor rapamycin in these FLCN-null cells.   
This constitutive activation of mTORC1 upon loss of functional FLCN also appears to 
contribute to the increased levels of HIF activity in a manner analogous to that observed in 
TSC2-deficient cells (Land and Tee, 2007).  This is supported by data from chapter 2, 
revealing that the increased levels of HIF activity observed in both the UOK257 and MEF 
cell lines are reduced upon treatment with rapamycin.  It is likely that mTORC1 enhances 
HIF transcriptional activity within FLCN-deficient cells.  
Activation of the PI3K/Akt/mTOR pathway also contributes to increased ROS production in 
cells via increased glucose metabolism (Kim et al., 2005).  It may be possible that increased 
glycolytic activity exhibited by the BHD-deficient UOK257 cells as a result of the arberrent 
levls of mTOR activity observed in these cells also contribute to production of ROS species 
such as H2O2 observed in BHD-deficient cells.   
The data presented suggest that in the BHD-deficient cells increased levels of Akt induce 
aberrant levels of mTOR signalling which may subsequently result in elevated levels of ROS 
production, increased levels of mitochondrial biogenesis, increased levels of HIF 
transcriptional activity and a metabolic profile which mimics the Warburg effect.   
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The data presented in chapter 3 provides evidence that endogenous FLCN located in the 
nucleus resolves as an upper isoform.  However, when mTORC1 activity is inhibited upon 
treatment with rapamycin, the lower isoform of FLCN becomes more apparent in the nuclear 
fraction.  These data suggests that the phosphorylation status of the nuclear pool of FLCN is 
reduced upon inhibition of mTORC1 signalling.  Furthermore, rapamycin treatment results in 
increased expression of the lower isoform of FLCN in the mitochondrial fraction; suggesting 
that dephosphorylated FLCN shuttles to the mitochondria.  Collectively, these data support 
the hypothesis proposed by Baba et al. that the mTORC1 pathway plays a role in the 
modulation of FLCN phosphorylation and presumably its tumour suppression function (Baba 
et al., 2006; Baba et al., 2008).  However, further investigation is required in order to 
determine whether FLCN is a direct mTORC1 substrate or a substrate of a kinase activated 
downstream of mTOR.  This may be achieved via conducting mTORC1 kinase assays on 
purified FLCN/FNIP protein complexes or purifying FLCN via immunoprecipitation and 
observing whether mTORC1 or S6K are co-purified. 
 
Data provided in chapter 2 also suggest that levels of AMPK activity are increased upon loss 
of functional FLCN.  AMPK may be upregulated upon loss of functional FLCN in response 
to the depleted ATP levels and mitochondrial dysfunction exhibited in BHD-deficient cells in 
order to inhibit processes which are energy demanding; thus conserving ATP within BHD-
deficient cells and promoting their survival (Yun et al., 2005; Chhipa et al., 2011).  AMPK 
has been shown to regulate PGC1α (Zong et al., 2002).  Therefore, FLCN may also regulate 
PGC1α through modulation of AMPK.  AMPK has also been shown to enhance HIF-1 
transcriptional activity (Lee et al., 2003).  It is therefore likely that the changes to the 
metabolic profile of cells upon loss of FLCN are also, at least in part, as a result of arberrent 
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levels of AMPK activity in response to the depleted ATP levels observed in BHD-deficient 
cells. 
As AMPK has previously been shown to bind to FLCN and its binding partners, FNIP1 or 
FNIP2, it may also be possible that FLCN directly regulates AMPK (Baba et al., 2006).  
Decreased expression of the lower isoform of FLCN was also observed in the mitochondrial 
fraction upon treatment with 2-DG.  These data support the notion that FLCN is 
phosphorylated by AMPK (Baba et al., 2006).  It may be possible that FLCN expressed in the 
nucleus regulates transcription of PGC1α, and that both mTORC1 and AMPK drive 
mitochondrial biogenesis through modulation of FLCN phosphorylation.   
5.5 Increased levels of autophagic activity observed upon loss of functional FLCN may 
provide a viable therapeutic target for BHD patients. 
 
Autophagy is induced within cells as a stress response and catabolises unnecessary structures 
such as old/damaged organelles and proteins (Hands et al., 2009).  Data presented in chapter 
4 suggests that autophagy might be enhanced in the UOK257 cells upon loss of BHD.  This 
may be via increased binding of AMPK to ULK, and direct phosphorylation of ULK via 
AMPK (Lee et al., 2010).  As it has been shown that dysfunctional mitochondria may be 
turned over by mitophagy (Tolkovsky et al., 2009), it might be possible that mitophagy is 
upregulated upon loss of functional FLCN. Mitophagy may provide protection for these 
tumour cells via catabolising the dysfunctional mitochondria observed in FLCN-deficient 
cells.  The enhanced level of autophagy in FLCN-deficient MEF cells is likely due to 
increased AMPK/ULK1 activity.  FLCN could directly regulate ULK.  However further 
investigation would be required to see whether FLCN regulates the kinase activity of ULK1.  
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The increased levels of autophagic activity exhibited by FLCN-deficient cells may also be as 
a result of the increased levels of HIF mediated transcription of BNIP3 observed, as BNIP3-
mediated mitophagy has been shown to be upregulated in response to mitochondrial 
dysfunction and initiation of the mitochondrial cell death pathway (Rikka et al., 2011).   
It has been shown that increased permeability of the mitochondrial membrane results in the 
release of proapoptotic factors contained within the mitochondrial membrane and that BNIP3 
can inhibit induction of apoptosis via Apoptosis Inducing Factor (AIF) (Akao et al., 2006, 
Burton et al. 2009).   It may be possible that the increased levels of BNIP3 observed upon 
loss of functional FLCN may be repressing apoptosis that would otherwise be induced as a 
result of the release of proapoptotic factors contained within the mitochondrial membrane.  
However this resistance to apoptosis observed may also be due to misregulation of TGFβ 
signalling upon loss of functional FLCN and subsequent downregulation of proapoptotic 
factors such as Bim (Cash et al., 2011).  
 
Data presented in chapter 4 suggests that autophagic activity is increased in FLCN-deficient 
cells in order to provide a protective function and that inhibition of autophagic activity via 
treatment with Chloroquine induced cell death.  This notion is supported by the fact that 
treatment with autophagy inhibitors Chloroquine and 3MA rescues the death-resistance 
phenotype exhibited by BHD-/- embryonic stem cells (Cash et al., 2011). 
 
Data presented in chapter 4 also revealed that treatment with the reagent Nelfinavir results in 
autophagic activity within these cells being increased to a level at which autophagy abandons 
its protective function.  This results in selective inhibition of cell proliferation and induction 
of cell death in these cells (both at the 20 µM and 30 µM concentration).  These data suggest 
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that inducing autophagy via treatment with reagents which induce the ERS response such as 
Nelfinavir may be of therapeutic benefit to BHD patients.   
 
Treatment with a combination of Nelfinavir and Chloroquine appears to have a synergistic 
effect in the selective inhibition of cell proliferation and promotion of cell death in the BHD-/- 
MEF cells when compared to treatment with either drug individually.  Furthermore, 
combined treatment with Nelfinavir and Chloroquine was more effective at selectively 
inducing cell death in the BHD-/- MEF cells than combination treatment with rapamycin and 
Chloroquine.  Both of these reagents are currently administered to humans for treatment of 
HIV (Nelfinavir) and malaria (Chloroquine).  Therefore, these drugs might be suitable 
candidate drugs for treating BHD.  However, further analysis will have to be conducted in 
order to confirm whether these drugs do indeed have therapeutic potential in BHD patients 
and whether the combination of these reagents at the concentrations required to have 
therapeutic benefit is safe to administer to patients. 
Other combinations of ER stress activators and autophagy inhibitors may also provide 
therapeutic benefit for BHD patients.  Further investigation would be required in order to 
determine whether treatment with any of these reagents, either individually or in 
combination, would selectively inhibit cell proliferation or induce cell death in FLCN-
deficient cells. 
5.6 FLCN may be required in order to relay negative feedback signals in order for AMPK 
and ULK1 to fully repress mTORC1signalling. 
 
It is unusual for both AMPK and mTOR signalling to be constitutively active in a cell line, as 
AMPK potently inhibits mTORC1 signalling (Chen et al., 2011; Gwinn et al., 2008).   
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Data obtained with the UOK257 cells suggest that increased levels of phosphorylation of 
Raptor at Ser792 (AMPK site) are observed in the UOK257 cells deficient in functional 
FLCN.  Work conducted by Li et al. has suggested that phosphorylation of Raptor at this site 
results in inhibition of mTOR (Li et al., 2010).  However although enhanced phosphorylation 
of Raptor by AMPK at this site is observed, this does not appear to result in inhibition of 
mTOR in cells deficient in functional FLCN.  Work conducted by Gwinn et al. has shown 
that AMPK also phosphorylates Raptor at Ser722 as well as Ser792, resulting in inhibition of 
mTOR (Gwinn et al., 2008).  It may be possible that a phosphorylation event such as the 
phosphorylation of Raptor by AMPK at Ser722 may not occur upon loss of FLCN. 
 
It has also been shown that ULK1 phosphorylates Raptor at multiple sites, including Ser855 
and Ser859, resulting in inhibition of mTORC1 (Dunlop et al., 2011).  mTORC1 has also 
been shown directly regulate the 3-MDa ULK1–Atg13–FIP200 complex (Hosokawa et al., 
2009), and further work conducted by Kim et al. has shown that mTORC1 inhibits ULK1 by 
direct phosphosphorylation (Kim et al., 2011).  However, although increased levels of ULK1 
mediated autophagy are observed in BHD-deficient cells, ULK1 does not appear to be 
inhibiting mTOR via phosphorylation of Raptor within these cells.  Furthermore, the 
increased level of mTOR activity observed within the FLCN-deficient cells does not appear 
to be resulting in inhibition of ULK1 in these cells.   It may be possible that FLCN is also 
required to relay these negative feedback signals to fully repress mTORC1.  Without FLCN, 
activation of AMPK and ULK1 does not result in the repression of mTORC1 (Figure 32a).   
 
144 
 
5.7 Aberrant levels of AMPK and mTOR signalling, HIF1α transcriptional activity and 
glycolytic activity upon loss of functional FLCN may provide potential therapeutic targets for 
BHD patients. 
 
The fact that the BHD- UOK257 cells exhibit a metabolic profile that parallels the 'Warburg 
effect' may also provide some potential therapeutic targets for Birt-Hogg-Dubé patients.  
Several groups have explored the selective killing of cancer cells by developing compounds 
which inhibit glycolysis (Figure 33) (Chen et al., 2007).  Increased glycolytic activity is 
exhibited in the BHD- UOK257 cells, as shown by increased levels of GLUT1 mRNA and 
protein, which would result in increased glucose uptake within these cells.   
Glycolytic activity within a cell can also be inhibited by inhibiting Hexokinase.  Hexokinase 
is the first rate-limiting enzyme in the glycolysis pathway which converts glucose to glucose-
6-phosphate.  Inhibition of Hexokinase will have a significant effect on both glycolysis and 
the pentose phosphate pathways, as glucose 6 phosphate is an intermediate for both of these 
pathways (Chen et al., 2007).  Known inhibitors of hexokinase include 2-deoxyglucose 
(2DG) (Chen et al., 2007).   
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Figure 32.  The tumour suppression function of FLCN 
(A)  FLCN may be required to relay negative feedback signals to fully repress mTORC1 via 
AMPK or ULK1.  In the absence of FLCN, activation of AMPK and ULK1 does not result in 
the repression of mTORC1.  (B) Loss of functional FLCN appears to result in increased HIF 
activity, increased mitochondrial biogenesis and increased autophagic activity via the 
regulation of AMPK and mTOR signalling. 
 
Work conducted in Dr. Andrew Tee’s lab suggested that treatment with 2-deoxyglucose 
selectively inhibits the proliferation of the BHD- UOK257 cells (Preston et al., 2011).  These 
data imply that inhibition of Hexokinase may be a potential therapeutic target for Birt-Hogg-
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Dubé patients.  Further investigation would be required in order to determine whether 
glycolytic inhibitors which target hexokinase, either individually or in combination with other 
reagents such as rapamycin (Xu et al., 2005a), would selectively inhibit cell proliferation or 
induce cell death in FLCN-deficient cells. 
 
As data obtained from the UOK257 cells have shown that these cells exhibit increased levels 
of LDH activity and that L-lactate may be taken up and oxidised by these cells upon loss of 
FLCN, it may also be possible that reagents which inhibit LDH provide potential therapeutic 
benefit for BHD patients.  The reagent oxamate inhibits LDH by competing with pyruvate as 
its substrate (Thornburg et al., 2008).  Further investigation would be required in order to 
determine whether glycolytic inhibitors which target LDH or Hexokinase would selectively 
inhibit cell proliferation or induce cell death in BHD-deficient cells without being highly 
toxic to BHD+ cells, thus providing a potential therapeutic benefit for BHD patients (Figure 
32). 
Studies have also shown that inhibition of HIF1α, through treatment with different 
therapeutic agents, has significant effect on tumour growth in several cancer types.  Data 
obtained from multiple cell lines have provided clear evidence that HIF1α transcriptional 
activity is increased in several cell lines deficient in FLCN.  Inhibition of HIF1α may 
therefore provide more potential benefit for BHD patients.  Sunitanib is a reagent which has 
been shown to inhibit HIF1α (Shin et al; 2010).  Further investigation would be required in 
order to determine whether inhibition of HIF1α using reagents such as Sunitanib would be of 
therapeutic benefit for BHD patients. 
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Figure 33.  Glycolytic inhibitors may provide therapeutic targets for BHD patients 
FLCN-deficient cells exhibit increased levels of MCT1, G6PD1, GLUT1, PDK1, Pyruvate 
Kinase and Lactate dehydrogenase.  Inhibition of these targets may provide therapeutic 
beneifit for BHD patients 
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Constitutive activation of mTOR signalling appears to be involved in upregulating HIF 
activity as well as mitochondrial biogenesis in the FLCN-deficient cells analysed, both of 
which appear to be required in order to meet the energy demands of these cells in response to 
mitochondrial dysfunction.  Therefore it may be possible that inhibition of mTOR provides 
more of a therapeutic benefit for BHD patients than inhibition of HIF1 activity alone. 
Results from several studies have also shown that the antidiabetic drug metformin inhibits 
cancer cell viability through the inhibition of mTORC1.  Metformin inhibits mTORC1 via 
increased expression of Redd1 in a p53-dependent manner (Sahra et al., 2011).  However, the 
data presented in chapters 2 and 3 as well as results from other studies suggest that inhibition 
of mTORC1 on its own in BHD deficient cells may not result in complete restoration of HIF 
activity (Knaup et al., 2009) or mitochondrial biogenesis to normal levels.  However, 
Metformin has been shown to activate AMPK and inhibit glucose phosphorylation and 
glycolysis in rat hepatocytes (Guigas et al., 2006).  2-deoxyglucose, which also activates 
AMPK and inhibits glycolysis, has been shown to selectively inhibit the proliferation of 
BHD- UOK257 cells by inhibiting glucose uptake (Preston et al., 2011).  It may be possible 
that a drug such as Metformin, which not only inhibits glycolysis and activates AMPK, but 
also inhibits mTORC1 signalling, may provide an effective potential therapeutic target for 
BHD patients.   
Loss of functional FLCN has also been shown to result in increased levels of mTORC2 
activity which in turn activates Akt and thus mTORC1 signalling (Baba et al., 2006; Hasumi 
et al., 2009).  Kinase inhibitors which target mTORC1 and mTORC2 may therefore provide 
another viable solution (Evangilisti et al., 2011).  Reagents such as Torin inhibit both 
mTORC1 and mTORC2 by inhibiting the kinase activity of mTOR (Dufour, 2011).  Further 
investigation would be required in order to determine whether treatment with inhibitors of 
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mTORC1, either individually or in combination with inhibitors of mTORC2 or other 
reagents, would provide an effective treatment for BHD patients. 
In conclusion, it appears that endogenous FLCN is localised to both the nucleus and 
mitochondria within a cell.  It may be possible that FLCN is involved in maintaining a level 
of communication between the nucleus and the mitochondria that could involve sensing ROS, 
DNA-damage repair, cell cycle check point control and energy homeostasis.  Loss of function 
of FLCN results in increased production of ROS species such as H2O2.  This leads to 
compromised mitochondrial membrane potential and decreased ATP production as a result of 
increased expression of uncoupling proteins in order to try and reduce the increased levels of 
ROS.  FLCN is also phosphorylated at multiple residues by both mTORC1 and AMPK and 
activity of both mTORC1 and AMPK is increased in response loss of functional FLCN.  This 
results in increased levels of mitochondrial biogenesis and increased levels of glycolytic 
activity via increased activation of HIFα proteins in order to compensate for this energy 
deficit.  Furthermore, it appears that both mTORC1 and AMPK could drive HIF transcription 
and mitochondrial biogenesis through modulation of FLCN phosphorylation.  ULK-mediated 
autophagy also appears to be upregulated upon loss of functional FLCN, possibly as a result 
of the increased levels of AMPK activation in order to provide a protection for these cells.  
This may be via catabolising of the dysfunctional mitochondria observed in cells upon loss of 
BHD, a process which may be exploited as a potential therapeutic target for BHD patients.  
However, further investigation is however required into FLCN’s involvement in sensing 
ROS, DNA-damage repair and the exact method as to how FLCN modulates HIF activity and 
mitochondrial biogenesis.  Investigations into these cellular processes may also provide clues 
to potential therapeutic targets for treatment of BHD patients (Figure 33B).   
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Appendix I Abbreviations 
 
Abbreviation       Full form 
2DG 2-Deoxyglucose 
4E-BP1 Eukaryotic Translation Initiation Factor 4E Binding Protein 
5-TOP 5’ tract of pyrimadines 
ACC Acetyl co-A Carboxylase 
ADPKD Autosomal dominant polycystic kidney disease 
AIF Apoptosis Inducing factor 
AMPK Adenosine monophosphate (AMP) -activated protein kinase 
AraA Adenine 9-β-D-arabinofuranoside 
ATG Autophagy related 
ATM Ataxia-telangiectasia mutated 
BHD Birt-Hogg-Dubé 
BNIP3 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 
CaMK calcium/calmodulin dependant kinase 
cAMP Cyclic AMP 
CCCP Carbonyl cyanide m-chloro phenyl hydrazone 
CCND1 Cell Cyclin D1 
CDK Cyclin Dependent kinases 
DEPTOR DEP domain containing MTOR-interacting protein 
DMEM Dulbecco's Modified Eagle Medium 
DNA Deoxyribonucleic acid 
ERAD Endoplasmic-reticulum-associated protein degradation 
ERK Extracellular Signal-Regulated Kinase 
FAT FRAP, ATM and TRRAP domains 
FH Fumarate Hydratase 
FLCN  Folliculin 
FNIP1 Folliculin Interacting Protein 1 
FNIP2 Folliculin Interacting Protein 2 
FRAP FKBP-12-rapamycin associated protein 
FRB FKBP-12/rapamycin  
G6PD1 Glucose-6-phosphate dehydrogenase 
GAP GTPase activating protein 
GDP Guanosine Diphosphate 
GLUT1 Glucose transporter type 1 
GSC Germline Stem Cells 
GTP Guanosine tri phosphate 
H2O2 Hydrogen Peroxide 
HDAC  Histone deacetylase 
HEAT 
Huntington Elongaion factor 3, A subunit of protein phosphatase 2A and 
Tor1  
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HIF Hypoxia inducible factor 
HK Hexokinase 
HK2 Human Kidney 2 
HLRCC Hereditary Leiomyomatosis and Renal cell carcinoma 
HOAD 3-hydroxy-acyl-CoA 
HSCs Hematopoeitic stem cells 
IGF Insulin like growth factor 1 
Jak/Stat Janus kinase/signal transducers and activators of transcription 
LDH Lactate Dehydrogenase 
Liver kinase 
B1 Liver kinase B1 
LST8 Lethal with sec13 protein 8 
MCT1 Monocarboxylate transporter 1 
MCT4 Monocarboxylate transporter 4 
MEF Mouse Embryonic Fibroblast 
MEK Mitogen-activated protein kinase kinase 
MIDM2 Murine double minute 2 
mTOR Mammalian Target of Rapamycin 
NF1 Neurofibromin 1 
NRF1 Nuclear Respiritory Factor 1 
NRF2 Nuclear Respiritory Factor 2 
ODDD Oxygen dependant degradation domain 
PC1 Polycystin 1 
PC2 Polycystin2 
PDH Pyruvate Dehydrogenase 
PDK1 Pyruvate dehydrogenase kinase 1 
PDK1  3-phosphoinositide-dependent protein kinase 1 
PGC1α Peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
PGC1β Peroxisome proliferator-activated receptor gamma coactivator 1-beta 
PI3K  Phosphoinositide-3-kinase 
Pip2 Phosphatidylinositol (3,4,5)-triphosphate (PtdIns(3,4,5)P2) 
Pip3 Phosphatidylinositol (3,4,5)-triphosphate (PtdIns(3,4,5)P3) 
PKB Protein Kinase B 
PP1 Protein Phosphatase 1 
PP2a Protein Phosphatase 2A 
PPAR Peroxisome proliferator-activated receptor  
PTEN Phosphatase and Tensin Homolog 
Raptor Regulatory associated protein of MTOR 
RCC Renal Cell Carcinoma 
RCND Renal Cystadenocarcinoma and Nodular Dermatofibrosis 
Rheb Ras homolog enriched in brain 
Rictor  Rapamycin-insensitive companion of Tor 
RNA Ribonucleic acid 
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ROS Reactive Oxygen Species 
RPL13 Ribosomal protein L13 
rpS6 Ribosomal protein S6 
RT Real Time 
RT Reverse transcriptase 
S6K1 P70-S6 Kinase 1 
SERCA Sarco/Endoplasmic Reticulum Ca2+-ATPase 
Sh Short hairpin 
Si  Small interfering 
Sin1 Stress-activated protein kinase-interacting protein 1 
SOD2 Superoxide dismutase 2 
STK11 Serine/threonine kinase 11 
TFAM Transcription factor A, mitochondrial 
TFE3  Transcription factor E3 
TFEB Transcription factor EB 
TH Thyroid hormone 
TOS Tor Signalling 
TRRAP Transformation/transcription domain-associated protein 
TSC Tuberous Sclerosis Complex 
UCP3 Uncoupling protein 3 
ULK1 UNC 51-like kinase 
UTR Untranslated region 
VEGF Vascular Endothelial Growth Factor  
VHL Von Hippel Lindau 
YY1 Ying-Yang 1 
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Appendix II.   Materials and methods 
 
Antibodies and Other Biochemicals 
Dr Arnim Pause (McGill University, Canada) kindly provided the anti-Folliculin antibodies.  
Rapamycin was purchased from Calbiochem/Merck (Beeston, Nottingham, UK).  2-
deoxyglucose was obtained from Sigma-Aldrich Company Ltd. (Dorset, UK).  Dr. Laura S. 
Schmitt kindly provided the N-terminal Flag-tagged BHD vector was a kind gift from 
(Bethesda, MD USA, described in (Baba, 2006)).  The PGC1a luciferase reporter construct 
was a kind gift from Dr. Kieth Barr (Davis, CA, USA).  The PR4-CMV renilla control for 
luciferase assays was a kind gift from Prof. Maurice Van Steensel’s lab (University of 
Maastricht, Netherlands).  Anti-BNIP3, anti-β-actin, anti-VEGF-A, anti-GLUT1, anti-PDK1, 
and anti-UCP3 antibodies were purchased from Abcam (Cambridge, UK). Anti-phospho-
rpS6 (Ser235/236), anti-rpS6, anti-phospho-Akt (Thr308, Ser476), anti-Akt antibodies, anti-
acetyl choline carboxylase and anti-raptor and anti-phospho raptor (Ser792), anti-phospho 
acetyl choline carboxylase (Ser79), anti-AMPKa and phospho-AMPKa (Thr172), as well as 
anti-4E-BP1 and anti-phospho 4E-BP1 (Ser65) antibodies, were purchased from Cell 
Signalling Technology (Danvers, MA, USA). Anti-GLUT4, anti-MCT4, anti-MCT1, anti-
PDH, and anti-phospho-PDH (Thr306, Ser473) antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA).  Anti-HIF1α and Anti-P62 ICK ligand antibodies 
were purchased from BD transduction laboratories (Oxford, UK).  Anti-LC3 and anti-HIF2α 
antibodies used in western blot analyses were purchased from Novartis (Surrey, UK).  Anti-
Lamin/A/C was purchased from Millipore (Watford, UK).  Anti-SOD2 was purchased from 
Genetex (Irvine, CA, USA).  3MA and Chloroquine diphosphate were purchased from 
Sigma-Aldrich Company Ltd. (Dorset, UK).  Nelfinavir in the form of Viracept tablets was 
purchased from Pfizer, Inc (New York, USA). 
 
Cell Culture 
UOK257-2 and UOK257 cells that were a kind gift from Dr. Laura S. Schmitt (Bethesda, MD 
USA) were cultured in Dulbecco’s Modified Eagle’s Medium supplemented with 100 µg/ml 
streptomycin, 100 U/ml penicillin and 10 % (v/v) foetal calf serum (Gibco, Paisley, UK). 
UOK257-2 and UOK257 cells were incubated at either 1% or 21 % oxygen either with or 
without 50 nM rapamycin treatment as indicated. After 18 h, these cells were harvested.  
CRUK HEK293 cells that were purchased from ATCC were cultured in Dulbecco’s Modified 
Eagle’s Medium supplemented with 100 µg/ml streptomycin 100 µg/ml streptomycin, 100 
U/ml penicillin and 10 % (v/v) foetal calf serum (Gibco, Paisley, UK). UOK257-2 and were 
incubated at 21 % oxygen. These cells were harvested after 18 h. 
Stable clones of Human Kidney 2 (HK2) cells expressing scrambled (HK2 G10) or BHD 
shRNA (HK2 5968 A5) were generated using mission shRNA constructs (purchased from -
Aldrich Company Ltd. (Dorset, UK)) by Tijs Claessens (Maastricht, Netherlands).  HK2 
5968 A5 (BHD-) and HK2 G10 (BHD+) cells were incubated at either 1 % or 21 % oxygen as 
indicated.  These cells were harvested after 18 h. 
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BHD+/+ and BHD-/- Mouse Embryonic Fibroblast (MEF) cells that were a kind gift from Prof. 
Arnim Pause (Quebec, Canada) were cultured in Dulbecco’s Modified Eagle’s Medium 
supplemented with 10 % (v/v) foetal calf serum, 100 U/ml penicillin and 100 µg/ml 
streptomycin (Gibco, Paisley, UK). UOK257-2 and UOK257 cells were incubated at either 1 
% or 21 % oxygen either with or without 50 nM rapamycin treatment as indicated. After 18 
h, these cells were harvested. 
 
DNA extraction 
Phosphate buffered saline (PBS) was used to wash the cells before they were lysed from the 6 
cm2 plates using 0.5 ml PBS. DNA was extracted using a DNeasy Blood and Tissue kit 
(Qiagen, West Sussex, United Kingdom) as described in the manufacturers’ protocol. 
mRNA extraction and reverse transcription 
Phosphate buffered saline (PBS) was used to wash the cells before, they were lysed from the 
6 cm2 plates using 0.5 ml RNAprotect Cell Reagent (Qiagen, West Sussex, United 
Kingdom). The rNA extraction process was performed using a RNeasy Plus mini kit (Qiagen, 
West Sussex, United Kingdom). During the RNA extraction procedure, Qiashredder tubes 
were used to homogenize the cell lysates as described in the manufacturer’s protocol.  A 
Quantitect reverse transcription kit (Qiagen, West Sussex, United Kingdom) and a thermal 
cycler (Applied Biosystems, California, USA) was then used to transcribe the total RNA 
from each sample (1 μg) into cDNA. 
 
Real Time Quantitative PCR 
96 well plates were used to conduct Quantitative Real Time PCR reactions using 25ng DNA 
per reaction, Sybr Green PCR Master mix (Qiagen, West Sussex, United Kingdom) and 
appropriate primer assays. The following procedure was then used to perform the assays: 
initial denaturation step (95 oC, 15 min), 40 cycles of denaturation (94 oC, 15 sec), annealing 
step (55 oC, 30 sec (RPL13, Cytochrome b), 60 oC (NRF1, NRF2, TFAM) 59 oC (PGC1 β) 
58 oC (PGC1 α)), extension step (72 oC, 40 sec).  The sequences of the Cytochrome B 
primers used were Forward 5’-GCGTCCTTGCCCTATTACTATC-3’; Reverse 5’-
CTTACTGGTTGTCCTCCGATTC -3’.  The sequences of the RPL13 primers used were 
Forward 5’-CTCAAGGTCGTGCGTCGTCTG-3’; Reverse 5’-
TGGCTTTCTCTTTCCTCTTCTC -3’. The sequences of the SOD2 primers used were 
Forward 5’-GCCTGCACTGAAGTTCAATG-3’; Reverse 5’-
ATCTGTAAGCGACCTTGCTC-3’.  The sequences of the UCP3 primers used were 
Forward 5’-GGATTTGTGCCCTCCTTTCTG-3’; Reverse 5’-
AGATTCCCGCAGTACCTGGACT-3’ The sequences of the PGC1β primers used were 
Forward 5’-GAACCCAACCAGTACAGCCCCGATG-3’; Reverse 5’-
GCTGAGGTGCATGATAGAGCGTCTC-3’.  The sequences of the PGC1α primers used 
were Forward 5’-CAAGATCAAGGTCTCCAGGCAGTAGATCC-3’; Reverse 5’-
CGATATTCTTCCCTCTTCAGCCTCTCGTG-3’.  The sequences of the NRF1 primers used 
were Forward 5'-GTCCAGATCCCTGTGAGCAT-3'; Reverse 5'-
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CAATGTCACCACCTCCACAG-3'.  The sequences of the NRF2/GABPA primers used 
were Forward 5'-ACCTTCATCACCAACCCAAG-3'; Reverse 5'-
AGAAGCTCACCTGGGAACAG-3'.  The sequences of the TFAM primers used were 
Forward 5'-TCCAAGAAGCTAAGGGTGATTC-3'; Reverse 5’-
CGAGTTTCGTCCTCTTTAGCA-3'.  The sequences of the human VEGF-A I–II primers 
used were Forward 5’-CTGCTGTCTTGGGTGCATTG-3’; Reverse 5’-
TTCACAATTTGTTGTGCTGTAG-3’, as described in Roland et al. (2000).  The sequences 
of the mouse VEGF-A I–II primers used were Forward 5’-
GGAGAGCAGAAGTCCCATGA-3’; Reverse 5’-ACTCCAGGGCTTCATCGTTA-3’, as 
described in Garcia et al. (2009).  All of the other primer sets were bought from Qiagen, who 
have to right to with hold primer sequence information.  Quantification of the amplification 
products took place during the extension step in the 40th cycle. The results were then 
determined using the ddCT method, and normalised first to either RPL13 or β-Actin.  I 
verified that only one PCR product was produced with each primer set and their specificity 
by performing a dissociation step.  The correct amplicon length for each of the PCR products 
was also verified via resolution on a 2 % polyacrylamide gel. The expected size of the 
amplified products was approximately 77 bp for GLUT1 catalogue number (QT00068957), 
70 bp for human VEGF-A, 104 bp for human b-actin (Catalogue number QT01680476), 73 
bp for human BNIP3 (Catalogue number QT00024178), 96 bp for CCND1 (Catalogue 
number QT00495285), 91 bp for G6PD1 (Catalogue number QT00071596), 104 bp for 
HIF1α (Catalogue number QT00083664), 127 bp for HIF2α (Catalogue number 
QT00069587), 196 bp for Cytochrome B, 250 bp for RPL13, 170 bp for human PGC1β, 196 
bp for human PGC1α, 250 bp for TFAM, 73 bp for UCP3, 102 bp for NRF1, 89 bp for 
NRF2, 82 bp for SOD2, 63 bp for mouse PGC1α (Catalogue number QT00156303), 61 bp 
for mouse ATP5G1 (Catalogue number QT01038198), 77 bp for mouse β-actin (Catalogue 
number QT01136772), 67 bp for mouse BNIP3 (Catalogue number QT00100233), 117 bp for 
mouse VEGF-A, 68 bp for human ULK1 (Catalogue number QT00009884), 85 bp for human 
ULK2 (Catalogue number QT00031381), 107 bp for mouse ULK1 (Catalogue number 
QT01759513) and for 150 bp for Beclin 1 (Catalogue number QT00004221).  The 
information given is in accordance to the minimum information for publication of real time 
quantitative PCR data (Bustin et al., 2009). 
 
Western Blotting 
PBS was used to was the cells before lysis buffer (20 mM Tris, 135 mM NaCl, 5 % (v/v) 
glycerol, 50 mM NaF and 0.1 % (v/v) triton X-100, pH 7.5 supplemented with complete mini 
protease inhibitor cocktail (Roche Diagnostics Ltd. Burgess Hill, United Kingdom) and 1 
mM Dithiothreitol (DTT)) was used to lyse them from the 6 cm2 plates using at 4 oC. After 
centrifugation at 13,000 rpm for 8 min at 4 oC the samples were boiled at 70 °C for 10 min 
with x4 NuPAGE LDS Sample buffer (Invitrogen, Paisley, United Kingdom) and 25 mM 
DTT and. For preparation of HIF2α and HIF1α protein samples, cells were lysed with 62.5 
mM Tris-HCl (pH 6.8), 2 % (w/v) SDS, 10 % (v/v) glycerol, 50 mM DTT, and 0.1 (w/v) 
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bromophenol blue followed by pulse sonication before being boiled at 95 oC for 5 min. 
Samples were then separated by electrophoresis using the NuPAGE gel system (Invitrogen, 
Paisley, United Kingdom) according to manufacturers’ protocol. Proteins were transferred to 
Polyvinylidene Difluoride membranes (Millipore, South West, United Kingdom), blocked in 
5 % (w/v) dry milk powder in Tris buffered saline (TBS-T) (2.42 g Tris base, 8 g NaCl, 1 l 
H2O2 pH 7.6, 1 ml Tween 20).  The required primary antibody and Horse Radish Peroxidse-
conjugated secondary antibody in TBST were then used to probe for each particular protein. 
Enhanced Chemiluminescent solution and Hyperfilm (both from GE Healthcare, 
Buckinghamshire, United Kingdom) were then used to visualise the proteins and each film 
was developed using a Konica Minolta SRX101A developer.  Densitometry analyses were 
performed where indicated using Image J software.  For larger gels; the samples were run for 
5 h and transferred overnight using omniPage maxi vertical electrophoresis according to 
manufacturers’ protocol using Running buffer (1.44.07 g glycine, 30.285 g Tris base, 10 g 
SDS made up to 1 l with dH2O). 
 
HIF Luciferase assay 
UOK257 cells and BHD-/- MEF cells were transfected with either Flag-tagged BHD or pRK7 
empty vector alongside a firefly luciferase reporter pGL2-TK-HRE plasmid (a gift from G 
Melillo (National Cancer Institute at Frederick, Maryland, USA) along with 1 µl 1mM PR4-
CMV renilla control using Lipofectamine 2000 transfection reagent (Invitrogen, Paisley, UK) 
according to the manufacturer’s protocol.  BHD- and BHD+ HK2 cells were transfected with 
the firefly luciferase reporter pGL2-TK-HRE plasmid (a gift from G Melillo (National 
Cancer Institute at Frederick, Maryland, USA)) along with 1 µl 1 mM PR4-CMV renilla 
control using Lipofectamine 2000 transfection reagent (Invitrogen, Paisley, UK) according to 
the manufacturer’s protocol. The pGL2-TK-HRE plasmid was generated using the protocol 
described by Rapisarda et al. (Rapisarda et al., 2002). 4 h post transfection, the medium was 
changed on cells and cells were incubated at 21 % oxygen either with or without 50 nM 
rapamycin treatment as indicated. The cells were washed in phosphate-buffered saline after 
24 h post transfection, before being lysed in lysis buffer (20 mM Tris, 135mM NaCl, 5% 
(v/v) glycerol, 50mM NaF and 0.1% (v/v) triton X-100, pH 7.5, which had been 
supplemented with complete mini-protease inhibitor cocktail (Roche Diagnostics Ltd) and 
1mM DTT) at 4 oC.  Renilla and firefly luciferase levels were analysed in 80 µg of protein 
lysate combined with 20 µg lysis buffer using a dual luciferase assay kit (Promega UK, 
Southampton, UK) and a luminometer 2 s and 10 s after initial injection according to 
manufacturers’ protocol. 
 
PGC1α Luciferase Assay 
UOK257 cells and BHD-/- MEF cells were transfected with either Flag-tagged BHD or pRK7 
empty vector alonside the PGC1α firefly luciferase reporter (a kind gift from Kieth Barr, 
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University of California, USA) and 1 µl 1 mM PR4-CMV vector as a renilla control using 
Lipofectamine 2000 transfection reagent (Invitrogen, Paisley, United Kingdom) according to 
the manufacturer’s protocol.  4 h post-transfection, the medium was changed on cells and 
cells were incubated at 21 % oxygen either with or without 50 nM rapamycin treatment as 
indicated.  The cells were washed in PBS after 24 h post transfection before being lysed in 
lysis buffer (20 mM Tris, 135 mM NaCl, 5 % (v/v) glycerol, 50 mM NaF and 0.1 % (v/v) 
triton X-100, pH 7.5 which was supplemented with complete mini protease inhibitor cocktail 
(Roche Diagnostics Ltd. Burgess Hill, United Kingdom) and 1 mM DTT) at 4 oC. After 
centrifuging the samples at 13,000 rpm for 8 minutes at 4 oC, 80 µg of protein lysate in 20 µl 
lysis buffer was combined with a dual luciferase assay kit (Promega UK, Southampton, UK) 
and analysed for renilla and firefly luciferase levels via a luminometer 2 s and 10 s after the 
first injection according to manufacturers’ protocol  
 
CellTitre-glo cell viability assay 
UOK257 cells and UOK257-2 cells were transferred to a 96 well tissue culture plate (2 wells 
per cell line, 10000 cells per well).  DMEM was then used to make up each well to 150 µl.  
150 µl CellTiter-Glo Reagent from a CellTiter-Glo Luminescent Cell Viability Assay 
(Promega UK. Southhampton, UK) was then placed into each well.  The reactions were then 
incubated at room temperature for 1 h before the plate was placed in a luminometer and the 
luminescence was read 
 
CyQUANT (R) cell proliferation assay. 
After counting, cells were plated onto a black 96-well plate (10,000 cells per well). In total, 
10, 20, 30 and 40 µM Nelfinavir, 5 mM 3MA, and 100 µM Chloroquine were added where 
indicated 24 h after cells were plated and the plates were incubated at 37 oC for 24 h. Medium 
was removed from the cells at the required time point, before the 96 well plates were frozen 
at 80 oC. After thawing, each well had 200 ml CyQUANT (R) mix, prepared as described in 
the CyQUANT (R) Cell Proliferation Assay (Invitrogen, Paisley, UK) manufacturer’s 
protocol, added to it. A fluorometer was then used to measure fluoresence at 485 and 520 nm. 
 
L-Lactate assay 
Cells were counted and 10,000 were plated per well of a black 96-well plate and grown in 
DMEM for 6 hours.  20 µl of DMEM was then taken from these cells and incubated with 80 
µl working reagent prepared using the EnzyChrom L-Lactate Assay Kit manufacturers’ 
protocol (Universal Biologicals LTD, Cambridge, UK).  Standards were also prepared 
according to manufacturers’ protocol and incubated with 80 µl working reagent. Absorbance 
levels were then read at 565 nm using a fluorometer.  Levels of L-lactate within the samples 
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were determined by comparing to the standard curve generated by measuring the absorbance 
of the standards prepared. 
 
Hydrogen Peroxide (H202) assay 
UOK257 and UOK257-2 cells growing in DMEM were washed with Krebs ringer buffer 
before being incubated in Krebs ringer buffer for 30 minutes in normoxia (21 %).  Media was 
then taken from the cells and incubated with Amplex red reagent as described in the Amplex 
red hydrogen peroxide assay (Invitrogen, Paisley, UK) manufacturer's instructions.  
Standards were also prepared according to manufacturers’ protocol before fluorescence was 
then measured using a fluorometer at 530-560 nm excitation and 590 nm emission.  Levels of 
H2O2 within the samples were determined by comparing to the standard curve generated by 
measuring the fluorescence of the standards prepared. 
 
Cell fractionation. 
UOK257-2, UOK257, and HEK 293 cells were grown to full confluency in 150 mm tissue 
culture plates.  Cells were then washed and scraped into phosphate buffered saline.  
Mitochondrial and cytosolic fractions were then generated using a mitochondrial cell 
fractionation kit (Active motif, La Hulpe, Belgium) according to manufacturer’s protocol.  
Nuclear fractions were generated by centrifuging the cells down at 13000 rpm for 10 s before 
removing the phosphate buffered saline and adding 400µl hypotonic solution (100 mM 
HEPES pH 7.9, 1.5mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF).  The cells were 
pulse vortexed and incubated on ice for 10 minutes.  The cells were then centrifuged at 13000 
rpm for 10 s before removing the hypotonic buffer and adding 100 µl hypertonic buffer (20 
mM HEPES, 25 % glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 
0.2 mM PMSF).  The cells were then pulse vortexed before being incubated on ice for 20 
minutes.  The cells were then centrifuged for 2 minutes at 13000 rpm at 4 oC.  
 
Cell death assay  
Cells were counted and 10,000 cells were plated per well of a black 96-well plate. In total, 20 
µM, and 30µM Nelfinavir and 50 µM and 100 µM Chloroquine, and 50nm rapamycin were 
added, where indicated, 24 h after cells were grown in 10 % FBS.  Cell death assays were 
then conducted using a Cell death detection elisa assay (Roche, Hertfordshire, UK) according 
to manufacturers’ protocol. Absorbance was then measured using a fluorometer at 405 nm. 
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Electron Microscopy work. 
BHD-/- and BHD+/+ MEF cells were maintained in 35 mm plates in DMEM and grown to full 
confluency on EM grids.  The cells were then fixed in 1 % glutaraldehyde and Transmission 
Electron microscopy work was conducted in order to obtain images of the mitochondria 
within these cells.  The surface area of the inner mitochondrial membrane of the 
mitochondria in the images obtained from these cells was then measured and the ratio of 
surface area of inner membrane/total area of mitochondria was determined.  (Work carried 
out by Mr. Chris Von Ruhland).  Image J 1.45 was used on overlay outlines of mitochondrial 
cristae to measure mitochondrial surface area as well as their total volume. 
 
Appendix III.  Statistical Analyses 
 
A Shapiro-Wilk test was used to determine normal distribution (Sample size <50) where 
appropriate.  If 2 groups were of normal distribution an Independent t-test was conducted. 
If there were more than 2 groups and they were of normal distribution, a One-way 
independent-measures ANOVA was conducted. 
Table 1 ANOVA analysis of BNIP3 mRNA levels in UOK257 cells 
 Multiple Comparisons  Dependent variable BNIP3   Tukey HSD 
(I) BHD (J) BHD 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval 
O2 
(%) BHD 
 
Rapam
ycin O2 (%) BHD 
 
Rapam
ycin 
Lower 
Bound 
Upper 
Bound 
21 + - 21 + + .00115 .26111 1.000 -.9029 .9051 
21 - - -.98922* .26111 .027 -1.8932 -.0852 
21 - + -.35940 .26111 .855 -1.2634 .5446 
1 + - -.16371 .26111 .998 -1.0677 .7403 
1 + + -.10106 .26111 1.000 -1.0051 .8029 
1 - - -2.38276* .26111 .000 -3.2868 -1.4788 
1 - + -.37249 .26111 .833 -1.2765 .5315 
21 + + 21 + - -.00115 .26111 1.000 -.9051 .9029 
21 - - -.99037* .26111 .027 -1.8944 -.0864 
21 - + -.36054 .26111 .853 -1.2645 .5435 
1 + - -.16486 .26111 .998 -1.0689 .7391 
1 + + -.10221 .26111 1.000 -1.0062 .8018 
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1 - - -2.38391* .26111 .000 -3.2879 -1.4799 
1 - + -.37363 .26111 .831 -1.2776 .5304 
21 - - 21 + - .98922* .26111 .027 .0852 1.8932 
21 + + .99037* .26111 .027 .0864 1.8944 
21 - + .62983 .26111 .299 -.2742 1.5338 
1 + - .82551 .26111 .087 -.0785 1.7295 
1 + + .88816 .26111 .056 -.0158 1.7922 
1 - - -1.39354* .26111 .001 -2.2975 -.4895 
1 - + .61674 .26111 .321 -.2873 1.5207 
21 - + 21 + - .35940 .26111 .855 -.5446 1.2634 
21 + + .36054 .26111 .853 -.5435 1.2645 
21 - - -.62983 .26111 .299 -1.5338 .2742 
1 + - .19568 .26111 .994 -.7083 1.0997 
1 + + .25833 .26111 .970 -.6457 1.1623 
1 - - -2.02336* .26111 .000 -2.9274 -1.1194 
1 - + -.01309 .26111 1.000 -.9171 .8909 
1 + - 21 + - .16371 .26111 .998 -.7403 1.0677 
21 + + .16486 .26111 .998 -.7391 1.0689 
21 - - -.82551 .26111 .087 -1.7295 .0785 
21 - + -.19568 .26111 .994 -1.0997 .7083 
1 + + .06265 .26111 1.000 -.8413 .9667 
1 - - -2.21904* .26111 .000 -3.1230 -1.3150 
1 - + -.20877 .26111 .991 -1.1128 .6952 
1 + + 21 + - .10106 .26111 1.000 -.8029 1.0051 
21 + + .10221 .26111 1.000 -.8018 1.0062 
21 - - -.88816 .26111 .056 -1.7922 .0158 
21 - + -.25833 .26111 .970 -1.1623 .6457 
1 + - -.06265 .26111 1.000 -.9667 .8413 
1 - - -2.28170* .26111 .000 -3.1857 -1.3777 
1 - + -.27142 .26111 .961 -1.1754 .6326 
1 - - 21 + - 2.38276* .26111 .000 1.4788 3.2868 
21 + + 2.38391* .26111 .000 1.4799 3.2879 
21 - - 1.39354* .26111 .001 .4895 2.2975 
21 - + 2.02336* .26111 .000 1.1194 2.9274 
182 
 
1 + - 2.21904* .26111 .000 1.3150 3.1230 
1 + + 2.28170* .26111 .000 1.3777 3.1857 
1 - + 2.01027* .26111 .000 1.1063 2.9143 
1 - + 21 + - .37249 .26111 .833 -.5315 1.2765 
21 + + .37363 .26111 .831 -.5304 1.2776 
21 - - -.61674 .26111 .321 -1.5207 .2873 
21 - + .01309 .26111 1.000 -.8909 .9171 
1 + - .20877 .26111 .991 -.6952 1.1128 
1 + + .27142 .26111 .961 -.6326 1.1754 
1 - - -2.01027* .26111 .000 -2.9143 -1.1063 
     *. The mean difference is significant at the 0.05 level. 
 
Table 2.  ANOVA analysis of CCND1 mRNA levels in UOK257 cells 
 
 
     Multiple Comparisons 
     Dependent variable CCND1 
Tukey HSD 
(I) BHD (J) BHD 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval 
O2 
(%) BHD 
 
Rapam
ycin O2 (%) BHD 
 
Rapam
ycin 
Lower 
Bound 
Upper 
Bound 
21 + - 21 + + -.00017 .14615 1.000 -.5062 .5058 
21 - - -.99940* .14615 .000 -1.5054 -.4934 
21 - + -.73795* .14615 .002 -1.2439 -.2320 
1 + - -.00280 .14615 1.000 -.5088 .5032 
1 + + -.00164 .14615 1.000 -.5076 .5043 
1 - - -1.84585* .14615 .000 -2.3518 -1.3399 
1 - + -.29444 .14615 .502 -.8004 .2116 
21 + + 21 + - .00017 .14615 1.000 -.5058 .5062 
21 - - -.99923* .14615 .000 -1.5052 -.4932 
21 - + -.73778* .14615 .002 -1.2438 -.2318 
1 + - -.00263 .14615 1.000 -.5086 .5034 
1 + + -.00147 .14615 1.000 -.5075 .5045 
183 
 
1 - - -1.84569* .14615 .000 -2.3517 -1.3397 
1 - + -.29427 .14615 .503 -.8003 .2117 
21 - - 21 + - .99940* .14615 .000 .4934 1.5054 
21 + + .99923* .14615 .000 .4932 1.5052 
21 - + .26145 .14615 .635 -.2445 .7674 
1 + - .99660* .14615 .000 .4906 1.5026 
1 + + .99776* .14615 .000 .4918 1.5038 
1 - - -.84645* .14615 .001 -1.3524 -.3405 
1 - + .70497* .14615 .004 .1990 1.2110 
21 - + 21 + - .73795* .14615 .002 .2320 1.2439 
21 + + .73778* .14615 .002 .2318 1.2438 
21 - - -.26145 .14615 .635 -.7674 .2445 
1 + - .73515* .14615 .002 .2292 1.2411 
1 + + .73631* .14615 .002 .2303 1.2423 
1 - - -1.10790* .14615 .000 -1.6139 -.6019 
1 - + .44351 .14615 .109 -.0625 .9495 
1 + - 21 + - .00280 .14615 1.000 -.5032 .5088 
21 + + .00263 .14615 1.000 -.5034 .5086 
21 - - -.99660* .14615 .000 -1.5026 -.4906 
21 - + -.73515* .14615 .002 -1.2411 -.2292 
1 + + .00116 .14615 1.000 -.5048 .5071 
1 - - -1.84306* .14615 .000 -2.3490 -1.3371 
1 - + -.29164 .14615 .513 -.7976 .2144 
1 + + 21 + - .00164 .14615 1.000 -.5043 .5076 
21 + + .00147 .14615 1.000 -.5045 .5075 
21 - - -.99776* .14615 .000 -1.5038 -.4918 
21 - + -.73631* .14615 .002 -1.2423 -.2303 
1 + - -.00116 .14615 1.000 -.5071 .5048 
1 - - -1.84421* .14615 .000 -2.3502 -1.3382 
1 - + -.29280 .14615 .509 -.7988 .2132 
1 - - 21 + - 1.84585* .14615 .000 1.3399 2.3518 
21 + + 1.84569* .14615 .000 1.3397 2.3517 
21 - - .84645* .14615 .001 .3405 1.3524 
21 - + 1.10790* .14615 .000 .6019 1.6139 
184 
 
1 + - 1.84306* .14615 .000 1.3371 2.3490 
1 + + 1.84421* .14615 .000 1.3382 2.3502 
1 - + 1.55142* .14615 .000 1.0454 2.0574 
1 - + 21 + - .29444 .14615 .502 -.2116 .8004 
21 + + .29427 .14615 .503 -.2117 .8003 
21 - - -.70497* .14615 .004 -1.2110 -.1990 
21 - + -.44351 .14615 .109 -.9495 .0625 
1 + - .29164 .14615 .513 -.2144 .7976 
1 + + .29280 .14615 .509 -.2132 .7988 
1 - - -1.55142* .14615 .000 -2.0574 -1.0454 
     *. The mean difference is significant at the 0.05 level. 
 
Table 3.  ANOVA analysis of G6PD1 mRNA levels in UOK257 cells 
 
 
     Multiple Comparisons 
     Dependent variable G6PD1 
Tukey HSD 
(I) BHD (J) BHD 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval 
O2 
(%) BHD 
 
Rapam
ycin O2 (%) BHD 
 
Rapam
ycin 
Lower 
Bound 
Upper 
Bound 
21 + - 21 + + .05290 .18869 1.000 -.6129 .7187 
21 - - -.84233* .16877 .004 -1.4379 -.2468 
21 - + -.59629* .16877 .050 -1.1918 -.0008 
1 + - .09569 .18869 .999 -.5701 .7615 
1 + + .11135 .16877 .997 -.4842 .7069 
1 - - -.92428* .16877 .002 -1.5198 -.3288 
1 - + -.29848 .16877 .648 -.8940 .2970 
21 + + 21 + - -.05290 .18869 1.000 -.7187 .6129 
21 - - -.89523* .18869 .006 -1.5610 -.2294 
21 - + -.64918 .18869 .058 -1.3150 .0166 
1 + - .04280 .20669 1.000 -.6866 .7722 
1 + + .05846 .18869 1.000 -.6074 .7243 
185 
 
1 - - -.97717* .18869 .003 -1.6430 -.3114 
1 - + -.35138 .18869 .594 -1.0172 .3144 
21 - - 21 + - .84233* .16877 .004 .2468 1.4379 
21 + + .89523* .18869 .006 .2294 1.5610 
21 - + .24605 .16877 .816 -.3495 .8416 
1 + - .93803* .18869 .004 .2722 1.6038 
1 + + .95368* .16877 .001 .3582 1.5492 
1 - - -.08194 .16877 1.000 -.6775 .5136 
1 - + .54385 .16877 .085 -.0517 1.1394 
21 - + 21 + - .59629* .16877 .050 .0008 1.1918 
21 + + .64918 .18869 .058 -.0166 1.3150 
21 - - -.24605 .16877 .816 -.8416 .3495 
1 + - .69198* .18869 .039 .0262 1.3578 
1 + + .70764* .16877 .015 .1121 1.3032 
1 - - -.32799 .16877 .546 -.9235 .2675 
1 - + .29781 .16877 .650 -.2977 .8933 
1 + - 21 + - -.09569 .18869 .999 -.7615 .5701 
21 + + -.04280 .20669 1.000 -.7722 .6866 
21 - - -.93803* .18869 .004 -1.6038 -.2722 
21 - + -.69198* .18869 .039 -1.3578 -.0262 
1 + + .01566 .18869 1.000 -.6502 .6815 
1 - - -1.01997* .18869 .002 -1.6858 -.3542 
1 - + -.39417 .18869 .465 -1.0600 .2716 
1 + + 21 + - -.11135 .16877 .997 -.7069 .4842 
21 + + -.05846 .18869 1.000 -.7243 .6074 
21 - - -.95368* .16877 .001 -1.5492 -.3582 
21 - + -.70764* .16877 .015 -1.3032 -.1121 
1 + - -.01566 .18869 1.000 -.6815 .6502 
1 - - -1.03563* .16877 .001 -1.6311 -.4401 
1 - + -.40983 .16877 .299 -1.0053 .1857 
1 - - 21 + - .92428* .16877 .002 .3288 1.5198 
21 + + .97717* .18869 .003 .3114 1.6430 
21 - - .08194 .16877 1.000 -.5136 .6775 
21 - + .32799 .16877 .546 -.2675 .9235 
186 
 
1 + - 1.01997* .18869 .002 .3542 1.6858 
1 + + 1.03563* .16877 .001 .4401 1.6311 
1 - + .62580* .16877 .036 .0303 1.2213 
1 - + 21 + - .29848 .16877 .648 -.2970 .8940 
21 + + .35138 .18869 .594 -.3144 1.0172 
21 - - -.54385 .16877 .085 -1.1394 .0517 
21 - + -.29781 .16877 .650 -.8933 .2977 
1 + - .39417 .18869 .465 -.2716 1.0600 
1 + + .40983 .16877 .299 -.1857 1.0053 
1 - - -.62580* .16877 .036 -1.2213 -.0303 
     *. The mean difference is significant at the 0.05 level. 
 
Table 4.  ANOVA analyses of GLUT1 mRNA levels UOK257 cells 
 
     Multiple Comparisons 
     Dependent variable GLUT1 
Tukey HSD 
(I) BHD (J) BHD 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval 
O2 
(%) BHD 
 
Rapam
ycin O2 (%) BHD 
 
Rapam
ycin 
Lower 
Bound 
Upper 
Bound 
21 + - 21 + + .03263 2.52805 1.000 -8.8880 8.9533 
21 - - -.56509 2.52805 1.000 -9.4858 8.3556 
21 - + -.07946 2.82645 1.000 -10.0531 9.8941 
1 + - -7.92092 2.52805 .099 -16.8416 .9997 
1 + + -4.79107 2.52805 .574 -13.7117 4.1296 
1 - - -16.97599* 2.82645 .001 -26.9496 -7.0024 
1 - + -9.51713* 2.52805 .033 -18.4378 -.5965 
21 + + 21 + - -.03263 2.52805 1.000 -8.9533 8.8880 
21 - - -.59773 2.52805 1.000 -9.5184 8.3229 
21 - + -.11209 2.82645 1.000 -10.0857 9.8615 
1 + - -7.95355 2.52805 .097 -16.8742 .9671 
1 + + -4.82371 2.52805 .567 -13.7444 4.0970 
187 
 
1 - - -17.00863* 2.82645 .001 -26.9822 -7.0350 
1 - + -9.54976* 2.52805 .032 -18.4704 -.6291 
21 - - 21 + - .56509 2.52805 1.000 -8.3556 9.4858 
21 + + .59773 2.52805 1.000 -8.3229 9.5184 
21 - + .48564 2.82645 1.000 -9.4880 10.4592 
1 + - -7.35583 2.52805 .144 -16.2765 1.5648 
1 + + -4.22598 2.52805 .704 -13.1466 4.6947 
1 - - -16.41090* 2.82645 .001 -26.3845 -6.4373 
1 - + -8.95204* 2.52805 .049 -17.8727 -.0314 
21 - + 21 + - .07946 2.82645 1.000 -9.8941 10.0531 
21 + + .11209 2.82645 1.000 -9.8615 10.0857 
21 - - -.48564 2.82645 1.000 -10.4592 9.4880 
1 + - -7.84146 2.82645 .178 -17.8151 2.1321 
1 + + -4.71162 2.82645 .706 -14.6852 5.2620 
1 - - -16.89654* 3.09622 .002 -27.8221 -5.9710 
1 - + -9.43767 2.82645 .070 -19.4113 .5359 
1 + - 21 + - 7.92092 2.52805 .099 -.9997 16.8416 
21 + + 7.95355 2.52805 .097 -.9671 16.8742 
21 - - 7.35583 2.52805 .144 -1.5648 16.2765 
21 - + 7.84146 2.82645 .178 -2.1321 17.8151 
1 + + 3.12984 2.52805 .907 -5.7908 12.0505 
1 - - -9.05508 2.82645 .088 -19.0287 .9185 
1 - + -1.59621 2.52805 .998 -10.5169 7.3245 
1 + + 21 + - 4.79107 2.52805 .574 -4.1296 13.7117 
21 + + 4.82371 2.52805 .567 -4.0970 13.7444 
21 - - 4.22598 2.52805 .704 -4.6947 13.1466 
21 - + 4.71162 2.82645 .706 -5.2620 14.6852 
1 + - -3.12984 2.52805 .907 -12.0505 5.7908 
1 - - -12.18492* 2.82645 .012 -22.1585 -2.2113 
1 - + -4.72605 2.52805 .589 -13.6467 4.1946 
1 - - 21 + - 16.97599* 2.82645 .001 7.0024 26.9496 
21 + + 17.00863* 2.82645 .001 7.0350 26.9822 
21 - - 16.41090* 2.82645 .001 6.4373 26.3845 
21 - + 16.89654* 3.09622 .002 5.9710 27.8221 
188 
 
1 + - 9.05508 2.82645 .088 -.9185 19.0287 
1 + + 12.18492* 2.82645 .012 2.2113 22.1585 
1 - + 7.45887 2.82645 .220 -2.5147 17.4325 
1 - + 21 + - 9.51713* 2.52805 .033 .5965 18.4378 
21 + + 9.54976* 2.52805 .032 .6291 18.4704 
21 - - 8.95204* 2.52805 .049 .0314 17.8727 
21 - + 9.43767 2.82645 .070 -.5359 19.4113 
1 + - 1.59621 2.52805 .998 -7.3245 10.5169 
1 + + 4.72605 2.52805 .589 -4.1946 13.6467 
1 - - -7.45887 2.82645 .220 -17.4325 2.5147 
     *. The mean difference is significant at the 0.05 level. 
 
Table 5.  ANOVA analysis of VEGF-A mRNA levels in UOK257 cells 
 
 
     Multiple Comparisons 
     Dependent variable VEGF 
Tukey HSD 
(I) BHD (J) BHD 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval 
O2 
(%) BHD 
 
Rapam
ycin O2 (%) BHD 
 
Rapam
ycin 
Lower 
Bound 
Upper 
Bound 
21 + - 21 + + .00594 .37774 1.000 -1.3018 1.3137 
21 - - -.99200 .37774 .216 -2.2998 .3158 
21 - + -.45278 .37774 .921 -1.7606 .8550 
1 + - -.05030 .37774 1.000 -1.3581 1.2575 
1 + + -.00609 .37774 1.000 -1.3139 1.3017 
1 - - -2.84558* .37774 .000 -4.1534 -1.5378 
1 - + -3.75703* .37774 .000 -5.0648 -2.4492 
21 + + 21 + - -.00594 .37774 1.000 -1.3137 1.3018 
21 - - -.99794 .37774 .211 -2.3057 .3098 
21 - + -.45872 .37774 .916 -1.7665 .8491 
1 + - -.05624 .37774 1.000 -1.3640 1.2515 
189 
 
1 + + -.01203 .37774 1.000 -1.3198 1.2958 
1 - - -2.85152* .37774 .000 -4.1593 -1.5437 
1 - + -3.76297* .37774 .000 -5.0707 -2.4552 
21 - - 21 + - .99200 .37774 .216 -.3158 2.2998 
21 + + .99794 .37774 .211 -.3098 2.3057 
21 - + .53922 .37774 .832 -.7686 1.8470 
1 + - .94170 .37774 .265 -.3661 2.2495 
1 + + .98591 .37774 .221 -.3219 2.2937 
1 - - -1.85359* .37774 .003 -3.1614 -.5458 
1 - + -2.76503* .37774 .000 -4.0728 -1.4572 
21 - + 21 + - .45278 .37774 .921 -.8550 1.7606 
21 + + .45872 .37774 .916 -.8491 1.7665 
21 - - -.53922 .37774 .832 -1.8470 .7686 
1 + - .40248 .37774 .955 -.9053 1.7103 
1 + + .44669 .37774 .926 -.8611 1.7545 
1 - - -2.39280* .37774 .000 -3.7006 -1.0850 
1 - + -3.30424* .37774 .000 -4.6120 -1.9965 
1 + - 21 + - .05030 .37774 1.000 -1.2575 1.3581 
21 + + .05624 .37774 1.000 -1.2515 1.3640 
21 - - -.94170 .37774 .265 -2.2495 .3661 
21 - + -.40248 .37774 .955 -1.7103 .9053 
1 + + .04421 .37774 1.000 -1.2636 1.3520 
1 - - -2.79528* .37774 .000 -4.1031 -1.4875 
1 - + -3.70673* .37774 .000 -5.0145 -2.3989 
1 + + 21 + - .00609 .37774 1.000 -1.3017 1.3139 
21 + + .01203 .37774 1.000 -1.2958 1.3198 
21 - - -.98591 .37774 .221 -2.2937 .3219 
21 - + -.44669 .37774 .926 -1.7545 .8611 
1 + - -.04421 .37774 1.000 -1.3520 1.2636 
1 - - -2.83949* .37774 .000 -4.1473 -1.5317 
1 - + -3.75094* .37774 .000 -5.0587 -2.4432 
1 - - 21 + - 2.84558* .37774 .000 1.5378 4.1534 
21 + + 2.85152* .37774 .000 1.5437 4.1593 
21 - - 1.85359* .37774 .003 .5458 3.1614 
190 
 
21 - + 2.39280* .37774 .000 1.0850 3.7006 
1 + - 2.79528* .37774 .000 1.4875 4.1031 
1 + + 2.83949* .37774 .000 1.5317 4.1473 
1 - + -.91144 .37774 .298 -2.2192 .3963 
1 - + 21 + - 3.75703* .37774 .000 2.4492 5.0648 
21 + + 3.76297* .37774 .000 2.4552 5.0707 
21 - - 2.76503* .37774 .000 1.4572 4.0728 
21 - + 3.30424* .37774 .000 1.9965 4.6120 
1 + - 3.70673* .37774 .000 2.3989 5.0145 
1 + + 3.75094* .37774 .000 2.4432 5.0587 
1 - - .91144 .37774 .298 -.3963 2.2192 
     *. The mean difference is significant at the 0.05 level. 
 
Table 6.  ANOVA analysis of HIF1α mRNA levels in UOK257 cells 
 
 
Multiple Comparisons 
HIF1 
Tukey HSD 
(I) BHD 
 
(J) BHD 
Mean Difference (I-
J) 
Std. 
Error Sig. 
95% Confidence Interval 
02 (%) BHD O2(%) BHD 
Lower 
Bound Upper Bound 
21 + 21 - -.99200 .33142 .067 -
2.0533 
.0693 
1 + -.05030 .33142 .999 -
1.1116 
1.0110 
1 - -2.84558* .33142 .000 -
3.9069 
-1.7842 
21 - 21 + .99200 .33142 .067 -.0693 2.0533 
1 + .94170 .33142 .083 -.1196 2.0030 
1 - -1.85359* .33142 .002 -
2.9149 
-.7922 
1 + 21 + .05030 .33142 .999 -
1.0110 
1.1116 
191 
 
21 - -.94170 .33142 .083 -
2.0030 
.1196 
1 - -2.79528* .33142 .000 -
3.8566 
-1.7339 
1 - 21 + 2.84558* .33142 .000 1.7842 3.9069 
  21 - 1.85359* .33142 .002 .7922 2.9149 
  1 + 2.79528* .33142 .000 1.7339 3.8566 
*. The mean difference is significant at the 0.05 level. 
 
 
Table 7.  ANOVA analysis of HIF2α mRNA levels in UOK257 cells 
 
 
Multiple Comparisons 
HIF2 
Tukey HSD 
(I) BHD 
 
(J) BHD 
Mean Difference (I-
J) 
Std. 
Error Sig. 
95% Confidence Interval 
02 (%) BHD O2(%) BHD 
Lower 
Bound Upper Bound 
21 + 21 - -.14733 1.20395 .999 -
4.0028 
3.7081 
1 + -4.60856* 1.20395 .021 -
8.4640 
-.7531 
1 - -4.23750* 1.20395 .032 -
8.0930 
-.3820 
21 - 21 + .14733 1.20395 .999 -
3.7081 
4.0028 
1 + -4.46123* 1.20395 .025 -
8.3167 
-.6058 
1 - -4.09017* 1.20395 .038 -
7.9456 
-.2347 
1 + 21 + 4.60856* 1.20395 .021 .7531 8.4640 
21 - 4.46123* 1.20395 .025 .6058 8.3167 
1 - .37106 1.20395 .989 -
3.4844 
4.2265 
192 
 
1 - 21 + 4.23750* 1.20395 .032 .3820 8.0930 
  21 - 4.09017* 1.20395 .038 .2347 7.9456 
  1 + -.37106 1.20395 .989 -
4.2265 
3.4844 
*. The mean difference is significant at the 0.05 level. 
 
Table 8.  ANOVA analysis of HIF luciferase assay in UOK257 cells 
 
Multiple Comparisons 
HIF_lucif 
Tukey HSD 
(I) BHD 
 
(J) BHD 
Mean Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval 
BHD Rapamycin BHD Rapamycin 
Lower 
Bound Upper Bound 
+ - + + 18.18182 5.54242 .052 -.1645 36.5281 
- - -52.77778* 6.19662 .000 -
73.2896 
-32.2660 
- + -22.72727* 5.54242 .019 -
41.0736 
-4.3810 
+ + + - -18.18182 5.54242 .052 -
36.5281 
.1645 
- - -70.95960* 6.19662 .000 -
91.4714 
-50.4478 
- + -40.90909* 5.54242 .001 -
59.2554 
-22.5628 
- - + - 52.77778* 6.19662 .000 32.2660 73.2896 
- + 70.95960* 6.19662 .000 50.4478 91.4714 
- + 30.05051* 6.19662 .008 9.5387 50.5623 
- + + - 22.72727* 5.54242 .019 4.3810 41.0736 
  + + 40.90909* 5.54242 .001 22.5628 59.2554 
193 
 
  - - -30.05051* 6.19662 .008 -
50.5623 
-9.5387 
*. The mean difference is significant at the 0.05 level. 
 
 
 
 
 
 
 
Table 9.  ANOVA analysis of HIF luciferase assay in ACHN cells 
 
Multiple Comparisons 
HIF_lucif 
Tukey HSD 
(I) BHD 
 
(J) BHD 
Mean Difference (I-
J) 
Std. 
Error Sig. 
95% Confidence Interval 
02 
(%) BHD O2(%) BHD 
Lower 
Bound Upper Bound 
21 + 21 - -8.83508 3.94384 .192 -21.4647 3.7945 
1 + -25.39267* 3.94384 .001 -38.0222 -12.7631 
1 - -92.01571* 3.94384 .000 -104.6453 -79.3861 
21 - 21 + 8.83508 3.94384 .192 -3.7945 21.4647 
1 + -16.55759* 3.94384 .013 -29.1872 -3.9280 
1 - -83.18063* 3.94384 .000 -95.8102 -70.5511 
1 + 21 + 25.39267* 3.94384 .001 12.7631 38.0222 
21 - 16.55759* 3.94384 .013 3.9280 29.1872 
1 - -66.62304* 3.94384 .000 -79.2526 -53.9935 
1 - 21 + 92.01571* 3.94384 .000 79.3861 104.6453 
  21 - 83.18063* 3.94384 .000 70.5511 95.8102 
  1 + 66.62304* 3.94384 .000 53.9935 79.2526 
*. The mean difference is significant at the 0.05 level. 
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Table 10.  ANOVA analysis of VEGF-A mRNA levels in ACHN cells 
 
 
     Multiple Comparisons 
     Dependent variable VEGF 
Tukey HSD 
(I) BHD (J) BHD 
Mean 
Difference 
(I-J) Std. Error Sig. 
95% Confidence 
Interval 
O2 
(%) BHD 
 
Rapam
ycin O2 (%) BHD 
 
Rapam
ycin 
Lower 
Bound 
Upper 
Bound 
21 + - 21 + + .13030 1.45726 1.000 -4.9150 5.1755 
21 - - -.56529 1.45726 1.000 -5.6105 4.4800 
21 - + .00308 1.45726 1.000 -5.0422 5.0483 
1 + - -.92704 1.45726 .998 -5.9723 4.1182 
1 + + -.68332 1.45726 1.000 -5.7286 4.3619 
1 - - -5.11544* 1.45726 .046 -10.1607 -.0702 
1 - + -2.07503 1.45726 .834 -7.1203 2.9702 
21 + + 21 + - -.13030 1.45726 1.000 -5.1755 4.9150 
21 - - -.69559 1.45726 1.000 -5.7408 4.3497 
21 - + -.12722 1.45726 1.000 -5.1725 4.9180 
1 + - -1.05734 1.45726 .995 -6.1026 3.9879 
1 + + -.81362 1.45726 .999 -5.8589 4.2316 
1 - - -5.24574* 1.45726 .039 -10.2910 -.2005 
1 - + -2.20533 1.45726 .790 -7.2506 2.8399 
21 - - 21 + - .56529 1.45726 1.000 -4.4800 5.6105 
21 + + .69559 1.45726 1.000 -4.3497 5.7408 
21 - + .56837 1.45726 1.000 -4.4769 5.6136 
1 + - -.36175 1.45726 1.000 -5.4070 4.6835 
1 + + -.11803 1.45726 1.000 -5.1633 4.9272 
1 - - -4.55015 1.45726 .093 -9.5954 .4951 
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1 - + -1.50974 1.45726 .961 -6.5550 3.5355 
21 - + 21 + - -.00308 1.45726 1.000 -5.0483 5.0422 
21 + + .12722 1.45726 1.000 -4.9180 5.1725 
21 - - -.56837 1.45726 1.000 -5.6136 4.4769 
1 + - -.93012 1.45726 .998 -5.9754 4.1151 
1 + + -.68640 1.45726 1.000 -5.7316 4.3589 
1 - - -5.11852* 1.45726 .045 -10.1638 -.0733 
1 - + -2.07811 1.45726 .833 -7.1234 2.9671 
1 + - 21 + - .92704 1.45726 .998 -4.1182 5.9723 
21 + + 1.05734 1.45726 .995 -3.9879 6.1026 
21 - - .36175 1.45726 1.000 -4.6835 5.4070 
21 - + .93012 1.45726 .998 -4.1151 5.9754 
1 + + .24372 1.45726 1.000 -4.8015 5.2890 
1 - - -4.18840 1.45726 .144 -9.2336 .8569 
1 - + -1.14799 1.45726 .991 -6.1932 3.8973 
1 + + 21 + - .68332 1.45726 1.000 -4.3619 5.7286 
21 + + .81362 1.45726 .999 -4.2316 5.8589 
21 - - .11803 1.45726 1.000 -4.9272 5.1633 
21 - + .68640 1.45726 1.000 -4.3589 5.7316 
1 + - -.24372 1.45726 1.000 -5.2890 4.8015 
1 - - -4.43212 1.45726 .108 -9.4774 .6131 
1 - + -1.39171 1.45726 .975 -6.4370 3.6535 
1 - - 21 + - 5.11544* 1.45726 .046 .0702 10.1607 
21 + + 5.24574* 1.45726 .039 .2005 10.2910 
21 - - 4.55015 1.45726 .093 -.4951 9.5954 
21 - + 5.11852* 1.45726 .045 .0733 10.1638 
1 + - 4.18840 1.45726 .144 -.8569 9.2336 
1 + + 4.43212 1.45726 .108 -.6131 9.4774 
1 - + 3.04041 1.45726 .462 -2.0048 8.0857 
1 - + 21 + - 2.07503 1.45726 .834 -2.9702 7.1203 
21 + + 2.20533 1.45726 .790 -2.8399 7.2506 
21 - - 1.50974 1.45726 .961 -3.5355 6.5550 
21 - + 2.07811 1.45726 .833 -2.9671 7.1234 
1 + - 1.14799 1.45726 .991 -3.8973 6.1932 
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1 + + 1.39171 1.45726 .975 -3.6535 6.4370 
1 - - -3.04041 1.45726 .462 -8.0857 2.0048 
     *. The mean difference is significant at the 0.05 level. 
 
 
 
Table 11.  Anova analysis of HIF luciferase assay in BHD MEF cells 
 
 
Multiple Comparisons 
HIF_lucif 
Tukey HSD 
(I) BHD 
 
(J) BHD 
Mean Difference (I-
J) 
Std. 
Error Sig. 
95% Confidence Interval 
BHD Rapamycin BHD Rapamycin 
Lower 
Bound Upper Bound 
+ - + + 9.76444 8.28955 .656 -16.7816 36.3105 
- - -89.10161* 8.28955 .000 -
115.6477 
-62.5556 
- + -19.92904 8.28955 .154 -46.4751 6.6170 
+ + + - -9.76444 8.28955 .656 -36.3105 16.7816 
- - -98.86604* 8.28955 .000 -
125.4121 
-72.3200 
- + -29.69347* 8.28955 .029 -56.2395 -3.1474 
- - + - 89.10161* 8.28955 .000 62.5556 115.6477 
- + 98.86604* 8.28955 .000 72.3200 125.4121 
- + 69.17257* 8.28955 .000 42.6265 95.7186 
- + + - 19.92904 8.28955 .154 -6.6170 46.4751 
  + + 29.69347* 8.28955 .029 3.1474 56.2395 
  - - -69.17257* 8.28955 .000 -95.7186 -42.6265 
*. The mean difference is significant at the 0.05 level. 
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Table 12.  T-test analysis of BNIP3 mRNA levels in BHD MEF cells 
T-test 
 
 
Table 13.  ANOVA analysis of HIF luciferase assay in HK2 cells 
 
 
Multiple Comparisons 
HIF_lucif 
Tukey HSD 
(I) BHD 
 
(J) BHD 
Mean Difference (I-
J) 
Std. 
Error Sig. 
95% Confidence Interval 
BHD Rapamycin BHD Rapamycin 
Lower 
Bound Upper Bound 
+ - + + 17.71995 9.25812 .295 -11.9278 47.3677 
- - -60.17348* 9.25812 .001 -89.8213 -30.5257 
- + -19.75217 9.25812 .222 -49.3999 9.8956 
+ + + - -17.71995 9.25812 .295 -47.3677 11.9278 
- - -77.89343* 9.25812 .000 -
107.5412 
-48.2457 
- + -37.47212* 9.25812 .016 -67.1199 -7.8244 
- - + - 60.17348* 9.25812 .001 30.5257 89.8213 
- + 77.89343* 9.25812 .000 48.2457 107.5412 
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- + 40.42131* 9.25812 .010 10.7735 70.0691 
- + + - 19.75217 9.25812 .222 -9.8956 49.3999 
  + + 37.47212* 9.25812 .016 7.8244 67.1199 
  - - -40.42131* 9.25812 .010 -70.0691 -10.7735 
*. The mean difference is significant at the 0.05 level. 
 
Table 14.  T-test analysis of L-Lactate assay in UOK257 cells 
T-test 
 
 
 
 
Table 15.  ANOVA analysis of Mitochondrial vs genomic DNA in UOK257 cells 
     Multiple Comparisons 
     Dependent variable mtDNA 
Tukey HSD 
(I) BHD (J) BHD 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence Interval 
O2 
(%) BHD 
 
Rapam
ycin O2 (%) BHD 
 
Rapa
mycin Lower Bound Upper Bound 
21 + - 21 + + .41186 .50947 .990 -1.3520 2.1757 
21 - - -4.40037* .50947 .000 -6.1642 -2.6365 
21 - + -1.55536 .50947 .105 -3.3192 .2085 
1 + - .31936 .50947 .998 -1.4445 2.0832 
1 + + .53928 .50947 .957 -1.2246 2.3031 
1 - - -.98708 .50947 .547 -2.7509 .7768 
1 - + -.65926 .50947 .888 -2.4231 1.1046 
21 + + 21 + - -.41186 .50947 .990 -2.1757 1.3520 
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21 - - -4.81223* .50947 .000 -6.5761 -3.0484 
21 - + -1.96722* .50947 .023 -3.7311 -.2034 
1 + - -.09250 .50947 1.000 -1.8564 1.6714 
1 + + .12742 .50947 1.000 -1.6364 1.8913 
1 - - -1.39894 .50947 .178 -3.1628 .3649 
1 - + -1.07112 .50947 .453 -2.8350 .6927 
21 - - 21 + - 4.40037* .50947 .000 2.6365 6.1642 
21 + + 4.81223* .50947 .000 3.0484 6.5761 
21 - + 2.84501* .50947 .001 1.0812 4.6089 
1 + - 4.71973* .50947 .000 2.9559 6.4836 
1 + + 4.93965* .50947 .000 3.1758 6.7035 
1 - - 3.41328* .50947 .000 1.6494 5.1771 
1 - + 3.74111* .50947 .000 1.9773 5.5050 
21 - + 21 + - 1.55536 .50947 .105 -.2085 3.3192 
21 + + 1.96722* .50947 .023 .2034 3.7311 
21 - - -2.84501* .50947 .001 -4.6089 -1.0812 
1 + - 1.87472* .50947 .033 .1109 3.6386 
1 + + 2.09464* .50947 .014 .3308 3.8585 
1 - - .56828 .50947 .944 -1.1956 2.3321 
1 - + .89610 .50947 .653 -.8678 2.6600 
1 + - 21 + - -.31936 .50947 .998 -2.0832 1.4445 
21 + + .09250 .50947 1.000 -1.6714 1.8564 
21 - - -4.71973* .50947 .000 -6.4836 -2.9559 
21 - + -1.87472* .50947 .033 -3.6386 -.1109 
1 + + .21992 .50947 1.000 -1.5439 1.9838 
1 - - -1.30644 .50947 .238 -3.0703 .4574 
1 - + -.97862 .50947 .557 -2.7425 .7852 
1 + + 21 + - -.53928 .50947 .957 -2.3031 1.2246 
21 + + -.12742 .50947 1.000 -1.8913 1.6364 
21 - - -4.93965* .50947 .000 -6.7035 -3.1758 
21 - + -2.09464* .50947 .014 -3.8585 -.3308 
1 + - -.21992 .50947 1.000 -1.9838 1.5439 
1 - - -1.52636 .50947 .117 -3.2902 .2375 
1 - + -1.19854 .50947 .325 -2.9624 .5653 
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1 - - 21 + - .98708 .50947 .547 -.7768 2.7509 
21 + + 1.39894 .50947 .178 -.3649 3.1628 
21 - - -3.41328* .50947 .000 -5.1771 -1.6494 
21 - + -.56828 .50947 .944 -2.3321 1.1956 
1 + - 1.30644 .50947 .238 -.4574 3.0703 
1 + + 1.52636 .50947 .117 -.2375 3.2902 
1 - + .32782 .50947 .997 -1.4360 2.0917 
1 - + 21 + - .65926 .50947 .888 -1.1046 2.4231 
21 + + 1.07112 .50947 .453 -.6927 2.8350 
21 - - -3.74111* .50947 .000 -5.5050 -1.9773 
21 - + -.89610 .50947 .653 -2.6600 .8678 
1 + - .97862 .50947 .557 -.7852 2.7425 
1 + + 1.19854 .50947 .325 -.5653 2.9624 
1 - - -.32782 .50947 .997 -2.0917 1.4360 
     *. The mean difference is significant at the 0.05 level. 
 
Table 16.  T-test analysis of UCP3 mRNA data for UOK257 cell line 
 
 
 
 
If the resulting p-value of a Levene's test is less than typically 0.05 there is a difference 
between the variances in the groups tested. 
Equal variances not assumed (Sig=0.022 therefore <0.05 for Levene’s test) therefore P=0.007 
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Table 17.  T-test analysis of SOD2 mRNA data for UOK257 cell line 
 
 
 
 
If the resulting p-value of a Levene's test is less than typically 0.05 there is a difference 
between the variances in the groups tested. 
. 
Equal variances assumed (Sig=0.056 therefore > 0.05 for Levene’s test) therefore P=0.000 
 
 
Table 18.  T-test analysis of PGC1β mRNA data for UOK257 cell line 
 
 
If the resulting p-value of a Levene's test is less than typically 0.05 there is a difference 
between the variances in the groups tested. 
Equal variances not assumed (Sig=0.028 therefore < 0.05 for Levene’s test) therefore 
P=0.005 
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Table 19.  T-test analysis of NRF1 mRNA data for UOK257 cell line 
 
 
 
If the resulting p-value of a Levene's test is less than typically 0.05 there is a difference 
between the variances in the groups tested. 
Equal variances assumed (Sig=0.072 therefore > 0.05 for Levene’s test) therefore P=0.006 
 
Table 20.  T-test analysis of NRF2 mRNA data for UOK257 cell line 
 
 
 
If the resulting p-value of a Levene's test is less than typically 0.05 there is a difference 
between the variances in the groups tested. 
Equal variances not assumed (Sig=0.017 therefore < 0.05 for Levene’s test) therefore 
P=0.034 
 
Table 21.  T-test analysis of TFAM mRNA data for UOK257 cell line 
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If the resulting p-value of a Levene's test is less than typically 0.05 there is a difference 
between the variances in the groups tested. 
Equal variances not assumed (Sig=0.021 therefore < 0.05 for Levene’s test) therefore 
P=0.596 
 
Table 23.  T-test analysis of ATP5G1 mRNA data for BHD MEF cell line 
 
 
If the resulting p-value of a Levene's test is less than typically 0.05 there is a difference 
between the variances in the groups tested. 
Equal variances not assumed (Sig=0.029 therefore < 0.05 for Levene’s test) therefore 
P=0.049 
 
Table 24.  T-test analysis of PGC1a mRNA data for BHD MEF cell line 
 
 
If the resulting p-value of a Levene's test is less than typically 0.05 there is a difference 
between the variances in the groups tested. 
Equal variances not assumed (Sig=0.029 therefore < 0.05 for Levene’s test) therefore 
P=0.046 
 
Table 25.  T-test analysis of PGC1α mRNA data for HK2 cell line 
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 If the resulting p-value of a Levene's test is less than typically 0.05 there is a difference 
between the variances in the groups tested. 
Equal variances not assumed (Sig=0.000 therefore < 0.05 for Levene’s test) therefore 
P=0.035 
 
Table 26.  PGC1b mRNA data for HK2 cell line 
 
If the resulting p-value of a Levene’s test is less than typically 0.05 there is a difference 
between the variances in the groups tested. 
Equal variances not assumed (Sig=0.000 therefore < 0.05 for Levene’s test) therefore 
P=0.101 
 
Table 27.   T-test for ATP levels in UOK257 cells 
 
 
If the resulting p-value of a Levene’s test is less than typically 0.05 there is a difference 
between the variances in the groups tested. 
Equal variances assumed (Sig=0.116 therefore > 0.05 for Levene’s test) therefore P=0.000 
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Table 28.  ANOVA analysis of PGC1α Luciferase assay in UOK257 cells 
 
Multiple Comparisons 
PGC1a_lucif 
Tukey HSD 
(I) BHD 
 
(J) BHD 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
02 (%) BHD O2(%) BHD 
Lower 
Bound Upper Bound 
21 + 21 - -53.36538* 1.98044 .000 -
59.7074 
-47.0233 
1 + 31.49038* 1.98044 .000 25.1483 37.8324 
1 - 18.87019* 1.98044 .000 12.5281 25.2123 
21 - 21 + 53.36538* 1.98044 .000 47.0233 59.7074 
1 + 84.85577* 1.98044 .000 78.5137 91.1978 
1 - 72.23558* 1.98044 .000 65.8935 78.5776 
1 + 21 + -31.49038* 1.98044 .000 -
37.8324 
-25.1483 
21 - -84.85577* 1.98044 .000 -
91.1978 
-78.5137 
1 - -12.62019* 1.98044 .001 -
18.9623 
-6.2781 
1 - 21 + -18.87019* 1.98044 .000 -
25.2123 
-12.5281 
  21 - -72.23558* 1.98044 .000 -
78.5776 
-65.8935 
  1 + 12.62019* 1.98044 .001 6.2781 18.9623 
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Multiple Comparisons 
PGC1a_lucif 
Tukey HSD 
(I) BHD 
 
(J) BHD 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
02 (%) BHD O2(%) BHD 
Lower 
Bound Upper Bound 
21 + 21 - -53.36538* 1.98044 .000 -
59.7074 
-47.0233 
1 + 31.49038* 1.98044 .000 25.1483 37.8324 
1 - 18.87019* 1.98044 .000 12.5281 25.2123 
21 - 21 + 53.36538* 1.98044 .000 47.0233 59.7074 
1 + 84.85577* 1.98044 .000 78.5137 91.1978 
1 - 72.23558* 1.98044 .000 65.8935 78.5776 
1 + 21 + -31.49038* 1.98044 .000 -
37.8324 
-25.1483 
21 - -84.85577* 1.98044 .000 -
91.1978 
-78.5137 
1 - -12.62019* 1.98044 .001 -
18.9623 
-6.2781 
1 - 21 + -18.87019* 1.98044 .000 -
25.2123 
-12.5281 
  21 - -72.23558* 1.98044 .000 -
78.5776 
-65.8935 
  1 + 12.62019* 1.98044 .001 6.2781 18.9623 
*. The mean difference is significant at the 0.05 level. 
 
 
 
 
 
 
Table 29.  ANOVA analysis of PGC1a Luciferase assay in BHD MEF cells 
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Multiple Comparisons 
PGC1a_lucif 
Tukey HSD 
(I) BHD 
 
(J) BHD 
Mean 
Difference (I-J) 
Std. 
Error Sig. 
95% Confidence Interval 
BHD Rapamycin BHD Rapamycin 
Lower 
Bound Upper Bound 
+ - 21 - 2.14856 6.79974 .988 -
19.6266 
23.9237 
1 + -45.31694* 6.79974 .001 -
67.0921 
-23.5418 
1 - -21.57602 6.79974 .052 -
43.3512 
.1991 
+ + 21 + -2.14856 6.79974 .988 -
23.9237 
19.6266 
1 + -47.46551* 6.79974 .001 -
69.2407 
-25.6903 
1 - -23.72458* 6.79974 .033 -
45.4997 
-1.9494 
 + 21 + 45.31694* 6.79974 .001 23.5418 67.0921 
21 - 47.46551* 6.79974 .001 25.6903 69.2407 
1 - 23.74093* 6.79974 .033 1.9658 45.5161 
1 - 21 + 21.57602 6.79974 .052 -.1991 43.3512 
  21 - 23.72458* 6.79974 .033 1.9494 45.4997 
  1 + -23.74093* 6.79974 .033 -
45.5161 
-1.9658 
*. The mean difference is significant at the 0.05 level. 
 
 
 
 
 
Table 30.  T-test analysis of H2O2 assay in UOK257 cells 
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T-Test 
 
 
If the resulting p-value of a Levene’s test is less than typically 0.05 there is a difference 
between the variances in the groups tested. 
Equal variances assumed (Sig=0.245 therefore > 0.05 for Levene’s test) therefore P=0.006 
 
Table 31.  T-test analysis of PGC1α mRNA levels in HK2 cells 
 
 
Table 32.  T-test analysis of PGC1β mRNA levels in HK2 cells 
 
 
 
 
 
 
Table 33.  T-test analysis of the surface area of cristae to total area of mitochondria ratio in 
BHD MEF cells. 
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If the resulting p-value of a Levene’s test is less than typically 0.05 there is a difference 
between the variances in the groups tested. 
Equal variances assumed (Sig=0.612 therefore > 0.05 for Levene’s test) therefore P=0.000 
 
Table 34.  T-test analysis of ULK1 mRNA data for UOK257 cell line 
 
 
If the resulting p-value of a Levene’s test is less than typically 0.05 there is a difference 
between the variances in the groups tested. 
Equal variances not assumed (Sig=0.102 therefore >0.05 for Levene’s test) therefore P=0.006 
 
Table 35.  T-test analysis of ULK2 mRNA data for UOK257 cell line 
 
If the resulting p-value of a Levene’s test is less than typically 0.05 there is a difference 
between the variances in the groups tested. 
Equal variances assumed (Sig=0.101 therefore > 0.05 for Levene’s test) therefore P=0.030 
 
Table 36.  T-test analysis of ULK1 mRNA data for BHD MEF cells 
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If the resulting p-value of a Levene’s test is less than typically 0.05 there is a difference 
between the variances in the groups tested. 
Equal variances assumed (Sig=0.074 therefore > 0.05 for Levene’s test) therefore P=0.001 
 
Table 37.  ANOVA analysis of CyQUANT (R) Cell Proliferation assay in BHD MEF cells 
(3MA (5nM) and Nelfinavir (50µM)) 
Multiple Comparisons 
Dependent Variable:Proliferation 
Tukey HSD Post-Hoc Test 
(I) BHD 
 
(J) BHD 
Mean 
Differenc
e (I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval 
BHD 3MA 
(nM) 
Nelfin
avir 
(µM) 
BHD 3MA 
(nM) 
Nelfin
avir 
(µM) 
Lower 
Bound 
Upper 
Bound 
+ 
 
0 
 
0 - 0 0 .00000 2.43300 1.000 -9.6314 9.6314 
+ 5 0 6.79184 2.43300 .255 -2.8396 16.4233 
- 5 0 -.02325 2.43300 1.000 -9.6547 9.6082 
+ 5 20 36.30740
* 
2.43300 .000 26.6760 45.9388 
- 5 20 25.54937
* 
2.43300 .000 15.9179 35.1808 
+ 5 30 23.44575
* 
2.43300 .000 13.8143 33.0772 
- 5 30 36.90504
* 
2.43300 .000 27.2736 46.5365 
+ 5 40 46.26332
* 
2.43300 .000 36.6319 55.8947 
- 5 40 46.76552
* 
2.43300 .000 37.1341 56.3969 
- 0 0 + 0 
 
0 .00000 2.43300 1.000 -9.6314 9.6314 
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+ 5 0 6.79184 2.43300 .255 -2.8396 16.4233 
- 5 0 -.02325 2.43300 1.000 -9.6547 9.6082 
+ 5 20 36.30740
* 
2.43300 .000 26.6760 45.9388 
- 5 20 25.54937
* 
2.43300 .000 15.9179 35.1808 
+ 5 30 23.44575
* 
2.43300 .000 13.8143 33.0772 
- 5 30 36.90504
* 
2.43300 .000 27.2736 46.5365 
+ 5 40 46.26332
* 
2.43300 .000 36.6319 55.8947 
- 5 40 46.76552
* 
2.43300 .000 37.1341 56.3969 
+ 5 0 + 0 0 -6.79184 2.43300 .255 -
16.4233 
2.8396 
- 0 0 -6.79184 2.43300 .255 -
16.4233 
2.8396 
- 5 0 -6.81509 2.43300 .251 -
16.4465 
2.8163 
+ 5 20 29.51557
* 
2.43300 .000 19.8841 39.1470 
- 5 20 18.75753
* 
2.43300 .000 9.1261 28.3890 
+ 5 30 16.65391
* 
2.43300 .001 7.0225 26.2853 
- 5 30 30.11320
* 
2.43300 .000 20.4818 39.7446 
+ 5 40 39.47148
* 
2.43300 .000 29.8401 49.1029 
- 5 40 39.97369
* 
2.43300 .000 30.3423 49.6051 
- 5 0 + 
 
0 
 
0 .02325 2.43300 1.000 -9.6082 9.6547 
- 0 0 .02325 2.43300 1.000 -9.6082 9.6547 
+ 5 0 6.81509 2.43300 .251 -2.8163 16.4465 
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+ 5 20 36.33066
* 
2.43300 .000 26.6992 45.9621 
- 5 20 25.57262
* 
2.43300 .000 15.9412 35.2040 
+ 5 30 23.46900
* 
2.43300 .000 13.8376 33.1004 
- 5 30 36.92829
* 
2.43300 .000 27.2969 46.5597 
+ 5 40 46.28657
* 
2.43300 .000 36.6551 55.9180 
- 5 40 46.78878
* 
2.43300 .000 37.1574 56.4202 
+ 5 20 + 
 
0 
 
0 -
36.30740
* 
2.43300 .000 -
45.9388 
-26.6760 
- 0 0 -
36.30740
* 
2.43300 .000 -
45.9388 
-26.6760 
+ 5 0 -
29.51557
* 
2.43300 .000 -
39.1470 
-19.8841 
- 5 0 -
36.33066
* 
2.43300 .000 -
45.9621 
-26.6992 
- 5 20 -
10.75803
* 
2.43300 .026 -
20.3895 
-1.1266 
+ 5 30 -
12.86166
* 
2.43300 .008 -
22.4931 
-3.2302 
- 5 30 .59763 2.43300 1.000 -9.0338 10.2291 
+ 5 40 9.95591* 2.43300 .041 .3245 19.5873 
- 5 40 10.45812
* 
2.43300 .031 .8267 20.0895 
- 5 20 + 
 
0 
 
0 -
25.54937
* 
2.43300 .000 -
35.1808 
-15.9179 
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- 0 0 -
25.54937
* 
2.43300 .000 -
35.1808 
-15.9179 
+ 5 0 -
18.75753
* 
2.43300 .000 -
28.3890 
-9.1261 
- 5 0 -
25.57262
* 
2.43300 .000 -
35.2040 
-15.9412 
+ 5 20 10.75803
* 
2.43300 .026 1.1266 20.3895 
+ 5 30 -2.10362 2.43300 .994 -
11.7350 
7.5278 
- 5 30 11.35566
* 
2.43300 .018 1.7242 20.9871 
+ 5 40 20.71395
* 
2.43300 .000 11.0825 30.3454 
- 5 40 21.21615
* 
2.43300 .000 11.5847 30.8476 
+ 5 30 + 
 
0 
 
0 -
23.44575
* 
2.43300 .000 -
33.0772 
-13.8143 
- 0 0 -
23.44575
* 
2.43300 .000 -
33.0772 
-13.8143 
+ 5 0 -
16.65391
* 
2.43300 .001 -
26.2853 
-7.0225 
- 5 0 -
23.46900
* 
2.43300 .000 -
33.1004 
-13.8376 
+ 5 20 12.86166
* 
2.43300 .008 3.2302 22.4931 
- 5 20 2.10362 2.43300 .994 -7.5278 11.7350 
- 5 30 13.45929
* 
2.43300 .006 3.8279 23.0907 
+ 5 40 22.81757
* 
2.43300 .000 13.1861 32.4490 
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- 5 40 23.31977
* 
2.43300 .000 13.6883 32.9512 
- 5 30 + 
 
0 
 
0 -
36.90504
* 
2.43300 .000 -
46.5365 
-27.2736 
- 0 0 -
36.90504
* 
2.43300 .000 -
46.5365 
-27.2736 
+ 5 0 -
30.11320
* 
2.43300 .000 -
39.7446 
-20.4818 
- 5 0 -
36.92829
* 
2.43300 .000 -
46.5597 
-27.2969 
+ 5 20 -.59763 2.43300 1.000 -
10.2291 
9.0338 
- 5 20 -
11.35566
* 
2.43300 .018 -
20.9871 
-1.7242 
+ 5 30 -
13.45929
* 
2.43300 .006 -
23.0907 
-3.8279 
+ 5 40 9.35828 2.43300 .059 -.2731 18.9897 
- 5 40 9.86049* 2.43300 .044 .2291 19.4919 
+ 5 40 + 
 
0 
 
0 -
46.26332
* 
2.43300 .000 -
55.8947 
-36.6319 
- 0 0 -
46.26332
* 
2.43300 .000 -
55.8947 
-36.6319 
+ 5 0 -
39.47148
* 
2.43300 .000 -
49.1029 
-29.8401 
- 5 0 -
46.28657
* 
2.43300 .000 -
55.9180 
-36.6551 
+ 5 20 -
9.95591* 
2.43300 .041 -
19.5873 
-.3245 
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- 5 20 -
20.71395
* 
2.43300 .000 -
30.3454 
-11.0825 
+ 5 30 -
22.81757
* 
2.43300 .000 -
32.4490 
-13.1861 
- 5 30 -9.35828 2.43300 .059 -
18.9897 
.2731 
- 5 40 .50220 2.43300 1.000 -9.1292 10.1336 
- 5 40 + 
 
0 
 
0 -
46.76552
* 
2.43300 .000 -
56.3969 
-37.1341 
- 0 0 -
46.76552
* 
2.43300 .000 -
56.3969 
-37.1341 
+ 5 0 -
39.97369
* 
2.43300 .000 -
49.6051 
-30.3423 
- 5 0 -
46.78878
* 
2.43300 .000 -
56.4202 
-37.1574 
+ 5 20 -
10.45812
* 
2.43300 .031 -
20.0895 
-.8267 
- 5 20 -
21.21615
* 
2.43300 .000 -
30.8476 
-11.5847 
+ 5 30 -
23.31977
* 
2.43300 .000 -
32.9512 
-13.6883 
- 5 30 -
9.86049* 
2.43300 .044 -
19.4919 
-.2291 
+ 5 40 -.50220 2.43300 1.000 -
10.1336 
9.1292 
*. The mean difference is significant at the 0.05 level. 
 
Table 38.  ANOVA analysis of CyQUANT (R) Cell Proliferation assay in BHD MEF cells 
(Chloroquine (100µM) and Nelfinavir (50µM)) 
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 One-Way ANOVA with Tukey Post-Hoc Test 
 
Multiple Comparisons 
Dependent Variable:Proliferation 
Tukey HSD Post-Hoc Test 
(I) BHD 
 
(J) BHD 
Mean 
Differen
ce (I-J) Std. Error Sig. 
95% Confidence 
Interval 
BHD Chloro
quine 
(µM) 
Nelfin
avir 
(µM) 
BHD Chloro
quine 
(µM) 
Nelfin
avir 
(µM) 
Lower 
Bound 
Upper 
Bound 
+ 
 
0 
 
0 - 0 0 .00000 8.06980 1.000 -29.9235 29.9235 
+ 0 10 .91972 8.06980 1.000 -29.0038 30.8432 
- 0 10 -8.15727 8.06980 1.000 -38.0808 21.7663 
+ 0 20 3.79277 8.06980 1.000 -26.1308 33.7163 
- 0 20 24.1497
9 
8.06980 .227 -5.7737 54.0733 
+ 0 30 4.64539 8.06980 1.000 -25.2781 34.5689 
- 0 30 47.5102
0* 
8.06980 .000 17.5867 77.4337 
+ 100 0 8.13381 8.06980 1.000 -21.7897 38.0573 
- 100 0 42.6845
4* 
8.06980 .001 12.7610 72.6081 
+ 100 10 23.2100
7 
8.06980 .280 -6.7134 53.1336 
- 100 10 70.2950
1* 
8.06980 .000 40.3715 100.218
5 
+ 100 20 27.3803
3 
8.06980 .102 -2.5432 57.3038 
- 100 20 83.5861
6* 
8.06980 .000 53.6626 113.509
7 
+ 100 30 45.8732
9* 
8.06980 .000 15.9498 75.7968 
- 100 30 90.0117
4* 
8.06980 .000 60.0882 119.935
3 
217 
 
- 0 0 + 0 
 
0 .00000 8.06980 1.000 -29.9235 29.9235 
+ 0 10 .91973 8.06980 1.000 -29.0038 30.8432 
- 0 10 -8.15727 8.06980 1.000 -38.0808 21.7663 
+ 0 20 3.79277 8.06980 1.000 -26.1308 33.7163 
- 0 20 24.1497
9 
8.06980 .227 -5.7737 54.0733 
+ 0 30 4.64539 8.06980 1.000 -25.2781 34.5689 
- 0 30 47.5102
1* 
8.06980 .000 17.5867 77.4337 
+ 100 0 8.13381 8.06980 1.000 -21.7897 38.0573 
- 100 0 42.6845
4* 
8.06980 .001 12.7610 72.6081 
+ 100 10 23.2100
8 
8.06980 .280 -6.7134 53.1336 
- 100 10 70.2950
1* 
8.06980 .000 40.3715 100.218
5 
+ 100 20 27.3803
3 
8.06980 .102 -2.5432 57.3039 
- 100 20 83.5861
6* 
8.06980 .000 53.6626 113.509
7 
+ 100 30 45.8732
9* 
8.06980 .000 15.9498 75.7968 
- 100 30 90.0117
5* 
8.06980 .000 60.0882 119.935
3 
+ 0 10 + 0 0 -.91972 8.06980 1.000 -30.8432 29.0038 
- 0 0 -.91973 8.06980 1.000 -30.8432 29.0038 
- 0 10 -9.07699 8.06980 .998 -39.0005 20.8465 
+ 0 20 2.87304 8.06980 1.000 -27.0505 32.7966 
- 0 20 23.2300
7 
8.06980 .279 -6.6935 53.1536 
+ 0 30 3.72566 8.06980 1.000 -26.1979 33.6492 
- 0 30 46.5904
8* 
8.06980 .000 16.6670 76.5140 
+ 100 0 7.21408 8.06980 1.000 -22.7094 37.1376 
218 
 
- 100 0 41.7648
1* 
8.06980 .001 11.8413 71.6883 
+ 100 10 22.2903
5 
8.06980 .338 -7.6332 52.2139 
- 100 10 69.3752
9* 
8.06980 .000 39.4518 99.2988 
+ 100 20 26.4606
0 
8.06980 .130 -3.4629 56.3841 
- 100 20 82.6664
3* 
8.06980 .000 52.7429 112.590
0 
+ 100 30 44.9535
6* 
8.06980 .000 15.0300 74.8771 
- 100 30 89.0920
2* 
8.06980 .000 59.1685 119.015
5 
- 0 10 + 
 
0 
 
0 8.15727 8.06980 1.000 -21.7663 38.0808 
- 0 0 8.15727 8.06980 1.000 -21.7663 38.0808 
+ 0 10 9.07699 8.06980 .998 -20.8465 39.0005 
+ 0 20 11.9500
3 
8.06980 .977 -17.9735 41.8736 
- 0 20 32.3070
6* 
8.06980 .024 2.3835 62.2306 
+ 0 30 12.8026
5 
8.06980 .960 -17.1209 42.7262 
- 0 30 55.6674
7* 
8.06980 .000 25.7439 85.5910 
+ 100 0 16.2910
7 
8.06980 .798 -13.6324 46.2146 
- 100 0 50.8418
0* 
8.06980 .000 20.9183 80.7653 
+ 100 10 31.3673
4* 
8.06980 .033 1.4438 61.2909 
- 100 10 78.4522
8* 
8.06980 .000 48.5288 108.375
8 
+ 100 20 35.5375
9* 
8.06980 .009 5.6141 65.4611 
219 
 
- 100 20 91.7434
2* 
8.06980 .000 61.8199 121.666
9 
+ 100 30 54.0305
5* 
8.06980 .000 24.1070 83.9541 
- 100 30 98.1690
1* 
8.06980 .000 68.2455 128.092
5 
+ 0 20 + 
 
0 
 
0 -3.79277 8.06980 1.000 -33.7163 26.1308 
- 0 0 -3.79277 8.06980 1.000 -33.7163 26.1308 
+ 0 10 -2.87304 8.06980 1.000 -32.7966 27.0505 
- 0 10 -
11.9500
3 
8.06980 .977 -41.8736 17.9735 
- 0 20 20.3570
3 
8.06980 .481 -9.5665 50.2805 
+ 0 30 .85262 8.06980 1.000 -29.0709 30.7761 
- 0 30 43.7174
4* 
8.06980 .001 13.7939 73.6410 
+ 100 0 4.34104 8.06980 1.000 -25.5825 34.2646 
- 100 0 38.8917
7* 
8.06980 .003 8.9682 68.8153 
+ 100 10 19.4173
1 
8.06980 .556 -10.5062 49.3408 
- 100 10 66.5022
5* 
8.06980 .000 36.5787 96.4258 
+ 100 20 23.5875
6 
8.06980 .258 -6.3360 53.5111 
- 100 20 79.7933
9* 
8.06980 .000 49.8699 109.716
9 
+ 100 30 42.0805
2* 
8.06980 .001 12.1570 72.0040 
- 100 30 86.2189
8* 
8.06980 .000 56.2955 116.142
5 
- 0 20 + 
 
0 
 
0 -
24.1497
9 
8.06980 .227 -54.0733 5.7737 
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- 0 0 -
24.1497
9 
8.06980 .227 -54.0733 5.7737 
+ 0 10 -
23.2300
7 
8.06980 .279 -53.1536 6.6935 
- 0 10 -
32.3070
6* 
8.06980 .024 -62.2306 -2.3835 
+ 0 20 -
20.3570
3 
8.06980 .481 -50.2805 9.5665 
+ 0 30 -
19.5044
1 
8.06980 .549 -49.4279 10.4191 
- 0 30 23.3604
1 
8.06980 .271 -6.5631 53.2839 
+ 100 0 -
16.0159
8 
8.06980 .816 -45.9395 13.9075 
- 100 0 18.5347
4 
8.06980 .628 -11.3888 48.4583 
+ 100 10 -.93972 8.06980 1.000 -30.8632 28.9838 
- 100 10 46.1452
2* 
8.06980 .000 16.2217 76.0687 
+ 100 20 3.23054 8.06980 1.000 -26.6930 33.1541 
- 100 20 59.4363
6* 
8.06980 .000 29.5128 89.3599 
+ 100 30 21.7234
9 
8.06980 .377 -8.2000 51.6470 
- 100 30 65.8619
5* 
8.06980 .000 35.9384 95.7855 
+ 0 30 + 
 
0 
 
0 -4.64539 8.06980 1.000 -34.5689 25.2781 
- 0 0 -4.64539 8.06980 1.000 -34.5689 25.2781 
+ 0 10 -3.72566 8.06980 1.000 -33.6492 26.1979 
221 
 
- 0 10 -
12.8026
5 
8.06980 .960 -42.7262 17.1209 
+ 0 20 -.85262 8.06980 1.000 -30.7761 29.0709 
- 0 20 19.5044
1 
8.06980 .549 -10.4191 49.4279 
- 0 30 42.8648
2* 
8.06980 .001 12.9413 72.7883 
+ 100 0 3.48842 8.06980 1.000 -26.4351 33.4119 
- 100 0 38.0391
5* 
8.06980 .004 8.1156 67.9627 
+ 100 10 18.5646
9 
8.06980 .626 -11.3588 48.4882 
- 100 10 65.6496
3* 
8.06980 .000 35.7261 95.5731 
+ 100 20 22.7349
4 
8.06980 .309 -7.1886 52.6585 
- 100 20 78.9407
7* 
8.06980 .000 49.0172 108.864
3 
+ 100 30 41.2279
0* 
8.06980 .001 11.3044 71.1514 
- 100 30 85.3663
6* 
8.06980 .000 55.4428 115.289
9 
- 0 30 + 
 
0 
 
0 -
47.5102
0* 
8.06980 .000 -77.4337 -
17.5867 
- 0 0 -
47.5102
1* 
8.06980 .000 -77.4337 -
17.5867 
+ 0 10 -
46.5904
8* 
8.06980 .000 -76.5140 -
16.6670 
- 0 10 -
55.6674
7* 
8.06980 .000 -85.5910 -
25.7439 
222 
 
+ 0 20 -
43.7174
4* 
8.06980 .001 -73.6410 -
13.7939 
- 0 20 -
23.3604
1 
8.06980 .271 -53.2839 6.5631 
+ 0 30 -
42.8648
2* 
8.06980 .001 -72.7883 -
12.9413 
+ 100 0 -
39.3764
0* 
8.06980 .002 -69.2999 -9.4529 
- 100 0 -4.82567 8.06980 1.000 -34.7492 25.0979 
+ 100 10 -
24.3001
3 
8.06980 .220 -54.2237 5.6234 
- 100 10 22.7848
1 
8.06980 .306 -7.1387 52.7083 
+ 100 20 -
20.1298
8 
8.06980 .499 -50.0534 9.7936 
- 100 20 36.0759
5* 
8.06980 .007 6.1524 65.9995 
+ 100 30 -1.63692 8.06980 1.000 -31.5604 28.2866 
- 100 30 42.5015
4* 
8.06980 .001 12.5780 72.4251 
+ 100 0 + 
 
0 
 
0 -8.13381 8.06980 1.000 -38.0573 21.7897 
- 0 0 -8.13381 8.06980 1.000 -38.0573 21.7897 
+ 0 10 -7.21408 8.06980 1.000 -37.1376 22.7094 
- 0 10 -
16.2910
7 
8.06980 .798 -46.2146 13.6324 
+ 0 20 -4.34104 8.06980 1.000 -34.2646 25.5825 
- 0 20 16.0159
8 
8.06980 .816 -13.9075 45.9395 
+ 0 30 -3.48842 8.06980 1.000 -33.4119 26.4351 
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- 0 30 39.3764
0* 
8.06980 .002 9.4529 69.2999 
- 100 0 34.5507
3* 
8.06980 .012 4.6272 64.4743 
+ 100 10 15.0762
7 
8.06980 .871 -14.8473 44.9998 
- 100 10 62.1612
1* 
8.06980 .000 32.2377 92.0847 
+ 100 20 19.2465
2 
8.06980 .570 -10.6770 49.1700 
- 100 20 75.4523
5* 
8.06980 .000 45.5288 105.375
9 
+ 100 30 37.7394
8* 
8.06980 .004 7.8160 67.6630 
- 100 30 81.8779
4* 
8.06980 .000 51.9544 111.801
5 
- 100 0 + 0 0 -
42.6845
4* 
8.06980 .001 -72.6081 -
12.7610 
- 0 0 -
42.6845
4* 
8.06980 .001 -72.6081 -
12.7610 
+ 0 10 -
41.7648
1* 
8.06980 .001 -71.6883 -
11.8413 
- 0 10 -
50.8418
0* 
8.06980 .000 -80.7653 -
20.9183 
+ 0 20 -
38.8917
7* 
8.06980 .003 -68.8153 -8.9682 
- 0 20 -
18.5347
4 
8.06980 .628 -48.4583 11.3888 
+ 0 30 -
38.0391
5* 
8.06980 .004 -67.9627 -8.1156 
- 0 30 4.82567 8.06980 1.000 -25.0979 34.7492 
224 
 
+ 100 0 -
34.5507
3* 
8.06980 .012 -64.4743 -4.6272 
+ 100 10 -
19.4744
6 
8.06980 .552 -49.3980 10.4491 
- 100 10 27.6104
8 
8.06980 .096 -2.3130 57.5340 
+ 100 20 -
15.3042
1 
8.06980 .859 -45.2277 14.6193 
- 100 20 40.9016
2* 
8.06980 .001 10.9781 70.8251 
+ 100 30 3.18875 8.06980 1.000 -26.7348 33.1123 
- 100 30 47.3272
1* 
8.06980 .000 17.4037 77.2507 
+ 100 10 + 0 0 -
23.2100
7 
8.06980 .280 -53.1336 6.7134 
- 0 0 -
23.2100
8 
8.06980 .280 -53.1336 6.7134 
+ 0 10 -
22.2903
5 
8.06980 .338 -52.2139 7.6332 
- 0 10 -
31.3673
4* 
8.06980 .033 -61.2909 -1.4438 
+ 0 20 -
19.4173
1 
8.06980 .556 -49.3408 10.5062 
- 0 20 .93972 8.06980 1.000 -28.9838 30.8632 
+ 0 30 -
18.5646
9 
8.06980 .626 -48.4882 11.3588 
- 0 30 24.3001
3 
8.06980 .220 -5.6234 54.2237 
225 
 
+ 100 0 -
15.0762
7 
8.06980 .871 -44.9998 14.8473 
- 100 0 19.4744
6 
8.06980 .552 -10.4491 49.3980 
- 100 10 47.0849
4* 
8.06980 .000 17.1614 77.0085 
+ 100 20 4.17025 8.06980 1.000 -25.7533 34.0938 
- 100 20 60.3760
8* 
8.06980 .000 30.4526 90.2996 
+ 100 30 22.6632
1 
8.06980 .314 -7.2603 52.5867 
- 100 30 66.8016
7* 
8.06980 .000 36.8781 96.7252 
- 100 10 + 0 0 -
70.2950
1* 
8.06980 .000 -
100.2185 
-
40.3715 
- 0 0 -
70.2950
1* 
8.06980 .000 -
100.2185 
-
40.3715 
+ 0 10 -
69.3752
9* 
8.06980 .000 -99.2988 -
39.4518 
- 0 10 -
78.4522
8* 
8.06980 .000 -
108.3758 
-
48.5288 
+ 0 20 -
66.5022
5* 
8.06980 .000 -96.4258 -
36.5787 
- 0 20 -
46.1452
2* 
8.06980 .000 -76.0687 -
16.2217 
+ 0 30 -
65.6496
3* 
8.06980 .000 -95.5731 -
35.7261 
- 0 30 -
22.7848
1 
8.06980 .306 -52.7083 7.1387 
226 
 
+ 100 0 -
62.1612
1* 
8.06980 .000 -92.0847 -
32.2377 
- 100 0 -
27.6104
8 
8.06980 .096 -57.5340 2.3130 
+ 100 10 -
47.0849
4* 
8.06980 .000 -77.0085 -
17.1614 
+ 100 20 -
42.9146
9* 
8.06980 .001 -72.8382 -
12.9912 
- 100 20 13.2911
4 
8.06980 .946 -16.6324 43.2147 
+ 100 30 -
24.4217
3 
8.06980 .214 -54.3452 5.5018 
- 100 30 19.7167
3 
8.06980 .532 -10.2068 49.6403 
+ 100 20 + 0 0 -
27.3803
3 
8.06980 .102 -57.3038 2.5432 
- 0 0 -
27.3803
3 
8.06980 .102 -57.3039 2.5432 
+ 0 10 -
26.4606
0 
8.06980 .130 -56.3841 3.4629 
- 0 10 -
35.5375
9* 
8.06980 .009 -65.4611 -5.6141 
+ 0 20 -
23.5875
6 
8.06980 .258 -53.5111 6.3360 
- 0 20 -3.23054 8.06980 1.000 -33.1541 26.6930 
+ 0 30 -
22.7349
4 
8.06980 .309 -52.6585 7.1886 
227 
 
- 0 30 20.1298
8 
8.06980 .499 -9.7936 50.0534 
+ 100 0 -
19.2465
2 
8.06980 .570 -49.1700 10.6770 
- 100 0 15.3042
1 
8.06980 .859 -14.6193 45.2277 
+ 100 10 -4.17025 8.06980 1.000 -34.0938 25.7533 
- 100 10 42.9146
9* 
8.06980 .001 12.9912 72.8382 
- 100 20 56.2058
3* 
8.06980 .000 26.2823 86.1294 
+ 100 30 18.4929
6 
8.06980 .632 -11.4306 48.4165 
- 100 30 62.6314
2* 
8.06980 .000 32.7079 92.5549 
- 100 20 + 0 0 -
83.5861
6* 
8.06980 .000 -
113.5097 
-
53.6626 
- 0 0 -
83.5861
6* 
8.06980 .000 -
113.5097 
-
53.6626 
+ 0 10 -
82.6664
3* 
8.06980 .000 -
112.5900 
-
52.7429 
- 0 10 -
91.7434
2* 
8.06980 .000 -
121.6669 
-
61.8199 
+ 0 20 -
79.7933
9* 
8.06980 .000 -
109.7169 
-
49.8699 
- 0 20 -
59.4363
6* 
8.06980 .000 -89.3599 -
29.5128 
+ 0 30 -
78.9407
7* 
8.06980 .000 -
108.8643 
-
49.0172 
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- 0 30 -
36.0759
5* 
8.06980 .007 -65.9995 -6.1524 
+ 100 0 -
75.4523
5* 
8.06980 .000 -
105.3759 
-
45.5288 
- 100 0 -
40.9016
2* 
8.06980 .001 -70.8251 -
10.9781 
+ 100 10 -
60.3760
8* 
8.06980 .000 -90.2996 -
30.4526 
- 100 10 -
13.2911
4 
8.06980 .946 -43.2147 16.6324 
+ 100 20 -
56.2058
3* 
8.06980 .000 -86.1294 -
26.2823 
+ 100 30 -
37.7128
7* 
8.06980 .004 -67.6364 -7.7893 
- 100 30 6.42559 8.06980 1.000 -23.4979 36.3491 
+ 100 30 + 0 0 -
45.8732
9* 
8.06980 .000 -75.7968 -
15.9498 
- 0 0 -
45.8732
9* 
8.06980 .000 -75.7968 -
15.9498 
+ 0 10 -
44.9535
6* 
8.06980 .000 -74.8771 -
15.0300 
- 0 10 -
54.0305
5* 
8.06980 .000 -83.9541 -
24.1070 
+ 0 20 -
42.0805
2* 
8.06980 .001 -72.0040 -
12.1570 
229 
 
- 0 20 -
21.7234
9 
8.06980 .377 -51.6470 8.2000 
+ 0 30 -
41.2279
0* 
8.06980 .001 -71.1514 -
11.3044 
- 0 30 1.63692 8.06980 1.000 -28.2866 31.5604 
+ 100 0 -
37.7394
8* 
8.06980 .004 -67.6630 -7.8160 
- 100 0 -3.18875 8.06980 1.000 -33.1123 26.7348 
+ 100 10 -
22.6632
1 
8.06980 .314 -52.5867 7.2603 
- 100 10 24.4217
3 
8.06980 .214 -5.5018 54.3452 
+ 100 20 -
18.4929
6 
8.06980 .632 -48.4165 11.4306 
- 100 20 37.7128
7* 
8.06980 .004 7.7893 67.6364 
- 100 30 44.1384
6* 
8.06980 .000 14.2149 74.0620 
- 100 30 + 0 0 -
90.0117
4* 
8.06980 .000 -
119.9353 
-
60.0882 
- 0 0 -
90.0117
5* 
8.06980 .000 -
119.9353 
-
60.0882 
+ 0 10 -
89.0920
2* 
8.06980 .000 -
119.0155 
-
59.1685 
- 0 10 -
98.1690
1* 
8.06980 .000 -
128.0925 
-
68.2455 
+ 0 20 -
86.2189
8* 
8.06980 .000 -
116.1425 
-
56.2955 
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- 0 20 -
65.8619
5* 
8.06980 .000 -95.7855 -
35.9384 
+ 0 30 -
85.3663
6* 
8.06980 .000 -
115.2899 
-
55.4428 
- 0 30 -
42.5015
4* 
8.06980 .001 -72.4251 -
12.5780 
+ 100 0 -
81.8779
4* 
8.06980 .000 -
111.8015 
-
51.9544 
- 100 0 -
47.3272
1* 
8.06980 .000 -77.2507 -
17.4037 
+ 100 10 -
66.8016
7* 
8.06980 .000 -96.7252 -
36.8781 
- 100 10 -
19.7167
3 
8.06980 .532 -49.6403 10.2068 
+ 100 20 -
62.6314
2* 
8.06980 .000 -92.5549 -
32.7079 
- 100 20 -6.42559 8.06980 1.000 -36.3491 23.4979 
   + 100 30 -
44.1384
6* 
8.06980 .000 -74.0620 -
14.2149 
*. The mean difference is significant at the 0.05 level. 
 
 
Table 39.  ANOVA analysis of Cell death Elisa assay on BHD MEF cells (Nelfinavir 30µM, 
Chloroquine 100µM) 
 
 
One-Way ANOVA with Tukey Post-Hoc Test 
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Multiple Comparisons 
Dependent Variable:Proliferation 
Tukey HSD Post-Hoc Test 
(I) BHD 
 
(J) BHD 
Mean 
Differen
ce (I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval 
BHD Chloro
quine 
(µM) 
Nelfin
avir 
(µM) 
BHD Chloro
quine 
(µM) 
Nelfi
navir 
(µM) 
Lower 
Bound 
Upper 
Bound 
+ 
 
0 
 
0 - 0 0 .00000 .49343 1.000 -1.7083 1.7083 
+ 0 30 .01815 .49343 1.000 -1.6902 1.7265 
- 0 30 -
3.57810
* 
.49343 .000 -5.2864 -1.8698 
+ 100 0 .00330 .49343 1.000 -1.7050 1.7116 
- 100 0 -
2.52613
* 
.49343 .002 -4.2345 -.8178 
+ 100 30 -.13303 .49343 1.000 -1.8414 1.5753 
- 100 30 -
2.64121
* 
.49343 .001 -4.3495 -.9329 
- 0 0 + 0 0 .00000 .49343 1.000 -1.7083 1.7083 
+ 0 30 .01815 .49343 1.000 -1.6902 1.7265 
- 0 30 -
3.57810
* 
.49343 .000 -5.2864 -1.8698 
+ 100 0 .00330 .49343 1.000 -1.7050 1.7116 
- 100 0 -
2.52613
* 
.49343 .002 -4.2345 -.8178 
+ 100 30 -.13303 .49343 1.000 -1.8414 1.5753 
- 100 30 -
2.64121
* 
.49343 .001 -4.3495 -.9329 
+ 0 30 + 0 0 -.01815 .49343 1.000 -1.7265 1.6902 
- 0 0 -.01815 .49343 1.000 -1.7265 1.6902 
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- 0 30 -
3.59625
* 
.49343 .000 -5.3046 -1.8879 
+ 100 0 -.01486 .49343 1.000 -1.7232 1.6935 
- 100 0 -
2.54428
* 
.49343 .002 -4.2526 -.8360 
+ 100 30 -.15119 .49343 1.000 -1.8595 1.5571 
- 100 30 -
2.65936
* 
.49343 .001 -4.3677 -.9510 
- 0 30 + 
 
0 
 
0 3.57810
* 
.49343 .000 1.8698 5.2864 
- 0 0 3.57810
* 
.49343 .000 1.8698 5.2864 
+ 0 30 3.59625
* 
.49343 .000 1.8879 5.3046 
+ 100 0 3.58139
* 
.49343 .000 1.8731 5.2897 
- 100 0 1.05197 .49343 .436 -.6564 2.7603 
+ 100 30 3.44506
* 
.49343 .000 1.7367 5.1534 
- 100 30 .93689 .49343 .570 -.7714 2.6452 
+ 100 0 + 
 
0 
 
0 -.00330 .49343 1.000 -1.7116 1.7050 
- 0 0 -.00330 .49343 1.000 -1.7116 1.7050 
+ 0 30 .01486 .49343 1.000 -1.6935 1.7232 
- 0 30 -
3.58139
* 
.49343 .000 -5.2897 -1.8731 
- 100 0 -
2.52943
* 
.49343 .002 -4.2378 -.8211 
+ 100 30 -.13633 .49343 1.000 -1.8447 1.5720 
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- 100 30 -
2.64451
* 
.49343 .001 -4.3528 -.9362 
- 100 0 + 
 
0 
 
0 2.52613
* 
.49343 .002 .8178 4.2345 
- 0 0 2.52613
* 
.49343 .002 .8178 4.2345 
+ 0 30 2.54428
* 
.49343 .002 .8360 4.2526 
- 0 30 -
1.05197 
.49343 .436 -2.7603 .6564 
+ 100 0 2.52943
* 
.49343 .002 .8211 4.2378 
+ 100 30 2.39310
* 
.49343 .003 .6848 4.1014 
- 100 30 -.11508 .49343 1.000 -1.8234 1.5932 
+ 100 30 + 
 
0 
 
0 .13303 .49343 1.000 -1.5753 1.8414 
- 0 0 .13303 .49343 1.000 -1.5753 1.8414 
+ 0 30 .15119 .49343 1.000 -1.5571 1.8595 
- 0 30 -
3.44506
* 
.49343 .000 -5.1534 -1.7367 
+ 100 0 .13633 .49343 1.000 -1.5720 1.8447 
- 100 0 -
2.39310
* 
.49343 .003 -4.1014 -.6848 
- 100 30 -
2.50818
* 
.49343 .002 -4.2165 -.7999 
- 100 30 + 
 
0 
 
0 2.64121
* 
.49343 .001 .9329 4.3495 
- 0 0 2.64121
* 
.49343 .001 .9329 4.3495 
+ 0 30 2.65936
* 
.49343 .001 .9510 4.3677 
- 0 30 -.93689 .49343 .570 -2.6452 .7714 
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+ 100 0 2.64451
* 
.49343 .001 .9362 4.3528 
- 100 0 .11508 .49343 1.000 -1.5932 1.8234 
+ 100 30 2.50818
* 
.49343 .002 .7999 4.2165 
*. The mean difference is significant at the 0.05 level. 
 
Table 40.  ANOVA analysis of Cell death Elisa assay on BHD MEF cells (Chloroquine 
50µM, Nelfinavir 20µM, Rapamycin 50nm) 
 
Multiple Comparisons 
Dependent Variable:Proliferation 
Tukey HSD Post-Hoc Test 
(I) BHD 
 
(J) BHD 
Mean 
Differen
ce (I-J) 
Std. 
Error Sig. 
95% 
Confidence 
Interval 
BHD 
 
Chloroq
uine 
(µM) 
 
Nelfi
navir 
(µM) 
 
Rap
amy
cin 
(nM
) 
BHD 
 
Chloro
quine 
(µM) 
 
Nelf
inav
ir 
(µM
) 
Rapa
myci
n 
(nM) 
Lower 
Boun
d 
Upper 
Bound 
1+ 
 
0 
 
0 0 - 0 0 0 .00000 .4689
1 
1.00
0 
-
1.690
7 
1.690
7 
+ 0 30 0 -.29249 .4689
1 
1.00
0 
-
1.983
2 
1.398
2 
- 0 30 0 -.95573 .4689
1 
.666 -
2.646
5 
.7350 
+ 100 0 0 -.16115 .4689
1 
1.00
0 
-
1.851
9 
1.529
6 
- 100 0 0 -.28516 .4689
1 
1.00
0 
-
1.975
9 
1.405
6 
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+ 100 30 0 -
1.86203
* 
.4689
1 
.022 -
3.552
8 
-.1713 
- 100 30 0 -
3.70182
* 
.4689
1 
.000 -
5.392
6 
-
2.011
1 
+ 0 0 50 -.02649 .4689
1 
1.00
0 
-
1.717
2 
1.664
2 
- 0 0 50 -.92969 .4689
1 
.700 -
2.620
4 
.7610 
+ 100 0 50 -
1.20199 
.4689
1 
.351 -
2.892
7 
.4887 
- 100 0 50 -
2.86458
* 
.4689
1 
.000 -
4.555
3 
-
1.173
9 
2- 0 0 0 + 
 
0 
 
0 0 .00000 .4689
1 
1.00
0 
-
1.690
7 
1.690
7 
+ 0 30 0 -.29249 .4689
1 
1.00
0 
-
1.983
2 
1.398
2 
- 0 30 0 -.95573 .4689
1 
.666 -
2.646
5 
.7350 
+ 100 0 0 -.16115 .4689
1 
1.00
0 
-
1.851
9 
1.529
6 
- 100 0 0 -.28516 .4689
1 
1.00
0 
-
1.975
9 
1.405
6 
+ 100 30 0 -
1.86203
* 
.4689
1 
.022 -
3.552
8 
-.1713 
- 100 30 0 -
3.70182
* 
.4689
1 
.000 -
5.392
6 
-
2.011
1 
236 
 
+ 0 0 50 -.02649 .4689
1 
1.00
0 
-
1.717
2 
1.664
2 
- 0 0 50 -.92969 .4689
1 
.700 -
2.620
4 
.7610 
+ 100 0 50 -
1.20199 
.4689
1 
.351 -
2.892
7 
.4887 
- 100 0 50 -
2.86458
* 
.4689
1 
.000 -
4.555
3 
-
1.173
9 
3+ 0 30 0 + 
 
0 
 
0 0 .29249 .4689
1 
1.00
0 
-
1.398
2 
1.983
2 
- 0 0 0 .29249 .4689
1 
1.00
0 
-
1.398
2 
1.983
2 
- 0 30 0 -.66323 .4689
1 
.949 -
2.354
0 
1.027
5 
+ 100 0 0 .13135 .4689
1 
1.00
0 
-
1.559
4 
1.822
1 
- 100 0 0 .00734 .4689
1 
1.00
0 
-
1.683
4 
1.698
1 
+ 100 30 0 -
1.56954 
.4689
1 
.086 -
3.260
3 
.1212 
- 100 30 0 -
3.40933
* 
.4689
1 
.000 -
5.100
1 
-
1.718
6 
+ 0 0 50 .26600 .4689
1 
1.00
0 
-
1.424
7 
1.956
7 
- 0 0 50 -.63719 .4689
1 
.961 -
2.327
9 
1.053
5 
237 
 
+ 100 0 50 -.90949 .4689
1 
.725 -
2.600
2 
.7812 
- 100 0 50 -
2.57209
* 
.4689
1 
.001 -
4.262
8 
-.8814 
4- 0 30 0 + 
 
0 
 
0 0 .95573 .4689
1 
.666 -.7350 2.646
5 
- 0 0 0 .95573 .4689
1 
.666 -.7350 2.646
5 
+ 0 30 0 .66323 .4689
1 
.949 -
1.027
5 
2.354
0 
+ 100 0 0 .79458 .4689
1 
.854 -.8962 2.485
3 
- 100 0 0 .67057 .4689
1 
.945 -
1.020
2 
2.361
3 
+ 100 30 0 -.90630 .4689
1 
.729 -
2.597
0 
.7844 
- 100 30 0 -
2.74609
* 
.4689
1 
.000 -
4.436
8 
-
1.055
4 
+ 0 0 50 .92924 .4689
1 
.700 -.7615 2.620
0 
- 0 0 50 .02604 .4689
1 
1.00
0 
-
1.664
7 
1.716
8 
+ 100 0 50 -.24626 .4689
1 
1.00
0 
-
1.937
0 
1.444
5 
- 100 0 50 -
1.90885
* 
.4689
1 
.018 -
3.599
6 
-.2181 
5+ 100 0 0 + 
 
0 
 
0 0 .16115 .4689
1 
1.00
0 
-
1.529
6 
1.851
9 
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- 0 0 0 .16115 .4689
1 
1.00
0 
-
1.529
6 
1.851
9 
+ 0 30 0 -.13135 .4689
1 
1.00
0 
-
1.822
1 
1.559
4 
- 0 30 0 -.79458 .4689
1 
.854 -
2.485
3 
.8962 
- 100 0 0 -.12401 .4689
1 
1.00
0 
-
1.814
7 
1.566
7 
+ 100 30 0 -
1.70088
* 
.4689
1 
.048 -
3.391
6 
-.0102 
- 100 30 0 -
3.54068
* 
.4689
1 
.000 -
5.231
4 
-
1.849
9 
+ 0 0 50 .13466 .4689
1 
1.00
0 
-
1.556
1 
1.825
4 
- 0 0 50 -.76854 .4689
1 
.878 -
2.459
3 
.9222 
+ 100 0 50 -
1.04084 
.4689
1 
.552 -
2.731
6 
.6499 
- 100 0 50 -
2.70344
* 
.4689
1 
.000 -
4.394
2 
-
1.012
7 
6- 100 0 0 + 
 
0 
 
0 0 .28516 .4689
1 
1.00
0 
-
1.405
6 
1.975
9 
- 0 0 0 .28516 .4689
1 
1.00
0 
-
1.405
6 
1.975
9 
+ 0 30 0 -.00734 .4689
1 
1.00
0 
-
1.698
1 
1.683
4 
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- 0 30 0 -.67057 .4689
1 
.945 -
2.361
3 
1.020
2 
+ 100 0 0 .12401 .4689
1 
1.00
0 
-
1.566
7 
1.814
7 
+ 100 30 0 -
1.57687 
.4689
1 
.083 -
3.267
6 
.1139 
- 100 30 0 -
3.41667
* 
.4689
1 
.000 -
5.107
4 
-
1.725
9 
+ 0 0 50 .25867 .4689
1 
1.00
0 
-
1.432
1 
1.949
4 
- 0 0 50 -.64453 .4689
1 
.958 -
2.335
3 
1.046
2 
+ 100 0 50 -.91683 .4689
1 
.716 -
2.607
6 
.7739 
- 100 0 50 -
2.57943
* 
.4689
1 
.001 -
4.270
2 
-.8887 
7+ 100 30 0 + 
 
0 
 
0 0 1.86203
* 
.4689
1 
.022 .1713 3.552
8 
- 0 0 0 1.86203
* 
.4689
1 
.022 .1713 3.552
8 
+ 0 30 0 1.56954 .4689
1 
.086 -.1212 3.260
3 
- 0 30 0 .90630 .4689
1 
.729 -.7844 2.597
0 
+ 100 0 0 1.70088
* 
.4689
1 
.048 .0102 3.391
6 
- 100 0 0 1.57687 .4689
1 
.083 -.1139 3.267
6 
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- 100 30 0 -
1.83979
* 
.4689
1 
.025 -
3.530
5 
-.1491 
+ 0 0 50 1.83554
* 
.4689
1 
.025 .1448 3.526
3 
- 0 0 50 .93234 .4689
1 
.696 -.7584 2.623
1 
+ 100 0 50 .66004 .4689
1 
.951 -
1.030
7 
2.350
8 
- 100 0 50 -
1.00255 
.4689
1 
.604 -
2.693
3 
.6882 
8- 100 30 0 + 
 
0 
 
0 0 3.70182
* 
.4689
1 
.000 2.011
1 
5.392
6 
- 0 0 0 3.70182
* 
.4689
1 
.000 2.011
1 
5.392
6 
+ 0 30 0 3.40933
* 
.4689
1 
.000 1.718
6 
5.100
1 
- 0 30 0 2.74609
* 
.4689
1 
.000 1.055
4 
4.436
8 
+ 100 0 0 3.54068
* 
.4689
1 
.000 1.849
9 
5.231
4 
- 100 0 0 3.41667
* 
.4689
1 
.000 1.725
9 
5.107
4 
+ 100 30 0 1.83979
* 
.4689
1 
.025 .1491 3.530
5 
+ 0 0 50 3.67533
* 
.4689
1 
.000 1.984
6 
5.366
1 
- 0 0 50 2.77214
* 
.4689
1 
.000 1.081
4 
4.462
9 
+ 100 0 50 2.49984
* 
.4689
1 
.001 .8091 4.190
6 
- 100 0 50 .83724 .4689
1 
.810 -.8535 2.528
0 
9+ 0 0 50 + 
 
0 
 
0 0 .02649 .4689
1 
1.00
0 
-
1.664
2 
1.717
2 
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- 0 0 0 .02649 .4689
1 
1.00
0 
-
1.664
2 
1.717
2 
+ 0 30 0 -.26600 .4689
1 
1.00
0 
-
1.956
7 
1.424
7 
- 0 30 0 -.92924 .4689
1 
.700 -
2.620
0 
.7615 
+ 100 0 0 -.13466 .4689
1 
1.00
0 
-
1.825
4 
1.556
1 
- 100 0 0 -.25867 .4689
1 
1.00
0 
-
1.949
4 
1.432
1 
+ 100 30 0 -
1.83554
* 
.4689
1 
.025 -
3.526
3 
-.1448 
- 100 30 0 -
3.67533
* 
.4689
1 
.000 -
5.366
1 
-
1.984
6 
- 0 0 50 -.90320 .4689
1 
.733 -
2.593
9 
.7875 
+ 100 0 50 -
1.17550 
.4689
1 
.381 -
2.866
2 
.5152 
- 100 0 50 -
2.83809
* 
.4689
1 
.000 -
4.528
8 
-
1.147
4 
- 0 0 50 + 
 
0 
 
0 0 .92969 .4689
1 
.700 -.7610 2.620
4 
- 0 0 0 .92969 .4689
1 
.700 -.7610 2.620
4 
+ 0 30 0 .63719 .4689
1 
.961 -
1.053
5 
2.327
9 
242 
 
- 0 30 0 -.02604 .4689
1 
1.00
0 
-
1.716
8 
1.664
7 
+ 100 0 0 .76854 .4689
1 
.878 -.9222 2.459
3 
- 100 0 0 .64453 .4689
1 
.958 -
1.046
2 
2.335
3 
+ 100 30 0 -.93234 .4689
1 
.696 -
2.623
1 
.7584 
- 100 30 0 -
2.77214
* 
.4689
1 
.000 -
4.462
9 
-
1.081
4 
+ 0 0 50 .90320 .4689
1 
.733 -.7875 2.593
9 
+ 100 0 50 -.27230 .4689
1 
1.00
0 
-
1.963
0 
1.418
4 
- 100 0 50 -
1.93490
* 
.4689
1 
.016 -
3.625
6 
-.2442 
+ 100 0 50 + 
 
0 
 
0 0 1.20199 .4689
1 
.351 -.4887 2.892
7 
- 0 0 0 1.20199 .4689
1 
.351 -.4887 2.892
7 
+ 0 30 0 .90949 .4689
1 
.725 -.7812 2.600
2 
- 0 30 0 .24626 .4689
1 
1.00
0 
-
1.444
5 
1.937
0 
+ 100 0 0 1.04084 .4689
1 
.552 -.6499 2.731
6 
- 100 0 0 .91683 .4689
1 
.716 -.7739 2.607
6 
+ 100 30 0 -.66004 .4689
1 
.951 -
2.350
8 
1.030
7 
243 
 
- 100 30 0 -
2.49984
* 
.4689
1 
.001 -
4.190
6 
-.8091 
+ 0 0 50 1.17550 .4689
1 
.381 -.5152 2.866
2 
- 0 0 50 .27230 .4689
1 
1.00
0 
-
1.418
4 
1.963
0 
- 100 0 50 -
1.66260 
.4689
1 
.057 -
3.353
3 
.0281 
- 100 0 50 + 
 
0 
 
0 0 2.86458
* 
.4689
1 
.000 1.173
9 
4.555
3 
- 0 0 0 2.86458
* 
.4689
1 
.000 1.173
9 
4.555
3 
+ 0 30 0 2.57209
* 
.4689
1 
.001 .8814 4.262
8 
- 0 30 0 1.90885
* 
.4689
1 
.018 .2181 3.599
6 
+ 100 0 0 2.70344
* 
.4689
1 
.000 1.012
7 
4.394
2 
- 100 0 0 2.57943
* 
.4689
1 
.001 .8887 4.270
2 
+ 100 30 0 1.00255 .4689
1 
.604 -.6882 2.693
3 
- 100 30 0 -.83724 .4689
1 
.810 -
2.528
0 
.8535 
+ 0 0 50 2.83809
* 
.4689
1 
.000 1.147
4 
4.528
8 
- 0 0 50 1.93490
* 
.4689
1 
.016 .2442 3.625
6 
+ 100 0 50 1.66260 .4689
1 
.057 -.0281 3.353
3 
*. The mean difference is significant at the 0.05 level. 
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Table 41.  T-test analysis of Beclin mRNA data in UOK257 cells 
 
Independent Samples Test 
 
Levene's Test for 
Equality of Variances t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence Interval 
of the Difference 
Lower Upper 
Beclin Equal variances 
assumed 
6.887 .059 -
2.013 
4 .114 -.024 .012 -.056 .009 
Equal variances 
not assumed 
  -
2.013 
2.000 .182 -.024 .012 -.074 .027 
 
If the resulting p-value of a Levene’s test is less than typically 0.05 there is a difference 
between the variances in the groups tested. 
Equal variances assumed (Sig=0.059 therefore > 0.05 for Levene’s test) therefore P=0.114 
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Appendicies IV.  DNA electrophorisis gel for RT-PCR primers 
250bp
100bp
150bp
100bp
150bp
100bp
100bp
 
Figure 34.  Electrophoresis gel showing amplicon length for RT-PCR primers 
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Appendicies V.   Standard curvesand R-values for RT-PCR Primer assays 
 
Mouse β-actin standard curve 
 
Mouse ATP5G1 standard curve 
 
Mouse BNIP3 standard curve 
R² = 0.741 
26.5 
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27.5 
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29 
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28 
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0 0.2 0.4 0.6 0.8 1 1.2 
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 Human Cytochrome b standard curve 
 
 
 
 
 
 
 
 
 
R² = 0.9257 
26 
26.5 
27 
27.5 
28 
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0 0.2 0.4 0.6 0.8 1 1.2 
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Human NRF2 standard curve 
 
Human NRF1 standard curve 
 
 
 
 
 
 
 
 
R² = 0.9344 
27.4 
27.6 
27.8 
28 
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28.4 
28.6 
28.8 
29 
0 0.2 0.4 0.6 0.8 1 1.2 
R² = 0.9935 
23.4 
23.6 
23.8 
24 
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Human PGC1β standard curve 
 
 
Human PGC1α standard curve 
 
 
 
 
 
 
 
R² = 0.5989 
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0 0.2 0.4 0.6 0.8 1 1.2 
R² = 1 
0 
5 
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Mouse PGC1α standard curve 
 
 
 
Human RPL13 standard curve 
 
 
 
 
 
 
R² = 0.615 
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Human SOD2 standard curve 
 
 
Human TFAM standard curve 
 
 
 
 
 
 
 
R² = 0.6223 
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R² = 0.9797 
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27.2 
27.4 
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0 0.2 0.4 0.6 0.8 1 1.2 
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Human UCP3 standard curve 
 
 
Human ULK 1standard curve 
 
 
 
 
 
 
 
R² = 0.9999 
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Mouse ULK1standard curve 
 
Human ULK2 standard curve  
 
 
 
 
 
 
 
 
R² = 0.9627 
32.5 
33 
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Mouse VEGF-A standard curve  
 
Human Β-Actin standard curve 
 
 
 
 
 
 
 
 
R² = 0.7974 
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Human BNIP3standard curve 
 
Human CCND1 standard curve 
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Human G6PD1standard curve 
 
Human HIF1α standard curve 
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Human VEGF-A standard curve 
 
Human GLUT1 standard curve 
 
 
 
 
 
 
 
 
R² = 0.945 
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Human HIF2α standard curve  
 
Beclin1 standard curve  
 
 
 
 
 
 
R² = 0.8567 
0 
5 
10 
15 
20 
25 
30 
35 
0 0.2 0.4 0.6 0.8 1 1.2 
R² = 0.8794 
0 
5 
10 
15 
20 
25 
30 
35 
0 0.2 0.4 0.6 0.8 1 1.2 
259 
 
